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SUMMARY 
In 1994, the Centers for Disease Control and Prevention (CDC) and the Public 
Health Service (PHS) released guidelines classifying donors at risk of transmitting human 
immunodeficiency virus (HIV) through organ transplantation. In 2013, the guidelines were 
updated to include donors at risk of transmitting hepatitis B (HBV) and hepatitis C (HCV). 
These donors are known as increased risk for disease transmission donors (IRD). Even 
though donors are now universally screened for HIV, HBV, and HCV by nucleic acid 
testing (NAT), NAT can be negative during the eclipse phase, when the virus is not 
detectable in blood. In part due to the opioid epidemic, over 19% of organ donors were 
classified as IRD in 2014. Despite the risks of disease transmission and associated mortality 
from accepting an IRD organ offer, patients also face mortality risks if they decline the 
organ and wait for a non-IRD organ. The main theme of this thesis is to build organ 
transplant and waitlist survival models and to help patients decide between accepting an 
IRD organ offer or remaining on the waitlist for a non-IRD organ. 
In chapter one, we introduced background information and the outline of the thesis. 
In chapter two, we used machine learning to build an organ transplant survival model for 
the kidney that achieves greater performance than the model currently being used in the 
U.S. kidney allocation system.  In chapter three, we used similar modeling techniques and 
simulation to compare the survival for patients accepting IRD kidney offers vs. waiting for 
non-IRD kidneys. We then extend our IRD vs. non-IRD survival comparisons to the liver, 
heart and lung in chapter four, using different models and parameters. In chapter five, we 
built a model that predicts how the health of a patient changes from waitlist registration to 
 xxi 
transplantation. In chapter six, we utilized the transplant and waitlist survival models built 
in chapters three and four to create an interactive tool that displays the survival curves for 
a patient receiving an IRD organ or waiting for a non-IRD organ. The tool can also show 
the survival curve if a patient chooses to receive a non-IRD organ immediately. We then 
concluded with a discussion and major takeaways in chapter seven. 
 1 
CHAPTER 1. INTRODUCTION 
In 1994, the Centers for Disease Control and Prevention (CDC) and the Public Health 
Service (PHS) released guidelines classifying donors at risk of transmitting human 
immunodeficiency virus (HIV) through organ transplantation (1). In 2013, the guidelines 
were updated to include donors at risk of transmitting hepatitis B (HBV) and hepatitis C 
(HCV). These donors are known as increased risk for disease transmission donors (IRD) 
(2). Even though donors are now universally screened for HIV, HBV, and HCV by nucleic 
acid testing (NAT), NAT can be negative during the eclipse phase (the time during early 
infection when a virus is not detectable in blood). In part due to the opioid epidemic, over 
19% of organ donors were classified as IRD during in 2014 (2). Many organ recipients 
may have to decide between accepting an IRD organ offer or remaining on the waitlist for 
a non-IRD organ. Despite the risks of disease transmission and associated morbidity and 
mortality from accepting an IRD organ offer, a patient also has mortality risks if they 
decline the organ and wait for a non-IRD organ.   
The main theme of this thesis is to build organ transplant and waitlist survival models 
and to help patients decide between accepting an IRD organ offer vs. waiting for a standard 
organ.  
1.1 Using Machine Learning and an Ensemble of Methods to Predict Kidney 
Transplant Survival 
In chapter two, we built a kidney transplant survival model for the general kidney 
population. The proposed model achieved better performance, measured by Harrell’s 
 2 
concordance index (3), than the Estimated Post Transplant Survival (EPTS) model (4) used 
in the U.S. kidney allocation system, when evaluated on the same dataset. The model has 
a five-year concordance index of 0.724 (in comparison, the concordance index is 0.697 for 
the EPTS model, the state of the art currently in use). To build our model, we used a 
combination of machine learning techniques including random survival forests and a Cox 
proportional hazard model. We further produced a ranking of the top variables that are 
predictive of kidney transplant survival, which include recipient age, recipient diabetes and 
kidney diagnosis.  
1.2 Using Machine Learning and Simulation to Estimate Survival Curves for 
Hepatitis C Negative Transplant Patients Receiving an Increased Risk for 
Disease Transmission Donor Kidney Versus Remaining on the Waitlist 
In chapter three, we used similar modeling techniques that we used in chapter one, 
to build transplant survival models for an HCV negative recipient receiving a kidney from 
an IRD donor, receiving a kidney from a non-IRD donor, and a waitlist survival model for 
waiting on the kidney waitlist. Using our models, we simulated 20,000 different recipient 
and donor scenarios and compared the survival for a patient accepting an IRD kidney offer 
or waiting for a non-IRD kidney offer at a later date for different wait times, including the 
mean (672 days), half the mean, and one standard deviation (666 days) above the mean 
wait times from the data. We found that those who received an IRD kidney had, on average, 
a 0.74% higher (absolute difference) 5-year survival probability than if they waited for one 
day and received a non-IRD kidney. As the waiting time increased, the benefit for receiving 
an IRD kidney also increased. Recipients who received an IRD kidney had, on average, a 
3.75% higher 5-year survival probability than those who waited for 672 days (the average 
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wait time in our data) and then received a non-IRD kidney. Further, we built a simple 
equation to estimate the benefit of receiving an IRD kidney for a particular set of recipient 
and donor characteristics. As IRD organs have found to be underutilized, these results can 
help clinicians, researchers and patients access the risk of receiving or declining IRD 
kidneys.  
1.3 Using Machine Learning to Estimate Survival Curves for Patients Receiving an 
Increased Risk for Disease Transmission Heart, Liver, or Lung Versus Waiting 
for a Standard Organ 
In chapter four, we used similar but different modeling and simulation techniques 
than in chapter three, to build transplant and waitlist survival models and compare the 
survival for patients accepting IRD organ offers or waiting for non-IRD organs for the 
heart, liver, and lung. Based on 20,000 simulations, the recipients had, on average, higher 
5-year survival probabilities receiving an IRD organ versus waiting for one day and 
receiving a non-IRD organ (within 1.33%) for all three organs. The 5-year survival 
probabilities of heart, liver, and lung recipients who accepted IRD organ offers increased 
on average by 11.56%, 13.2% and 8.92%, respectively, compared to receiving a non-IRD 
organ after an average wait time (191, 249, and 227 days respectively). We also developed 
a simple equation to estimate benefits of receiving an IRD heart, liver and lung versus 
waiting for a non-IRD organ, for a particular set of recipient/donor characteristics. 
1.4 Predicting a Patient’s Functional Status at Kidney Transplantation Based on 
Information at Waitlist Registration 
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In 2016, there were over 100,000 patients waiting for a kidney transplant in the 
United States (5). With median waiting times of 3.6 years (based on those that entered the 
waitlist in 2009) (5), it is important to understand if and how the functional status of a 
patient may change while on the waitlist, e.g., in evaluating the tradeoffs between accepting 
an offer for a deceased donor organ versus remaining on the waitlist. Recorded both at 
registration and at the time of transplantation, the patient’s functional status is measured 
using the Karnofsky Performance Score and takes on values ranging from 0-100 in 
increments of 10 (6,7). In chapter five, using machine learning techniques, we built a 
generalized additive model to predict a patient’s functional status at transplantation based 
on information known at the time of waitlist registration. The model’s predictions result in 
an average root mean squared error of 13.05 based on 20 random cross-validation samples 
of 80% training data and 20% out-of-sample data, from a total sample size of 273,205 
transplant records. In comparison, predicting that the functional status remains the same at 
transplantation as the status at registration, results in an average root mean squared error 
of 14.68. To our knowledge, this is the first model that predicts how a patient’s functional 
status changes from waitlist registration to transplantation. We also found that diabetes, 
functional status at registration, UNOS region, and the year placed on the waiting list, most 
likely impact potential changes in functional status. 
1.5 Organ transplant decision support tool 
In chapter six, we utilize the transplant and waitlist survival models we built in 
chapters 3 and 4 to create an interactive tool that displays the survival curves for a patient 
receiving an IRD organ or waiting for a non-IRD organ. The tool allows the user to enter 
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custom characteristics of the recipient and donor. The tool can also show the survival 
curves if a patient chooses to receive a non-IRD organ immediately.  
1.6 Conclusion 
In chapter seven we conclude the thesis with a discussion and the main take-aways 
from our work. 
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CHAPTER 2. USING MACHINE LEARNING AND AN 
ENSEMBLE OF METHODS TO PREDICT KIDNEY 
TRANSPLANT SURVIVAL  
2.1 Introduction 
 In 2013, the Organ Procurement and Transplantation Network (OPTN) adopted a 
new kidney allocation system using the Estimated Post Transplant Survival (EPTS) score 
(4,8). Other kidney transplant survival models such as the Recipient Risk Score (RSS) (9) 
and Life Years from Transplant (LYFT) (10), have also been proposed by researchers. 
These techniques use a Cox proportional hazards model, which estimates the probability 
of a recipient’s post-transplant survival over a given time horizon (11). The Cox 
proportional hazards model is the most widely used model for kidney transplant survival 
estimation (12). Additional models include a Bayesian Belief Network (BBN) that was 
used to predict kidney graft failure (13).  
 We took a different approach, and used an ensemble of methods including random 
survival forests constructed from conditional inference trees. Our approach first clusters 
the data (e.g., into cohorts) and then chooses a model that achieves the best performance 
for each cluster. The advantage of combining different models to predict kidney transplant 
survival is that different models may work better than others on different cohorts of the 
data. We assessed the predictive accuracy of our proposed model using various metrics, 
including Harrell’s concordance index (C-index) (3), which is the percentage of patient 
pairs correctly “ranked” by the model based on their post-transplant survival duration in a 
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given timeframe. The C-index for the proposed model is better than that of the EPTS model 
and other kidney transplant survival models proposed recently in the literature (4,10,12). 
The results of the model applied to kidney transplant data are presented here, but the 
approach can be applied to other organs as well.  
2.2 Data 
The dataset was provided by the United Network for Organ Sharing (UNOS) and 
consists of recipients who underwent kidney transplant surgery in the U.S. from 1987 to 
2014 (14,15). The data includes both living and deceased donors, pediatric and adult 
recipients, and censored observations. An observation is censored when it does not record 
a transplant recipient’s survival duration after surgery; in these censored observations, the 
date of the last follow-up is recorded. All data in this study were fully anonymized prior to 
access by any of the authors. More information on the UNOS data and instructions for 
researchers to request this data can be found at https://unos.org/data/.  
2.2.1 Data preparation 
 In 2003, the UNOS board of directors instructed the Kidney Allocation Review 
Subcommittee to review the kidney allocation system (8). Hence, we tested the following 
hypothesis: There is a statistically significant difference between the survival curves of 
recipients who underwent a kidney transplant before and after 2002. A log-rank test and 
visual inspection of the survival curves verified the significant difference (Figure 2-1 and 
Table A-1) (16). Moreover, starting in 2012, a new allocation system was proposed that 
used the kidney donor risk index (KDRI) in addition to the EPTS model (17). Therefore, 
in the analysis we used data that includes all kidney transplants performed between January 
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1, 2002 and December 31, 2011. Observations after 2012 would not have a 5-year post-
transplant window at the time of this study. 5-year or longer time horizons for kidney 
transplant survival models have often been used in the literature (12,17,18). 
 
 
Figure 2-1: Survival probabilities of different transplant cohorts. The survival 
probabilities are calculated from the Kaplan-Meier estimate. 
 
There were 163,199 observations available during the chosen ten-year time period 
with 487 variables. We removed variables not present in more than 95% of the observations 
unless they were identified as important in the previous literature (19-21). In the latter case 
we removed variables not present in more than 80% of the observations. We also removed 
variables that were recorded twice, or were known only after the kidney transplant. The 
resulting data set had 73 variables.  
The following approaches were used in addressing the issue of missing data: (i) 
imputation by predictive mean matching (PMM), and (ii) removing missing data for non-
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categorical variables. In approach (ii), we labeled missing data for categorical variables as 
‘unknown’ and removed the non-categorical observations with missing data. Variable 
selection and all other analysis was carried out using approach (ii), unless specified 
otherwise. We cross-validated our proposed predictive model using both approaches. 
When cross-validating our final predictive model with approach (ii), 17% of the data were 
removed. 
Table 2-1: Study inclusion/exclusion criteria. 
Table 2-1 continued 
Inclusion/exclusion criteria Years of data Number of observations 
Historical kidney transplants 
with a recorded number of days 
until last follow-up after 
surgery or time to death. 
Observations without a 
censored status were not 
considered. 
January 1, 2002 and 
December 31, 2011 163,199 
 
2.2.2 Grouping categorical variables 
In the data, some of the categorical variables have a large number of possible values. 
For example, the variable kidney diagnosis, has 75 different possible values. To avoid 
overfitting and large model variance, we used the approach described in Text A-1 and 
illustrated in Table A-2 to group different values of the variable together. The values 
grouped together have a similar effect on the hazard function, controlling for relevant 
variables. Following this approach, we decreased the number of different kidney diagnosis 




2.3.1 Variable selection 
For variable selection, we first used the Breiman-Cutler permutation importance 
measure for random survival forests to rank the variables in order of variable importance 
(22). Harrell’s concordance index was used to measure the error rate for assessing the 
decrease in accuracy when permuting each predictor variable in the permutation 
importance calculation. 
Recipient age was ranked as the most important variable by permutation importance 
on the entire dataset. Hence, we decided to split the data into age-based cohorts and 
produced two separate rankings of variables, one ranking for older recipients and one for 
younger recipients. This allowed us to build two predictive models for the different cohorts. 
To find the split value for recipient age, we built 100 survival decision trees (23,24), each 
with one split using only recipient age. Each decision tree finds the recipient age that gives 
the best binary split of two groups based on parameters suggested by Strobl et al. (25). The 
average split value for the 100 trees was 48.7 years. Hence, rounding up to 50, we 
performed variable selection separately for transplant recipients aged 50 and under (cohort 
1), and recipients aged 51 and older (cohort 2). The average 5-year survival probabilities 
are 93% and 80% for cohorts 1 and 2, respectively, based on the Kaplan-Meier (26) 
estimate. Figure 2-2 and Figure 2-3 depict the top ten variables for cohorts 1 and 2, 




Figure 2-2: Variable importance for recipients ages 50 and under based on Breiman-





Figure 2-3: Variable importance for recipients ages 51 and older based on Breiman-
Cutler permutation importance. 
 
We then used a Cox model regularized with the Lasso (L1) penalty to help 
determine how many of the top variables to select (27). We used 10-fold cross-validation 
to determine the optimal Lasso penalty. Figure 2-4 shows the number of nonzero 
coefficients for different penalty values for cohort 1. The top row represents the number of 
non-zero coefficients per different values of the Lasso penalty. The vertical line L0 
corresponds to the optimal penalty, which minimizes the Partial Likelihood Deviance 
(PLD). The line Lσ corresponds to the largest penalty value corresponding to the PLD 
values within one standard deviation of the minimum PLD. Figure A-1 gives the analogous 
results for cohort 2. To keep the predictive model simple and minimize the number of 
variables, we used the Lσ penalty, which has fewer nonzero coefficients than using L0. 
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Figure 2-4: Cox Lasso variable selection for recipients ages 50 and under. The top row 
represents the number of non-zero coefficients per Lasso penalty value, lambda. The 
vertical line L0 corresponds to the optimal penalty, which minimizes the PLD. The line Lσ 
corresponds to the largest penalty value corresponding to the PLD values within one 
standard deviation of the minimum PLD. 
 
 
For each cohort, variables that have nonzero coefficients in the Lasso model and 
which are also among the top 20 variables chosen by permutation importance are included 
in the predictive model. Table 2-2 lists the final selections of variables for each cohort. 
Table A-3 provides a description of the variables we used in our proposed predictive 
survival model. Table A-4 gives the mean values from the data for numeric variables and 
the percentages of observations for each category for categorical variables. 
 
Table 2-2: Variables in the proposed predictive model. A description of each variable is 
given in Table A-3. 
Table 2-2 continued 




Table 2-2 continued 
















2.3.2 Predictive models 
For cohort 1, we built a random survival forest model with conditional inference 
trees as base learners (23,24). We grew a forest with 800 trees and four randomly selected 
variables considered for each split. Random forest parameters suggested by Strobl et al. 
(25) were used with a slight modification. We restricted a tree split to occur only if the 
splitting test statistic exceeded 0.3, instead of guaranteeing the inclusion of all splits. In 
testing, we found that this allowed the use of smaller trees with the same predictive 
performance measured by Harrell’s concordance index.  
For cohort 2, the Cox proportional hazards model achieved a better concordance 
index than using random survival forests (0.664 vs. 0.655 based on 10 cross-validation 
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samples of 80% training data and 20% out-of-sample data). Hence for cohort 2, we fit a 
Cox proportional hazards model. Table A-5 shows the coefficients for the Cox model when 
it was trained on 100,000 observations. 
  In the proposed predictive model, we use the combination of random survival 
forests for cohort 1, and the Cox model for cohort 2. We evaluated the performance of the 
proposed model compared to other models by two metrics using cross-validation: (i) 
Harrell’s concordance index, and (ii) the integrated Brier score (28). In addition to 
comparing the performance of our model to the reported performance of the EPTS model 
(4), we evaluated the EPTS model on the same data that we used for our model. We used 
PMM for missing data because the EPTS model does not allow for variable inputs to be 
unknown. We validated our proposed model in multiple ways, using PMM imputation and 
without imputation. 
 Our methodology for building the proposed predictive model is described by the 
following high-level summary:  
1. Identify important predictive variables by performing variable selection 
techniques such as Lasso or permutation importance.   
2. Test the performance of multiple predictive models on the data using the variables 
identified in step 1. Use cross-validation and metrics such as the concordance 
index to evaluate the performance.   
3. Determine the best binary split in the data using methods such as decision trees.  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Repeat steps 1–3 for both subsets of the data a specified number of times. The final 
model consists of combining the predictions from the models that perform best on the 
different subsets of the data. 
The analysis was undertaken using the statistical software R version 3.3.2 as well as 
several key packages listed in the references (29-35). 
2.4 Results 
Table 2-3 shows the 5-year Harrell’s concordance index and the integrated Brier 
score for the prosed model using 10 random samples of 80,000 training observations and 
20,000 out-of-sample observations. It also reports the performance of a number of other 
models from the recent literature. Harrell’s 5-year concordance index for our proposed 
model is 0.724 versus 0.69 reported for the EPTS model (4) and 0.697 for the EPTS model 
applied to the data used for this study. The concordance index of the proposed model is 
0.717 when we remove the donor variables and include only the recipient variables. This 
provides a more direct comparison to the EPTS model since the EPTS model does not use 
donor variables. The performance of the proposed model was nearly the same when we 
also validated it using PMM imputation as opposed to validation without imputation.   
 
Table 2-3: Performance of the proposed predictive model compared to other models. 
Performance from 10 random samples of 80,000 training observations and 20,000 out-of-
sample observations for all models except those marked ‘Reported’, where the metrics 
shown were provided in the literature for their respective models. *These two predictive 
models used the variable selection techniques we used for each cohort separately but 
instead applied to all the data. **Donor variables that were removed were: AGE_DON, 
d 
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COD_CAD_DON, COLD_ISCH_KI, DEATH_MECH_DON, HIST_DIABETES_DON, 
and HIST_HYPERTENS_DON. 
Table 2-3 continued 




LYFT Reported (10) 0.680 Not Reported 
EPTS Reported (4) 0.69 Not Reported 
EPTS Using the Same Cross-
Validation Data as the Proposed 
Model 
0.697 Not Calculated 
Li et al. (12) Reported 0.700 Not Reported 
Cox Model for Both Cohorts* 0.706 0.063 
Random Forests for Both Cohorts* 0.718 0.062 
Proposed Model without Donor 
Variables** 0.717 0.060 
Proposed Model 0.724 0.061 
Proposed Model using PMM 
Imputation 0.724 0.060 
 
 Figure 2-5 and Figure 2-6 illustrate the behavior of our proposed model trained 
using a random sample of 100,000 observations and validated on 25,000 out-of-sample 
observations. The solid lines represent the survival predictions and the dotted lines depict 
the observed Kaplan-Meier estimates for the out-of-sample observations. We also illustrate 
the model’s survival predictions for different values of its variables, holding the remaining 
variables constant, in Figure A-2 (also see Table A-6 and Table A-7). Table A-8 and Table 
A-9 present results on the performance of our proposed model at different numbers of days 
after transplantation and on different categories respectively. Table A-10 gives results for 
additional tests on the performance of our proposed model and the EPTS model on data 
without pediatric recipients and living donors. Table A-11 shows the performance of the 
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Figure 2-5: Predicted survival of the proposed model. Trained on 100,000 observations 
and validated on 25,000 out-of-sample observations. The survival curves are separated 






Figure 2-6: Predicted survival of the proposed model for a ‘typical’ kidney transplant 
recipient. Trained on 100,000 observations and validated on 25,000 out-of-sample 
observations. In the out-of-sample data, an observation is considered ‘typical’ if the 
values are within one standard deviation of the mean for recipient age, donor age, and 
cold ischemia time, and the most common values from the data for recipient diabetes, 
recipient dialysis status, recipient medical condition, and donor hypertension status. 
 
2.5 Discussion 
The current kidney allocation system, adopted in 2013, matches the best 20% of 
kidneys as determined by the KDRI, to the top 20% of potential recipients with the highest 
predicted transplant survival probabilities, estimated by the EPTS model (17). Improving 
the predictive performance of kidney transplant survival models can help the kidney 
allocation system more accurately rank potential recipients based on estimates of post-
transplant survival. Table 2-3 shows that our proposed model has a higher concordance 
index than the EPTS model and other models recently published in the literature, such as 
the LYFT model and the flexible parametric model proposed by Li et al. (12). Hence, when 
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considering a random pair of candidates and determining which candidate in the pair has a 
higher post-transplant survival probability (in a given time frame, e.g., 5 years), our model 
will result in more correct pair rankings than the EPTS model, and has the potential to 
significantly improve the matching of organs to recipients. We also found that by using a 
model that combines different predictive models and variables for different age groups, we 
achieved better performance than by using the same model and variables for both cohorts.  
 A comparison of kidney transplant survival models over time shows a concordance 
index of 0.68 in 2009 for the LYFT model (Wolfe et al., 2009), a concordance index of 
0.69 in 2013 for the EPTS model currently used in the kidney allocation system (Clayton 
et al., 2014), and an index of 0.70 in 2016 from Li et al. (2016). A gain in the index of 0.01 
can have a dramatic impact considering that these models are used in the U.S. kidney 
allocation system, which is responsible for allocating tens of thousands of kidneys per year. 
Our model yields an improvement in the concordance index of 0.03 over the EPTS model 
when tested on the same data, which can have a significant impact on ranking kidney 
waitlist patients by their post-transplant survival more accurately. 
 Unlike the EPTS model, the proposed model has the flexibility to take into account 
characteristics of donors; hence, it can help predict which donor-recipient matching can 
result in the highest post-transplant survival, among several choices. The proposed model 
can also be used without the donor variables, and still result in a better concordance index 
than the EPTS model. This can be useful in estimating the survival of transplant recipients 
before the donor information is known, such as when determining recipient priority in the 
allocation system.  
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 Our findings suggest that there may be a benefit for building separate models for 
different cohorts of patients (in this case cohorts separated by recipient age). For example, 
the variable region, was in the top ten ranked variables for cohort 1 but not for cohort 2. 
Hence, the impact of region on post-transplant survival is higher for cohort 1 than cohort 
2.  
 The proposed model uses machine learning methods, and although it does not result 
in a simple equation to predict transplant survival, such methods are straightforward to 
apply. Further, the proposed model uses 18 different predictive variables versus 4 used by 
EPTS. While the model complexity could be viewed as a limitation, with the increasing 




CHAPTER 3. USING MACHINE LEARNING AND 
SIMULATION TO ESTIMATE SURVIVAL CURVES FOR 
HEPATITIS C NEGATIVE TRANSPLANT PATIENTS 
RECEIVING AN INCREASED RISK FOR DISEASE 
TRANSMISSION DONOR KIDNEY VERSUS REMAINING ON 
THE WAITLIST 
3.1 Introduction 
 In 1994, the Centers for Disease Control and Prevention (CDC) and the Public 
Health Service (PHS) released guidelines that classified donors at risk of transmitting 
human immunodeficiency virus (HIV) through organ transplantation (36). In 2013, the 
guidelines were updated to include donors at risk of transmitting hepatitis B (HBV) and 
hepatitis C (HCV) (2). These donors are known as increased risk for disease transmission 
donors (IRD). Since the guidelines were released, the discard rates have been higher for 
IRD organs than for non-IRD organs (37). IRD kidneys were found to be one-third less 
likely to be used for transplantation than non-IRD kidneys with similar characteristics (38). 
Further, a highly publicized case of HIV and HCV transmission from a single IRD donor 
in 2007 led to increased fear of IRD organs and reports of lower IRD organ usage (39). In 




 Prior literature suggests that the risk of infection for IRD organs is very small 
(41) and that accepting IRD kidney offers rather than discarding them or declining them is 
associated with increased survival (20,42,43). Increased utilization of IRD organs can 
reduce the gap between demand (the number of people on the transplant waitlist) and 
supply (organs available for transplantation) for organ transplants. Between 2003 and 2013, 
the number of people who either died while on the waitlist or were too sick to receive a 
kidney transplant exceeded 50,000. 
 Despite previous literature suggesting the benefits of IRD kidneys, they remain 
underutilized (44), indicating the need for further research and more definitely establishing 
the benefits compared to waiting for a non-IRD kidney, with different wait times. In 2017, 
Volk et al., concluded that “The PHS ‘increased risk’ label appears to be associated with 
nonutilization of hundreds of organs per year” (44). With over 19% of deceased donors 
marked as IRD as of 2014 (2), many individuals may be offered an IRD kidney and face 
the question of whether to accept the offer. Using machine learning techniques, we built 
transplant and waitlist survival models, and simulated thousands of different recipient-
donor scenarios. We found that in the simulations, patients had, on average, a 0.74% higher 
5-year survival probability receiving an IRD kidney than waiting for one day and receiving 
a non-IRD kidney. As the waiting time increased, the benefit for receiving an IRD kidney 
also increased. We also quantified the survival benefit for receiving an IRD kidney rather 
than waiting for different wait times, including the mean (672 days), half the mean and one 
standard deviation (666 days) above the mean wait times from the data. Further, to our 
knowledge, we are the first to provide a simple equation to estimate the individual-level 
benefit of receiving an IRD kidney versus waiting for a non-IRD kidney for a particular set 
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of recipient and donor characteristics. These estimated survival benefits of receiving IRD 
kidneys vs. waiting for non-IRD kidneys can help clinicians when informing patients about 
the benefits and risks of IRD kidneys.  
3.2 Methods 
 To assess the tradeoffs of receiving an IRD kidney instead of waiting for a non-
IRD kidney, we developed three separate survival models (using random survival forests) 
: (i) MIRD: an HCV negative recipient receiving an IRD kidney; (ii) Mnon-IRD: an HCV 
negative recipient receiving a non-IRD kidney (after a certain wait time); and (iii) Mwait: 
an HCV negative recipient remaining on the kidney waitlist. We then simulated thousands 
of different recipient-donor scenarios using our survival models and compared the 
predicted survival probabilities for receiving an IRD kidney to those of waiting for a non-
IRD kidney. From the simulation results, we produced a simple equation to estimate the 5-
year survival difference between these two options. The analysis was undertaken using R 
3.3.2 (29) and used several key packages listed in the references (29-35). 
3.2.1 Data and data preparation 
 Our dataset, a Standard Transplant Analysis and Research (STAR) file, was 
obtained from the United Network for Organ Sharing (UNOS) (14,15). The data can be 
accessed from https://optn.transplant.hrsa.gov/data/request-data/. The data contains 
transplant records performed in the U.S from 1987 to 2014. 
 We analyzed patients who entered the waitlist or received a non-multiple organ 
transplant between August 8, 2000 (the date of the first IRD kidney transplant in the data) 
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and August 26, 2013 (when the new IRD guidelines were updated). We considered IRD 
donors using the 1994 guidelines, because at the time of our study, we did not have more 
than five years of transplantation follow-up data from the most-recent IRD guidelines 
published in 2013 and many of the 1994 and 2013 criteria overlap. Details regarding the 
differences in the guidelines can be found in Kucirka et al (2).  
 We removed variables that had more than 5% of observations missing except if 
they had been identified as important in several previous studies (20,21,45-47). These 
important variables were removed only if they had more than 20% of the data missing.  
 Table B-1 contains a summary of all the variables considered in the analysis after 
the initial data preparation. We used predictive mean matching multiple imputation to 
predict the missing data for non-categorical variables, Bayesian logistic regression models 
for imputation of binary categorical variables, and a Bayesian multinomial regression for 
imputation of categorical variables with more than two categories (48). We did not use 
imputation for recipient HCV and donor IRD status, which had 8% and 49% missing data, 
respectively. We also did not use imputation for donor HCV antibody, HCV RNA, or HCV 
RIBA status which had 71%, 97%, and 98% missing observations, respectively. However, 
for these latter variables, missing observations were not removed. Instead, we removed 
donors that tested positive for these variables when building the predictive models. 
Imputing HCV status could be misleading because we could not find variables in our 
dataset that can be used to impute it accurately. 
One of the variables, kidney diagnosis, originally contained 74 different categories. 
To reduce possible overfitting and large model variance, we grouped the number of 
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different variable values of kidney diagnosis and decreased the number of categories from 
74 to 5 (see Table B-2).  
 When training the models MIRD and Mnon-IRD, we considered an observation (a 
transplant record) to be censored if the recipient’s survival time after transplantation was 
not known. Instead, the date of the last follow-up was recorded. In the model Mwait, an 
observation (a record of a patient waiting for a transplant) was considered censored if the 
potential transplant recipient was still waiting at the last recorded follow-up time, or was 
removed from the waitlist for any reason other than death. Observations without either a 
follow-up time or survival time, and observations without a censored status were also 
removed from the analysis. Table 3-1 shows the number of observations, the percentage of 
observations with missing data, the percentage of censored observations, and the number 
of variables considered before variable selection for the predictive models.   
 
Table 3-1: Data used in the analysis. We included all patients who entered the waitlist or 
received a non-multiple organ transplant between August 8, 2000 (the date of the first 
IRD kidney transplant in the data) and August 26, 2013. When building and testing the 
predictive models, transplants from donors who tested positive for HCV antibody, HCV 
RNA, or HCV RIBA status were removed. The percent of missing data for each scenario 
was calculated in the following way: let n be the number of transplant records in the 
scenario, k be the number of variables used in the predictive model (including censored 
status and follow-up/death time), and m be the total number of missing values for all 
variables. The percent of missing data is m/nk. 
Table 3-1 continued 







MIRD IRD 6679 0.80% 89.8% 98 HCV negative recipients 
d 
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Table 3-1 continued 
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3.2.2 Selecting variables for survival models 
 Table B-3 gives a description of the subset of variables used in our predictive 
models.  
 We selected which variables to use for each of the predictive survival models, 
MIRD, Mnon-IRD, and Mwait, respectively, by taking the intersection of the top 10 variables 
ranked by permutation importance from random survival forests (22), and the variables 
corresponding to the non-zero coefficients for a Cox Lasso regression model (27) (see 
Table B-4 for variables among the top 10 in permutation importance also selected by 
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Lasso). Imputation was used before running the variable selection methods. Once the 
variables were selected, we used imputation again on a dataset consisting only of the 
variables used in each predictive model, when training each particular model. 
 For Mnon-IRD, the time a patient remained on the waitlist was included in the model 
to account for any changes in the health of the patient while on the waitlist. For MIRD and 
Mnon-IRD, we added a variable to the models indicating recipient functional status, to control 
for differences in the conditions of the recipients receiving IRD organs and non-IRD organs 
in the historical data. Table 3-2 lists the variables that were used in each of the predictive 
models.   
 
Table 3-2: Variables used in predictive models. See Table B-3 for a description of the 
variables. Initially, the variable ON_DIALYSIS was selected for each model, but we 
replaced it with ON_DIALYSIS_REGISTRATION for Mnon-IRD and Mwait , and 
DIAL_TRR for MIRD because some observations of ON_DIALYSIS may have been 
recorded sometime between waitlist registration and transplantation, instead of at 
registration. 
Table 3-2 continued 
MIRD Mnon-IRD Mwait 
AGE DAYSWAIT_CHRON DIAB 
AGE_DON DIAB ETHCAT 
CREAT_TRR ETHCAT FUNC_STAT_TCR 
DIAB FUNC_STAT_TCR INIT_AGE 
DIAG_KI INIT_AGE ON_DIALYSIS_REGISTRATION 





FUNC_STAT_TRR ON_IEXPAND_DONOR REGION 
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Table 3-2 continued 
HIST_HYPERTEN
S_DON PERIP_VASC TOT_SERUM_ALBUM 
 TOT_SERUM_ALBUM WAITLIST_YEAR 
 WAITLIST_YEAR  
 
3.2.3 Building survival models 
 Each model, MIRD, Mnon-IRD and Mwait, predicts the probability of surviving up to 
a certain timeframe starting from either receiving an IRD transplant or deciding to wait for 
a non-IRD transplant.  
 MIRD and Mnon-IRD were trained on HCV negative recipients who had a transplant 
from an IRD and a non-IRD donor, respectively. 
Mwait was trained on all patients who have either waited for or received a kidney 
transplant. HCV status was only recorded for those who have had a transplant. Hence, to 
obtain the survival probability of HCV negative potential recipients on the waitlist, we 
shifted the waitlist survival predictions from Mwait by the following amount at each time 
point: the average transplant survival probability of HCV-negative kidney recipients at 
that time minus the average transplant survival probability of all kidney transplant 
recipients at that time point. 
The models were built using random survival forests with conditional inference 
trees as base learners (24,30,49,50). We used random forest parameters suggested by 
Strobl et al., for the construction of unbiased random forests suggested by Strobl et al.  
(25). For each model we used 500 trees, and in each decision tree we only allowed a split 
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to occur if the splitting test statistic exceeded 0.25. This helped reduce the model size 
while achieving high accuracy based on Harrell’s concordance index (C index) (3).   
 The random survival forests models were implemented using the ‘cforest’ 
function of the R package ‘party’ and the cox model was implemented using the ‘coxph’ 
function in the ‘survival’ package. The following parameters were used in the ‘cforest’ 
function: mtry=ceiling(sqrt([number of variables in model])), ntree = 500, teststat = 'quad', 
testtype = 'Univ', mincriterion = .25, replace = FALSE, fraction = min(0.632,  
40000/[training data size]). 
3.2.4 Simulations 
 Using our three predictive models, we simulated different patient and donor 
scenarios and compared the survival of a potential recipient either receiving an IRD organ 
or waiting for a non-IRD organ for different wait times in each scenario. We built our 
simulations by selecting 20,000 random samples of values from variables chosen for the 
models including: sampling with replacement from the general kidney transplant 
population data (see Table B-1 for the distribution of data from the general kidney 
transplant population) for each numeric variable; and up to the top 3 most-common 
categories for categorical variables, where the probability of sampling each category was 
proportional to the data. For variables that were recorded both at transplant and at 
registration, such as the recipient functional status at transplant and functional status at 
registration, the simulation sampled the values at transplantation. We also randomly 
sampled wait times including: 1 day, the mean (672 days in our data set), half the mean, 
and 1 standard deviation (666 days) above the mean wait time. The simulated scenarios 
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represent thousands of different patient phenotypes with characteristics representative of 
common transplant recipients and donors, across four different wait times.   
 For each simulated scenario, we first computed the survival curve of the patient 
receiving the IRD organ, using MIRD. We then computed, using Mwait, the survival curve if 
that patient had remained on the waitlist. Finally, we computed, using Mnon-IRD, the survival 
curve for the patient receiving a non-IRD organ after the specified wait time of the scenario. 
We note that for variables recorded both at waitlist registration and at transplantation, MIRD 
uses the recording at the time of transplant, while Mwait and Mnon-IRD use the recording at 
the time of waitlist registration. Because the models do not all use the same set of variables, 
not all variables in a scenario are used in each model. For example, since we do not know 
the future (potential) donor characteristics for a patient on the waitlist, there are no donor 
features used in Mwait or Mnon-IRD.  
3.2.5 Benefit equation 
 After computing the survival curve estimates for each scenario, we ran a linear 
regression (which we call the benefit equation), regressing the 5-year survival probability 
for a patient receiving an IRD organ minus the 5-year survival probability of waiting for a 
non-IRD organ, on the variables used in the simulation (see Table 3-2). We multiply the 
prediction from this regression (i.e., the estimated difference in the 5-year survival 
probabilities when receiving an IRD organ vs. waiting for a non-IRD organ) by 100, so 
that the values, which we call the IRD kidney benefit, are on a scale of -100 to 100. Positive 
values correspond to the scenarios where receiving an IRD organ versus remaining on the 
waitlist increases the 5-year survival probability. The coefficients of the benefit equation 
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can be interpreted as follows: a one unit increase in the value of a variable in the benefit 
equation is associated with an increase (or decrease) in the IRD kidney benefit, equal to 
the coefficient for that variable, holding the rest of the variables constant; for a binary 
categorical variable, the increase (or decrease) in the IRD kidney benefit is instead 
associated with being in that category as opposed to not being in that category, holding the 
rest of the variables constant. To test the performance of the benefit equation and the 
estimated IRD organ benefit, we used 10 random samples of 80% training data and 20% 
out-of-sample data for validation, comparing the equation's predicted increase/decrease in 
survival due to receiving an IRD organ to the value predicted from the simulation. 
3.2.6 Predicted IRD Transplant Survival for Recipients Who Died on the Waitlist 
 For patients who died on the waitlist (in our dataset), we predicted their survival 
probability if they had received an IRD kidney, with average donor characteristics, after 
remaining on the waitlist for three possible wait times: 50%, 75% and 90% of the waiting 
time that they remained on the waitlist prior to death. We obtained the survival predictions 
by first using Mwait to predict a patient’s probability of survival to a certain time point on 
the waitlist. We then predicted their survival probability if they had received an IRD kidney 
using a modification, M'IRD, of MIRD. In M'IRD, we added a variable indicating the wait time 
to the model; and for all variables in MIRD recorded both at the time of waitlist registration 
and at the time of transplant, we used the variable at the time of waitlist registration. These 
modifications allowed the model to control for how the functional status of the patient may 
have changed from waitlist registration to transplantation. In M'IRD, any information not 
known until after the waitlist registration, such as the donor variables, was assigned the 
respective mean values for recipients from the data set who received an IRD kidney. Since 
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the population who died on the waitlist included both HCV negative and HCV positive 
patients, we did not exclude HCV positive recipients in M'IRD. We also did not shift their 
waitlist survival to adjust it to the HCV negative population when using Mwait. The training 
data for M'IRD included 7525 observations, 1.6% missing data and 89.3% censored data. 
For each patient who died on the waitlist, we recorded the probability that they would have 
survived longer if they had received an IRD organ after waiting for each of the three 
different wait times.  
3.3 Results 
3.3.1 Survival Curves 
 Example survival probability curves from each of the three models are shown in 
Figure 3-1. Table B-5 depicts the performance of each model using 10 cross-validation 
samples. Our IRD, non-IRD, and waitlist models achieve strong performance with a 5-year 
C index of 0.690, 0.698, and 0.688, respectively, based on 10 cross-validation samples of 
20% out-of-sample data. As a comparison, the 5-year C index of the Estimated Post 
Transplant Survival (EPTS) model used in the U.S. kidney allocation system (4) is 0.682, 
0.696, and 0.634, respectively, for IRD, non-IRD, and waitlist survival (based on 10 cross-




Figure 3-1: Example of survival probability curve comparison between receiving an IRD 
kidney and waiting for a non-IRD kidney. The predicted survival curves are for a patient 
who has characteristics of the average numerical variables, and the most common 
categorical variables used in the predictive models for each scenario. Here, the patient 
stays on the waitlist for 672 days, the mean waiting time in our data. When waiting for a 
non-IRD organ, the survival curve starts off as the survival curve for the waitlist. After 
the waiting time is over, the survival curve then becomes the curve for receiving a non-
IRD organ. 
 
3.3.2 Simulation Results 
 Simulation results suggest that the difference in predicted 5-year survival 
probabilities between recipients receiving IRD kidneys immediately versus those waiting 
for non-IRD kidneys depend on the expected wait time (see Table 3-3). In the simulations, 
54.95% of recipients had a higher 5-year probability of survival if they received an IRD 
kidney versus waited for one day and received a non-IRD kidney. Those who received an 
IRD kidney had, on average, a 0.74% higher 5-year survival probability than if they waited 
for one day and received a non-IRD kidney. As the waiting time increased, the benefit for 



















Wait for Non−IRD Kidney
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average, a 3.75% higher 5-year survival probability than those who waited for 672 days 
(the average wait time in our data) and then received a non-IRD kidney. 
 
Table 3-3: Percent of simulations with higher 5-year survival probability of receiving an 
IRD kidney versus waiting for a non-IRD kidney; and the predicted 5-year survival 
probability for receiving an IRD kidney minus the 5-year predicted survival probability 
of waiting for a non-IRD kidney. 
Table 3-3 continued 
Days on 
waitlist 
Percent of simulations with 
higher 5-year survival 
probability of receiving an IRD 
kidney versus waiting for a 
non-IRD kidney 
Predicted 5-year survival 
probability of receiving an IRD 
kidney minus the 5-year predicted 
survival probability of waiting for a 
non-IRD kidney, averaged over all 
scenarios 
1 54.95% 0.74% 
336 63.79% 1.72% 
672 73.05% 3.75% 
1338 82.02% 9.41% 
 
 Figure 3-2 and Figure 3-3 illustrate the results presented in Table 3-3, at different 





Figure 3-2: Percent of simulations with a higher 5-year survival probability of receiving 
an IRD organ than waiting for a non-IRD organ at different time points after the decision, 




Figure 3-3: The predicted survival probabilities for receiving an IRD organ subtracted by 
the predicted survival probabilities for waiting for a non-IRD organ, averaged over all 
simulations with 672 days on the waitlist, for different time points after the decision. 
 











































































 The coefficients of the regression equation are shown in Table 3-4. These 
coefficients can be used to determine the increase or decrease in the 5-year survival 
probability for receiving an IRD kidney instead of waiting for a non-IRD kidney. The 
average root mean squared error (RMSE) of the 10 cross validations (80% training data 
and 20% out-of-sample data for each cross-validation) for the equation is 5.10, comparing 
the equation’s predicted increase/decrease in survival probability on a scale of -100 to 100, 
of receiving an IRD organ, to the value predicted from the simulation (random guessing 
from a normal distribution with a mean and standard deviation from the simulation results, 





Table 3-4: Benefit equation for the 5-year survival probability of receiving an IRD 
kidney minus the 5-year survival probability of waiting for a non-IRD kidney. The 
benefit equation predicts the increase (positive value) or decrease (negative value) in 
probability (multiplied by 100) of surviving to 5 years with an IRD kidney vs. waiting for 
a non-IRD kidney. Reference levels for categorical factors: DIAB:  No. DIAG_KI:  
Group_1†. DIAL_TRR:  No. ECD_DONOR:  0. ETHCAT:  Black. FUNC_STAT_TRR:  
60-70 percent performs activities of daily living with some assistance. 
HIST_HYPERTENS_DON:  No. ON_EXPAND_DONOR:  0. 
ON_IEXPAND_DONOR:  0. PERIP_VASC:  No. 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATION:  Medicaid. REGION: 2. 
†See Table B-2 for categories in this group. Using the coefficients, the equation is: 
890.202 + 7.303(DIAL_TRR: Y) + 4.211(PERIP_VASC: Y) + 2.695(DIAB: YES) + 
2.106(ON_EXPAND_DONOR: 1) + 1.667(ETHCAT: WHITE) + 1.429(DIAB: NOT 
KNOWN) + 1.41(ON_IEXPAND_DONOR: 1) + 
0.481(PROJECTED_PAYMENTSOURCE_AT_REGISTRATION: MEDICARE) + 
0.463(CREAT_TRR) + 0.07(AGE) + 0.007(WAITLISTDAYS) -0.071(AGE_DON) -
0.151(REGION: 5) -0.202(REGION: 3) -0.39(FUNC_STAT_TRR: 80-100 PERCENT 
PERFORMS ACTIVITIES OF DAILY LIVING WITH NO ASSISTANCE) -
0.445(WAITLIST_YEAR) -0.673(ETHCAT: HISPANIC) -
0.694(PROJECTED_PAYMENTSOURCE_AT_REGISTRATION: SOME PRIVATE 
BY PRIMARY OR SECONDARY) -0.898(FUNC_STAT_TRR: NOT KNOWN) -
1.281(HIST_HYPERTENS_DON: Y) -1.876(DIAG_KI: GROUP_3†) -
2.234(TOT_SERUM_ALBUM) -2.381(ECD_DONOR: 1) -2.846(DIAG_KI: 
GROUP_5†) 
Table 3-4 continued 
Variable Coefficients P-values 
(INTERCEPT) 890.202 <0.01 
DIAL_TRR: Y 7.303 <0.01 
PERIP_VASC: Y 4.211 <0.01 
DIAB: YES 2.695 <0.01 
ON_EXPAND_DONOR: 1 2.106 <0.01 
ETHCAT: WHITE 1.667 <0.01 
DIAB: NOT KNOWN 1.429 <0.01 
ON_IEXPAND_DONOR: 1 1.410 <0.01 
PROJECTED_PAYMENTSOURCE_AT_RE
GISTRATION: MEDICARE 0.481 <0.01 
CREAT_TRR 0.463 <0.01 
AGE 0.070 <0.01 
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Table 3-4 continued 
WAITLISTDAYS 0.007 <0.01 
AGE_DON -0.071 <0.01 
REGION: 5 -0.151 0.08 
REGION: 3 -0.202 0.03 
FUNC_STAT_TRR: 80-100 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH NO ASSISTANCE 
-0.390 <0.01 
WAITLIST_YEAR -0.445 <0.01 
ETHCAT: HISPANIC -0.673 <0.01 
PROJECTED_PAYMENTSOURCE_AT_RE
GISTRATION: SOME PRIVATE BY 
PRIMARY OR SECONDARY 
-0.694 <0.01 
FUNC_STAT_TRR: NOT KNOWN -0.898 <0.01 
HIST_HYPERTENS_DON: Y -1.281 <0.01 
DIAG_KI: GROUP_3† -1.876 <0.01 
TOT_SERUM_ALBUM -2.234 <0.01 
ECD_DONOR: 1 -2.381 <0.01 
DIAG_KI: GROUP_5† -2.846 <0.01 
 
3.3.4 Results from patients who died while on the waitlist 
 Using Mwait and M'IRD, Table 3-5 depicts the percentage of patients who died on the 
waitlist, who had over a 50% predicted probability of surviving longer if they had received 
an IRD organ after waiting for 50%, 75% and 90% of the waiting time prior to death while 
on the waitlist. Table 3-5 shows that most of these patients were more likely to live longer 
if they had accepted an IRD organ offer.  
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Table 3-5: Percent patients who died on the waitlist, who would have a greater than 50% 
predicted probability of surviving longer if they had received an IRD kidney after waiting 
50%, 75%, and 90%, respectively, of their total time on the waitlist. 
Table 3-5 continued 
Hypothetical wait time (as a % of the actual time on 
the waitlist prior to death) before receiving an IRD 
organ 
50% 75% 90% 
Greater than 50% probability of surviving longer with 
IRD organ 99.2% 97.8% 96.4% 
 
3.4 Discussion 
 We found that in the majority of simulations, recipients had a higher probability 
of survival if they received an IRD kidney instead of if they remained on the waitlist to 
receive a non-IRD kidney after the average wait time (672 days). In over half of the 
simulations, patients had greater survival if they received an IRD kidney versus if they 
waited for only one day and received a non-IRD kidney. In practice, given the high 
uncertainty about wait times, the majority of transplant recipients may have a higher 
survival probability receiving the IRD kidney; in fact, it has been shown that among those 
patients who received an IRD kidney offer and declined, only 31.0% received a non-IRD 
kidney within 5 years (43). Our IRD, non-IRD, and waitlist models achieve strong 
performance compared to using the Estimated Post Transplant Survival (EPTS) model, the 
state of the art used in the U.S. kidney allocation system (4) when cross-validated on the 
same data.  
 While other studies have shown the advantages of increased utilization of IRD 
kidneys (20,42,43),  our study also quantifies the benefit compared to waiting for a non-
IRD kidney, at different wait times. To our knowledge, our study is the first to establish a 
d 
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simple equation that can be used to estimate the benefit of receiving an IRD kidney vs. 
waiting for a non-IRD kidney for different wait times and recipient/donor characteristics. 
Our study also differs from previous IRD comparison studies by using random survival 
forests (versus Cox proportional hazard models) with different variables for the waitlist 
and transplant survival models, using machine learning variable selection techniques. 
Using different variables for each model adds an advantage because variables that predict 
waitlist survival well, may not predict transplant survival well. We further train our survival 
model for IRD kidneys using only historical IRD transplants, instead of using observations 
from standard criteria donors given the risk profile of IRD kidneys (20). 
 One of the reasons why our study likely shows a benefit for IRD kidneys is that 
transmission of HIV or HCV through transplantation of IRD organs is rare (51). For 
example, it has been shown that the probability of undetected donor HIV given a negative 
nucleic acid testing (NAT) screening if the donor exhibited non-medical intravenous drug 
use (IVDU), one of the IRD donor criteria, one or more days before the NAT screening, is 
at most 0.92% (51). Other studies also show a low risk of disease transmission (52). 
Another reason why our simulations likely showed a benefit for receiving the IRD kidneys 
is that organs recovered from IRD donors are more likely to be from younger and healthier 
donors (2).   
 In recent years, treatment regimens for infectious diseases such as HBV, HCV, 
and HIV have improved (53-55). Hence our survival predictions for recipients of IRD 
kidneys may be conservative; beyond the time period of our data, the benefit of accepting 
an IRD organ may be even greater.   
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 In addition to survival probabilities, there are other factors that should be 
considered when deciding whether to receive an IRD organ, such as costs or the quality of 
life with a functioning organ. For example, the LYFT kidney transplant survival model 
used a factor of 0.8 to adjust for quality of life on dialysis as opposed to that with a 
functioning kidney (21). However our analysis provides strong evidence that utilization of 




CHAPTER 4. USING MACHINE LEARNING TO ESTIMATE 
SURVIVAL CURVES FOR PATIENTS RECEIVING AN 
INCREASED RISK FOR DISEASE TRANSMISSION HEART, 
LIVER, OR LUNG VERSUS WAITING FOR A STANDARD 
ORGAN 
   
4.1 Introduction 
 We now expand our survival comparisons in chapter 3, to the heart, liver and 
lung, using similar but different modeling techniques. For each organ, we computed the 
survival probability difference for receiving an IRD organ versus the alternative of waiting 
for a non-IRD organ, at different time points including the mean, half the mean, and one 
standard deviation above the mean wait time.  
 Minimal risk for IRD organs and similar survival rates to non-IRD organs have 
been reported for the heart (56,57), liver (58), and lung (59,60). Further, survival benefits 
have been reported for accepting IRD organ offers compared to declining them for the 
kidney (20) and liver (61). Yet, IRD organs continue to be underutilized compared to non-
IRD organs (44), and there has been reported fear of using them (39), indicating the need 
for more research to investigate and disseminate the potential advantages of their use. In 
2017, Volk et al., concluded that “The PHS ‘increased risk’ label appears to be associated 
with nonutilization of hundreds of organs per year” (44). 
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 To our knowledge, this is the first study to quantify the benefit of accepting an IRD 
heart, lung, or liver, in a simple equation that incorporates individual recipient and donor 
characteristics, i.e., for a specific patient-organ pair. Further, for the heart, liver, and lung, 
this study is the first to simulate thousands of different patient scenarios and compare 
survival probabilities for receiving an IRD organ versus waiting for a non-IRD organ for 
various wait times. 
4.2 Methods 
 For each of the three organs, we created three separate survival models for HCV-
negative recipients (i) MIRD: a patient receiving an IRD organ; (ii) Mnon-IRD: a patient 
receiving a non-IRD organ (after a certain wait time); and (iii) Mwait: a patient remaining 
on the transplant waitlist. Hence, we developed 9 survival models in total. For each organ, 
we then simulated 20,000 different scenarios based on common recipient-donor 
characteristics and compared the survival if the recipient received an IRD organ 
immediately or waited for a non-IRD organ. We used the simulation results to develop a 
linear regression model for each of the 3 organs, with each regression yielding a simple 
“benefit equation” to estimate the predicted difference in the 5-year survival probability of 
receiving an IRD organ versus waiting for a non-IRD organ, for a particular set of recipient-
donor characteristics. In addition, for patients who died on the waitlist, we estimated 
survival probabilities for the scenarios if they had received an IRD organ after waiting for 
50%, 75%, and 90% of the actual time they were on the waitlist prior to their death. 
 The computations were performed using the statistical software R version 3.3.2 
(29). Several key packages are listed in the references (24,31-35).  
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4.2.1 Data and data preparation 
 The data, a Standard Transplant Analysis and Research (STAR) file, was obtained 
from the United Network for Organ Sharing (UNOS) (14,15). This data can be accessed 
from https://optn.transplant.hrsa.gov/data/request-data/. The dataset contains records of 
transplants performed in the U.S. from 1987 to 2014. 
 For each organ, we used data from patients who entered the waitlist or received 
a single-organ transplant from the date of the first IRD transplant record in the dataset (June 
16, 2001 for heart and liver, and March 30, 2004 for lung) until August 26, 2013 when the 
IRD guidelines were updated. Given the many common aspects of the 1994 and 2013 
guidelines (2), we considered the 1994 guidelines, because at the time of this study we did 
not have more than 5 years of survival data from transplant records after the announcement 
of the 2013 guidelines. When building and testing the predictive models, transplants from 
donors who tested positive for HCV antibody, HCV RNA, or HCV RIBA status were 
removed, because the risks of bloodborne viral transmission are different for this 
population. Further, only HCV negative transplant recipients were considered when 
building and testing the predictive models. 
 For each organ, we removed variables if they had more than 5% missing data, 
unless they had been identified as important predictors for recipient survival for that organ 
in several previous studies (46,62-76). In the latter case, we removed an “important” 
variable if it had more than 20% missing data. To predict the values of missing data for the 
variables included in the model, we used predictive mean matching imputation for 
numerical variables, Bayesian logistic regression for categorical variables with 2 
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categories, and multinomial Bayesian regression for categorical variables with more than 
2 categories (48). We did not use data imputation for recipient HCV status or for donor 
IRD status (the proportions of missing data for these variables were 10% and 23% for the 
heart, 11% and 26% for the liver, and 10% and 1% for the lung, respectively); we removed 
the corresponding observations with missing values when building the models. We also 
did not use imputation for donor HCV antibody, HCV RNA, or HCV RIBA status (which 
had over 95% missing data for each organ); however, we did not remove the observations 
with missing values and instead, removed donors who tested positive. Imputing HCV status 
could be misleading because we could not find variables in our dataset that can be used to 
impute it accurately. 
 One of the variables, patient diagnosis, contained a large number of categories 
(greater than 30 for each organ). Hence we grouped the values for these categories into 5 
larger groups, by combining categories with similar transplant survival after controlling for 
other factors (Table C-1). 
 We considered an observation as censored in our transplant survival models 
(MIRD and Mnon-IRD) if the transplant record does not have an exact time of death after 
surgery and instead has the last known follow-up time for which the patient was alive. We 
considered an observation as censored in our waitlist survival models (Mwait) if a patient 
was still waiting at the last recorded follow-up time, or was removed from the waitlist for 
any reason other than death. Observations without a censored status or follow-up/death 
time were removed from the analysis. Table 4-1 shows the number of observations, 
variables, observations with missing data, and censored observations for the data we used 
to build the three models for each organ. 
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Table 4-1: Data used in the analysis. For each organ, we used data from patients who 
entered the waitlist or received a single-organ transplant from the date of the first IRD 
transplant record in the dataset (June 16, 2001 for heart and liver, and March 30, 2004 for 
lung) until August 26, 2013 when the IRD guidelines were updated. When building and 
testing the predictive models, transplants from donors who tested positive for HCV 
antibody, HCV RNA, or HCV RIBA status were removed, and for patients that received 
a transplant, only HCV negative recipients where considered. *We used a random sample 
of 100,000 observations to train our predictive model for scenarios where the number of 
observations exceeded 100,000. The percent of missing data for each scenario was 
calculated in the following way: let n be the number of transplant records in the scenario, 
k be the number of variables used in the predictive model (including censored status and 
follow-up/death time), and m be the total number of missing values for all variables. The 
percent of missing data is m/nk. 
Table 4-1 continued 






MIRD IRD 1578 0.7% 79.8% 128 
Mnon-IRD Non-IRD 16346 2.7% 78.5% 30 
Mwait Waitlist 38388 0.8% 88.4% 26 
Liver 
MIRD IRD  1980 0.6% 82.5% 125 
Mnon-IRD Non-IRD 24952 1% 81.3% 30 
Mwait Waitlist 124679* 0.6% 85.4% 26 
Lung MIRD IRD 1010 0.5% 62.7% 123 
d 
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Table 4-1 continued 





Mnon-IRD Non-IRD 12013 0.4% 60.4% 28 
Mwait Waitlist 19217 0.6% 89.6% 29 
 
4.2.2 Selecting variables for survival models 
 We selected the variables to use in each of our nine models except for the lung 
IRD model, by taking the intersection of the top 10 variables chosen by permutation 
importance using random survival forests (22,49) and the variables corresponding to the 
non-zero coefficients of a Cox-Lasso model (77). For the lung IRD model, we took the 
intersection of the top 5 variables (instead of the top 10) chosen by permutation importance 
and the non-zero coefficients of a Cox-Lasso model, because the lung had a small number 
of IRD observations. Using too many variables may overfit the model. Harrell’s 
concordance index was used to calculate the difference in error rates before and after in the 
permutation importance calculation (3). Imputation was used to predict the values of 
missing data prior to variable selection. Imputation was then performed again using only 
the variables selected when training the predictive models. The response variable (survival 
time and censored status), was not used when performing imputation in the out-of-sample 
data when cross-validating our models. 
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 For MIRD and Mnon-IRD for all organ types, we added the variables, recipient 
functional status at transplantation and recipient age (if it was not already selected by the 
variable selection methods), to control for differences in the population who received IRD 
transplants vs. those who received non-IRD transplants. The functional status takes on 
values ranging from 0 to 100 in increments and gives information on a patient’s ability to 
perform daily tasks and the amount of assistance they need. Because Mwait and Mnon-IRD are 
used to predict the survival if a patient chooses to wait for a non-IRD organ, we only 
considered the variables that are known at waitlist registration (for example, there is no 
donor variable in Mwait) in these models. For Mnon-IRD, after using our variable selection 
method, we added a variable to indicate the time that a patient was on the waitlist because 
the estimated wait time is an input in our simulation. This variable helps take into account 
how the health status and variable values of the patient may have changed between 
registration and transplantation. 
 Table 4-2 shows the variables selected for each of the nine models. Table C-2 
gives a description of the variables used in the predictive models, and Table C-3 shows the 
variables with the top 10 permutation importance measures that were also selected by 
Lasso. Table C-4, Table C-5, and Table C-6 give a summary of the variables used in the 
predictive models for the heart, liver and lung respectively. 
 
Table 4-2: Variables used in the predictive models. See Table C-2 for a description of the 
variables. 
Table 4-2 continued 
Organ MIRD Mnon-IRD Mwait 
d 
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Table 4-2 continued 
Heart 
AGE CIG_USE ECMO_TCR 
AGE_DON DAYSWAIT_CHRON FUNC_STAT_TCR 
CREAT_TRR ETHCAT HGT_CM_TCR 
DEATH_MECH_DO
N FUNC_STAT_TCR INIT_AGE 
DIAG INIT_AGE INIT_STAT 
FUNC_STAT_TRR MOST_RCNT_CREAT INOTROPES_TCR 








_AT_TRANSPLANT THORACIC_DGN VAD_DEVICE_TY_TCR 
TRANSFUSIONS TOT_SERUM_ALBUM VENTILATOR_TCR 
 WAITLIST_YEAR WAITLIST_YEAR 
Liver 
AGE DAYSWAIT_CHRON EXC_HCC 
ASCITES_TX DGN_TCR FUNC_STAT_TCR 
BMI_CALC DIAB INIT_AGE 
FINAL_DIALYSIS_
PRIOR_WEEK FUNC_STAT_TCR INIT_ALBUMIN 





LIFE_SUP_TRR INIT_SERUM_CREAT INIT_SERUM_CREAT 
MED_COND_TRR NUM_PREV_TX INIT_STAT 






  WAITLIST_YEAR 
Lung 
AGE DAYSWAIT_CHRON CIG_USE 
DIAG FUNC_STAT_TCR FUNC_STAT_TCR 
FUNC_STAT_TRR GROUPING GROUPING 
GROUPING INIT_AGE INIT_AGE 
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Table 4-2 continued 
HGT_CM_DON_CA
LC INIT_BLU_FLG INIT_O2 






 REGION THORACIC_DGN 
 THORACIC_DGN WAITLIST_YEAR 
 
4.2.3 Building survival models 
 MIRD and Mnon-IRD predict the post-transplant survival and Mwait  predicts the 
waitlist survival probabilities (for up to 5 years in our computations). We compared the 
predictive performance of the Cox proportional hazard model (11) to random survival 
forests with conditional inference trees as base learners (24,30,49) based on Harrell’s 
concordance index. We used random forest parameters for the construction of unbiased 
random forests (25). The random survival forest models each used 500 trees, and each 
decision tree only allowed a split to occur if the split statistic exceeded 0.25. The Cox 
model performed better or the same across all scenarios except for MIRD for the heart (in 
which the Harrell’s concordance index was 0.005 lower in the Cox model). Hence we built 
MIRD, Mnon-IRD and Mwait using the Cox model. 
 For each organ, MIRD and Mnon-IRD were trained on all HCV negative transplant 
recipients who received that organ from an IRD donor and a non-IRD donor, respectively. 
For each organ, Mwait was first trained on all waitlist patients for that organ, and some of 
those patients may be HCV positive. Note that HCV status of patients was not recorded in 
our data at waitlist registration (it was recorded at the time of transplantation). In general, 
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it is expected that the average difference of the survival probability of an HCV negative 
versus an HCV positive recipient with the same characteristics (if they had received the 
same organ) would be positive. Let us denote the post-transplant survival probability 
difference t days after transplantation between HCV negative recipients, and all recipients 
(which includes both HCV positive and negative recipients) by ∆t. To estimate the waitlist 
survival for HCV negative patients, we added ∆t to Mwait at each time point, from the 
estimated waitlist survival model trained on all patients.  
 The random survival forests models were implemented using the ‘cforest’ 
function of the R package ‘party’ (24,30) and the cox model was implemented using the 
‘coxph’ function in the ‘survival’ package (33). The following parameters were used in the 
‘cforest’ function: mtry=ceiling(sqrt([number of variables in model])), ntree = 500, teststat 
= 'quad', testtype = 'Univ', mincriterion = .25, replace = FALSE, fraction = min(0.632,  
40000/[training data size]). 
4.2.4 Simulations 
 For each organ, we generated 20,000 random samples of the following 
combinations of all variable values used in the predictive models: sampling with 
replacement from the data (from the general population, without excluding IRD donors and 
HCV positive recipients or donors; see Table C-4, Table C-5, and Table C-6 for the 
distributions of the general transplant populations for the heart, liver, and lung 
respectively.) for each numeric variable; and up to the top 3 most-common categories for 
categorical variables where the probability of sampling each category was proportional to 
the data. For each recipient, we chose a random waiting time based on the wait time data 
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for each organ: either 1 day, half the mean, the mean (191, 249, 227 days for the heart, 
liver and lung respectively), or one standard deviation (348, 468, 406 days for the heart, 
liver and lung respectively) above the mean. For variables recorded both at transplantation 
and at waitlist registration, we used the mean and standard deviation of the values recorded 
at transplantation. These scenarios represent common characteristics of recipient-donor 
combinations for the four different wait times. 
 Using the predictive models MIRD, Mwait, and Mnon-IRD, for each recipient we 
compared the survival probabilities of receiving an IRD organ (MIRD) to waiting and 
receiving a non-IRD organ (Mwait followed by Mnon-IRD).  
4.2.5 Benefit equation 
 For each scenario in the simulation, we calculated the difference between the 
predicted probability of surviving 5 years after waiting and receiving the non-IRD organ, 
and the predicted probability of surviving 5 years after receiving the IRD organ 
immediately. For each of the three organs, we then used a linear regression to estimate the 
benefit (increase or decrease in 5-year survival probability) from receiving an IRD organ 
compared to waiting for a non-IRD organ for each recipient-donor pair. We call this model 
the benefit equation. We multiply the predictions from the equation by 100 so that the 
values are on a scale of -100 to 100. The values from the equation predict the increase (or 
decrease) in survival probability, multiplied by 100 to be on a scale of -100 to 100, for 
receiving an IRD organ vs. waiting for a non-IRD organ for a particular set of recipient and 
donor characteristics and wait times. 
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 The coefficients of the linear regression can be interpreted as follows: for numerical 
variables, a variable’s coefficient is the recipient’s percentage increase/decrease in 5-year 
survival when receiving the IRD organ compared to waiting for a non-IRD organ, for every 
one-unit increase in the value of the variable, holding the rest of the variables constant; for 
a binary categorical variable, the coefficient is the recipient’s percentage increase/decrease 
in 5-year survival when receiving the IRD organ vs. waiting for a non-IRD organ, for being 
in that category (corresponding to the coefficient) compared to not being in that category, 
holding the rest of the variables constant. For each organ, we tested the performance of the 
benefit equation using 10 random samples of 80% training data and 20% out-of-sample 
data and compared our equation’s predicted benefit with the results of the simulations. 
4.2.6 Predicted IRD transplant survival for recipients who died on the waitlist 
 For each organ, we calculated the predicted survival of patients (in our data) who 
died on the waitlist, if they had instead received an IRD organ with average donor 
characteristics after waiting for one of three possible wait times: 50%, 75% or 90% of the 
time that they remained on the waitlist before they died. We first used Mwait to compute 
their survival probabilities on the waitlist. We then used M'IRD, a modification of MIRD to 
compute their survival probabilities receiving an IRD organ. In M'IRD, for all variables 
recorded both at transplant and at waitlist registration, we used the variable at registration 
and we added a variable to indicate the amount of time the patient waited on the waitlist to 
account for changes in the patient’s characteristics and health status between waitlist 
registration and transplant. We set the value for variables that were only known at 
transplantation to be the average in our data, because this information was not known yet 
for the patients on the waitlist. For each organ, these averages were calculated using IRD 
transplants for that particular organ. Imputation was used to predict the missing values for 
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the variables with partially missing information. M'IRD was trained on 1760 observations 
with 0.7% missing data and 79.4% censored observations for the heart, 4029 observations 
with 6.4% missing data and 78.5% censored data for the liver and 1126 observations with 
0.4% missing data and 62.3% censored data for the lung. When training the model for 
M'IRD, we did not exclude HCV negative recipients because the patients who died on the 
waitlist included both HCV positive and negative recipients. We also did not shift their 
survival to adjust it to the HCV negative population when using Mwait.. 
4.3 Results 
 Table C-7 shows the performance of each of the nine models based on ten cross 
validation samples with 80% training data and 20% out-of-sample data. It also shows the 
comparison of the predictive models using both the Cox proportional hazards model and 
the random survival forests model. 
4.3.1 Survival curves 
 Figure 4-1 shows example survival probabilities from our models. In general, for 
average wait times and characteristics, the survival probabilities are higher for recipients 







Figure 4-1: Survival probability curve of recipients receiving an IRD organ (in blue) and 
recipients waiting for a non-IRD organ (in black and red) by organ for the heart, liver and 
lung. The predicted survival curves are for a patient who has characteristics of the 
average numerical variables, and the most common categorical variables used in the 
predictive models for each scenario. The mean waiting times are 191, 249, and 227 days 
for the heart, liver, and lung, respectively. Before transplantation with a non-IRD organ, 
the survival curve represents the waitlist survival (in black). After transplantation with a 
non-IRD organ, the survival curve then becomes the curve for patients who have received 
a non-IRD organ (in red). 
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4.3.2  Simulations results 
 Table 4-3 shows that for all three organs, the majority of scenarios have a higher 
predicted 5-year survival if a recipient accepts the IRD organ offer versus waits and 
receives a non-IRD organ, with the difference in survival probabilities being 11.56% for 
hearts, 13.2% for livers, and 8.92% for lungs, respectively, for average organ waitlist times 
(191 days for the heart, 249 days for the liver, and 227 days for the lung). The percentage 
of simulations with a higher survival probability was 84.72% for hearts, 85.91% for livers, 
and 75.33% for lungs. Longer estimated wait times lead to a greater positive difference in 
survival probabilities for patients accepting IRD organ offers. Figure 4-2 shows the 
survival probabilities for IRD organ recipients at time points other than 5-years. 
 
Table 4-3: Percent of simulations with higher 5-year survival probability of receiving an 
IRD organ versus waiting for a non-IRD organ; and the predicted 5-year survival 
probability for receiving an IRD organ minus the 5-year predicted survival probability of 
waiting for a non-IRD organ. 
Table 4-3 continued 
Organ Days on Waitlist 
Percent of simulations 
with higher 5-year 
survival probability of 
receiving an IRD 
organ versus waiting 
for a non-IRD organ 
Predicted 5-year survival 
probability of receiving an 
IRD organ minus the 5-year 
predicted survival 
probability of waiting for a 
non-IRD organ, averaged 
over all scenarios 
Heart 
1 55.04% 0.48% 
95 (1/2 
mean) 78.14% 7.99% 
191 (mean) 84.72% 11.56% 
539 (1 SD 
above mean) 90.43% 17.82% 
Liver 1 55.98% 1.33% 
d 
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Table 4-3 continued 
Organ Days on Waitlist 
Percent of simulations 
with higher 5-year 
survival probability of 
receiving an IRD 
organ versus waiting 
for a non-IRD organ 
Predicted 5-year survival 
probability of receiving an 
IRD organ minus the 5-year 
predicted survival 
probability of waiting for a 
non-IRD organ, averaged 
over all scenarios 
124 81.53% 9.18% 
249 85.91% 13.2% 
717 88.19% 21.08% 
Lung 
1 57.72% 1.15% 
114 71.69% 6.5% 
227 75.33% 8.92% 








Figure 4-2: Simulation results from Table 4-3 at different time points. On the left: percent 
of simulations with a higher 5-year survival probability of receiving an IRD organ than 
waiting for a non-IRD organ at different time points after the decision, with the average 
wait time for each organ (191 days for the heart, 249 days for the liver, and 227 days for 
the lung); on the right: the predicted survival probabilities for receiving an IRD organ 
subtracted by the predicted survival probabilities for waiting for a non-IRD organ with 
the average wait time on the waitlist, averaged over all simulations, for different time 
points after the decision. 
 



















































































































































































































































 Table 4-4 shows the benefit equation built from the simulation results for each 
organ. Table C-8 shows an example use of the benefit equation for each organ. Table C-9 
shows the results of the linear regression used to construct the benefit equation. The root 
mean square error (RMSE) of testing the benefit equations on the simulation results 
(comparing our equations’ predicted benefit with the results of the simulations) are 5.1, 
8.7, and 5.6 for the heart, liver, and lung respectively (in comparison, the RMSE using 
random guessing from a normal distribution with the mean and standard deviation from 
the results of the simulation is 20.2, 22.7, and 21.4  respectively). 
 
Table 4-4: Benefit equations for the 5-year survival probability of receiving an IRD organ 
minus the 5-year survival probability of waiting for a non-IRD organ. The benefit 
equations predict the increase (positive value) or decrease (negative value) in probability 
(multiplied by 100) of surviving to 5 years with an IRD organ vs. waiting for a non-IRD 
organ. See Table C-8 for an example usage of the benefit equations and Table C-9 for the 
p-values and reference levels for the linear regression used to construct the equation. 
*See Table C-1 for categories in this group. 
Table 4-4 continued 
Organ Benefit equations 
Heart 
2275.823 +  
10.85(ECMO_TCR: 1) +  
8.949(PAYMENTSOURCE_AT_TRANSPLANT: SOME 
PRIVATE BY PRIMARY OR SECONDARY) +  
8.203(FUNC_STAT_TRR: NOT APPLICABLE (PATIENT < 1 
YEAR OLD)) + 7.824(DIAG: GROUP_4*) +  
7.492(INSULIN_DON: Y) + 
5.125(PAYMENTSOURCE_AT_TRANSPLANT: MEDICARE) +  
4.623(VAD_DEVICE_TY_TCR: LVAD/RVAD/TAH 
UNSPECIFIED) + 4.501(MOST_RCNT_CREAT) +  
4.469(PRIOR_CARD_SURG_TCR: Y) + 
4.1(VENTILATOR_TCR: 1) +  
2.422(VAD_DEVICE_TY_TCR: NONE) +  
1.992(CIG_USE: Y) +  
0.772(LIFE_SUP: Y) +  




Table 4-4 continued 




1.299(DEATH_MECH_DON: STAB OR GUNSHOT WOUND) – 
1.964(FUNC_STAT_TRR: 60-70 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH SOME ASSISTANCE) - 
2.334(TOT_SERUM_ALBUM) -2.862(DIAG: GROUP_3*) – 
2.914(DEATH_MECH_DON: INTRACRANIAL 
HEMORRHAGE/STROKE) – 
3.424(INIT_STAT: HR: STATUS 1B) – 
5.324(TRANSFUSIONS: Y) – 
5.508(CREAT_TRR) – 
5.688(INIT_STAT: HR: STATUS 2) – 
6.45(ETHCAT: HISPANIC) – 
6.629(ETHCAT: WHITE) 
Liver 
1024.296 +  
14.262(INIT_STAT: >= 25) +  
10.852(EXC_HCC: NON-HCC) +  
9.019(FINAL_DIALYSIS_PRIOR_WEEK: N) +  
7.795(DGN_TCR: GROUP_4*) +  
6.131(FINAL_DIALYSIS_PRIOR_WEEK: Y) +  
5.147(NUM_PREV_TX) + 4.976(VENTILATOR_TCR: 1) +  
4.442(DGN_TCR: GROUP_3*) +  
3.207(DIAB: YES) +  
2.877(PREV_AB_SURG_TCR: Y) +  
1.724(INIT_MELD_OR_PELD: PELD) +  
1.691(INIT_STAT: 18-11) +  
1.521(INIT_SERUM_CREAT) +  
0.619(LIFE_SUP_TRR: Y) +  
0.412(INIT_INR) +  
0.392(INIT_BILIRUBIN) +  





1.525(DIAB: NOT KNOWN) -
1.677(PROJECTED_PAYMENTSOURCE_AT_REGISTRATION: 
MEDICARE) – 
2.198(FUNC_STAT_TRR: 60-70 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH SOME ASSISTANCE) -
2.324(ASCITES_TX: SLIGHT) – 
2.616(MED_COND_TRR: NOT HOSPITALIZED) – 
3.864(MED_COND_TRR: IN INTENSIVE CARE UNIT) – 
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Table 4-4 continued 
3.964(ON_VENT_TRR: 1) – 
4.201(PROJECTED_PAYMENTSOURCE_AT_REGISTRATION: 
SOME PRIVATE BY PRIMARY OR SECONDARY) – 
4.612(INIT_ALBUMIN) – 
5.079(FUNC_STAT_TRR: 80-100 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH NO ASSISTANCE) – 
8.173(ASCITES_TX: MODERATE) 
Lung 1601.523 +  
17(GROUPING: C) +  
5.642(GROUPING: D) +  
3.707(DIAG: GROUP_4*) +  
1.708(INIT_O2) +  
1.674(REGION: 4) +  




1.59(FUNC_STAT_TRR: 60-70 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH SOME ASSISTANCE) - 
1.687(FUNC_STAT_TRR: 80-100 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH NO ASSISTANCE) – 
1.995(CIG_USE: Y) – 
2.099(PROJECTED_PAYMENTSOURCE_AT_REGISTRATION: 
MEDICARE) – 
2.436(INIT_RLU_FLG: 1) – 
4.904(REGION: 5) – 
6.337(INIT_BLU_FLG: 1) – 
7.477(PROJECTED_PAYMENTSOURCE_AT_REGISTRATION: 
SOME PRIVATE BY PRIMARY OR SECONDARY) -
15.121(DIAG: GROUP_3*) – 
15.214(HIST_CIG_DON: Y) 
 
4.3.4 Patients who died while on the waitlist 
 For a patient p who died on the waitlist, let Wp denote the number of days the 
patient remained on the waitlist until death. Our models predict that over 97% of the 
patients who died on the waitlist were predicted live longer if each patient p received an 
IRD organ after waiting for Wp/2 days (Table 4-5). For those 97% of patients, if they had 
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received an IRD organ, the post-transplant survival probability would be >50% after Wp 
days. Table 4-5 also shows the percent of patients that were predicted to live longer if they 
had received an IRD organ after a wait time of 0.75Wp and 0.9Wp days.   
 
Table 4-5: Percent of potential recipients who died on the waitlist, with a greater than 
50% predicted probability of surviving longer if they had received an IRD organ. The 
results of the table are shown by organ type and by days on waiting list, after waiting 
50%, 75% and 90% of the waiting time that they actual died on the waitlist. 
Table 4-5 continued 
Hypothetical days on waitlist until receiving IRD 
organ as a percentage of the time the patient 
actual died on the waitlist. 
50% 75% 90% 
Greater than 50% probability of surviving longer 
with IRD heart 98.9% 98.4% 98.1% 
Greater than 50% probability of surviving longer 
with IRD liver 97.5% 96.3% 95.8% 
Greater than 50% probability of surviving longer 
with IRD lung 98.1% 97.8% 97.9% 
 
4.4 Discussion 
 For all three organs, the majority of simulated patients had a higher predicted 
survival accepting an IRD organ offer compared to waiting for a non-IRD organ with 
average wait times. These simulated scenarios represent typical recipient and donor 
characteristics. For the heart, liver and lung, the simulation had, on average, higher 5-year 
survival probabilities receiving an IRD organ versus waiting for one day and receiving a 
non-IRD organ (within 1.33%). As estimated wait times increase, the difference also 
increases, suggesting that patients who are likely to wait for longer times would benefit 
more from receiving an IRD organ (versus waiting and receiving a non-IRD organ later). 
d 
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For any of the three organs, an estimated increase (or decrease) in 5-year survival 
probability for receiving an IRD organ for a particular set of recipient and donor 
characteristics, and particular wait time, can be quickly found using the benefit equations. 
 For the heart, liver and lung, previous studies compared the survival of IRD 
organs to non-IRD organs using a retrospective analysis that divided the population into 
two groups. While a large scale simulation, where comparisons were made for thousands 
of scenarios, was conducted for the kidney (20), to our knowledge, this has not been 
performed for the heart, liver and lung.  
 Further, to our knowledge, this is the first study to develop a simple equation that 
estimates the difference in the survival probabilities for receiving an IRD organ versus 
waiting and receiving a non-IRD organ (heart, liver, or lung) for a given recipient-donor 
pair.  
 There are several reasons behind the benefits of receiving an IRD organ. The risk 
of undetected infection resulting in transmission is very small. The estimated risk of 
undetected HIV infection by serologic screening among IRD donors was found to be 
1/11,000 for HIV and 1/1,000 for HCV (78). According to the same study, NAT screening 
was projected to have even lower undetected risks. In addition, advances in treatment for 
HIV and HCV have resulted in improved mortality (79,80). Another reason why our 
simulations likely showed a benefit for receiving the IRD organs is that organs recovered 
from IRD donors are more likely to be from younger and healthier donors (2). 
 A limitation of our analysis is that our simulations cannot estimate whether there 
are survival probability increases (or decreases) for receiving IRD organs beyond a 5-year 
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horizon.  As the post-transplant time horizon increases, the number of patients with 
available survival data decreases. It is possible that receiving an IRD organ for a particular 
scenario may result in a higher 5-year survival probability, but waiting for a non-IRD organ 
may result in a higher survival probability many years later, although this appears unlikely 
given advances in HIV and HCV treatment (79,80).  
 Another limitation is that we have a relatively small sample size of data from IRD 
heart, liver, and lung transplants (e.g., compared to kidney transplants). However, we still 
have over 1,000 observations for IRD transplants for each organ, and by conducting 20,000 
simulations of recipient/donor scenarios for each organ, we were able to predict and assess 
the survival benefits for significantly more scenarios; hence, our study complements other 
studies that focus on retrospective data analysis. Third, because treatment for HIV and 
HCV has improved, our models, which use data prior to 2013, are likely to be 
“conservative,” i.e., under-estimate the survival probabilities for IRD organ recipients. 
With current advances in HIV and HCV treatments, we expect that the survival benefits 
for receiving IRD organs would be even higher. 
 While a comparison of survival probabilities between IRD and non-IRD organs 
is important, there are other factors to take into account when deciding whether to receive 
an IRD organ such as cost and quality of life. The quality of life for a patient on the waitlist 
is likely lower compared to a recipient with a functioning transplant (21). Patients and 
physicians might overestimate the risks of receiving an IRD organ and better tools for 
accurately discussing the risks during informed consent are needed (38,44,81). This study’s 
comparison between receiving an IRD heart, liver, and lung and waiting for a non-IRD 
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organ can help physicians, patients, and researchers assess whether to accept or decline an 
IRD organ.  
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CHAPTER 5. PREDICTING A PATIENT’S FUNCTIONAL 
STATUS AT KIDNEY TRANSPLANTATION BASED ON 
INFORMATION AT WAITLIST REGISTRATION  
5.1 Introduction 
 In 2016, the number of patients on the kidney transplant waiting list exceeded 
100,000, roughly double the number in 2002 (5,82). With median waiting times exceeding 
3.6 years based on patients that entered the waitlist in 2009 (5), it is important to understand 
how the functional status of a patient changes during the potentially long time period 
between waitlist registration and transplantation. A patient’s pre-transplant functional 
status is an important predictor of post-transplant survival for the kidney (6,83,84) and 
other organs (85,86). Functional status has also been shown to predict the likelihood of 
receiving a kidney (87) and survival in chronic kidney disease (88). Understanding 
potential changes in functional status while on the waitlist is also important while deciding 
whether to accept a deceased donor organ offer or remain on the waitlist. We built a 
machine learning model to predict the functional status of a patient at transplantation, given 
information known about the patient at waitlist registration. 
 We identified important predictive variables and provided a comparison of the 
predictive performance for different models. 
5.2 Methods 
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 We first cleaned and prepared the data, and then performed variable selection to 
determine variables that are predictive of functional status at transplantation based on 
information known at waitlist registration . We then applied machine learning and a variety 
of statistical methods to build a model that predicts a patient’s functional status at 
transplantation. The analysis was performed using R 3.3.2 (29).  
5.2.1 Data and data preparation 
 The dataset, a Standard Transplant Analysis and Research (STAR) file, was 
obtained from the United Network for Organ Sharing (UNOS) (14,15). The data can be 
accessed from https://optn.transplant.hrsa.gov/data/request-data/. The data contains 
records for transplants performed in the U.S from October 1, 1987 to March 31, 2014, with 
658,697 patients waitlisted for a kidney transplant.  
 We used all records where a patient was originally registered and listed for, and 
eventually received a kidney transplant. We did not consider transplant records if (i) the 
patient’s functional status at transplantation was missing or not known; or (ii) the functional 
status at either registration or transplantation was considered “not applicable.” After data 
cleaning, the resulting dataset contained 273,205 transplant records. 
 Variables with more than 25% missing data were removed from the analysis, 
unless they were found to be predictive variables of waitlist or transplant survival based on 
several previous research articles (20,21,45-47). In the latter case, variables were removed 
if they had over 50% missing data. Variables not known until after the waitlist registration 
and variables that stopped being recorded in 2014, were also removed from the analysis. 
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Table D-1 contains a description of the variables considered in the analysis and Table D-2 
provides summary statistics of the variables. 
 To deal with missing data, we used predictive mean matching multiple 
imputation for non-categorical variables, Bayesian logistic regression for binary 
categorical variables, and Bayesian multinomial regression for categorical variables with 
more than two categories (48) prior to variable selection. After variable selection, we used 
missing value imputation by chained random forests (89) with only the variables selected 
for our predictive models, when building and cross-validating the predictive models. When 
using imputation for the out-of-sample observations, we did not include functional status 
at transplantation to impute missing values for the other variables, because functional status 
at transplantation will not be known for new data we want to predict. 
 The patient’s functional status is measured using the Karnofsky Performance 
Score (KPS) and takes on values ranging from 0-100 in increments of 10 (6,7). It is 
recorded both at the time of registration and transplantation (“FUNC_STAT_TCR” and 
“FUNC_STAT_TRR”, respectively, in the dataset). The functional status is based on a 
patient’s ability to perform daily tasks and the amount of assistance they need. For 
example, the scores range from “10% - Moribund, fatal processes progressing rapidly”, to 
“100% - Normal, no complaints, no evidence of disease’, with values in the middle range 
such as “50% - Requires considerable assistance and frequent medical care”. During data 
preparation, we grouped multiple categories for the same increment of 10 into one group. 
For example, “100% - Normal, no complaints, no evidence of disease” and “100% - Fully 
active, normal” were both grouped into the group “100”. In addition, three of the original 
categories did not correspond to a numerical score in the data and only had a description; 
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hence, we grouped them into the most-similar category we could identify based on the 
descriptions. Table D-3 lists the original categories for the variables and the resulting 
grouped categories after data preparation.  
 Figure 5-1 illustrates the distribution of functional status values at registration 
and at transplantation. We find that for 66% of the patients, the functional status remains 
the same between registration and transplantation. The functional status decreases for 22% 
of the patients and increases for 13% of the patients from registration to transplantation 
(see Figure 5-2). Figure 5-3 shows the distribution of functional status at transplantation 
based on the status at registration. It illustrates how on average, patients with a functional 
status at registration above 80 have a lower functional status at transplantation, while 





Figure 5-1: Distribution of functional status recorded at registration and at transplantation 




Figure 5-2: Distribution in change of functional status from registration to transplantation 






Figure 5-3: Distribution of functional status at transplantation by functional status at 
registration. 
 
Table 5-1: Study inclusion/exclusion criteria 
Table 5-1 continued 
Inclusion/exclusion criteria Years of data (transplant date) 
Number of 
observations 
Patients who received a kidney 
transplant with a recorded 
functional status at transplantation. 
Patients who were not originally 
listed to receive a kidney or 
patients who received a kidney-
pancreas transplant were removed 
October 1, 1987 to 
March 31, 2014 273,205 
 
 
5.2.2 Selecting variables for the predictive models 
d 
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 We utilized three different variable selection methods, namely, (i) group Lasso 
(90), (ii) permutation importance from random forests (PIRF) (91) focusing on the top 10 
variables, and (iii) Multivariate Adaptive Regression Splines (MARS) (92). When using 
group lasso, we grouped all binary variables for a particular categorical variable into the 
same group. These methods identified three sets of variables as candidates for the 
predictive model. 
 To consider interaction effects between variables, we applied two additional 
variable selection approaches: (iv) we used the joint-VIMP approach to identify interaction 
effects by focusing on the top 15 variables chosen by PIRF (22). We then constructed this 
fourth set of variables by including the top 5 interaction effects (ranked by the absolute 
difference between their paired importance and their sum of individual variable importance 
measures) and the top 10 variables chosen by PIRF. (v) We applied MARS with all the 
variables originally selected by MARS and their pairwise interactions.  
 We refer to our five sets of variables sets as (i) Lasso, (ii) PIRF 10, (iii) MARS, 
(iv) PIRF interactions, and (v) MARS interactions. 
5.2.3 Building predictive models 
 The predictive models we compared are: linear regression, linear regression with 
a Box-Cox transformation (93), a generalized additive model with penalized cubic 
regression splines, and a Gaussian link function (94,95), random forests (91), gradient 
boosting with regression trees (96), support vector machines (97), and feed-forward neural 
networks with a single hidden layer (98). For each of the five sets of variables chosen by 
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the variable selection methods, we tested the performance of our predictive models using 
20 cross-validation samples of 80% training data and 20% out-of-sample observations. 
 In the generalized additive model with interactions, we used the tensor product 
for pairs of variables selected by the interaction variable importance methods. In addition 
to approaching the problem from a regression framework, we also used a model from a 
classification framework, and used gradient boosting with a softmax (99) objective 
function, where each increment of ten on the functional status scale was treated as a 
separate class.  
When implementing support vector machines and neural networks, we normalized 
the data as suggested by Graf et al. (100), and LeCun et al. (101). We used Z-score 
normalization, where the means and standard deviations for each variable in both the in-
sample and out-of-sample data were taken from the training data set. For the random 
forests, gradient boosting, support vector machines and neural network models, we used 
cross-validation on the training data to select hyper-parameters for the models using a grid 
search. We rounded the resulting predictions for all the models to the nearest 10 to be on 
the same scale as the true functional status values, which are recorded in increments in 10.  
We also built a stacking model that combined the predictions of the generalized 
additive model, gradient boosting, support vector machines, and neural networks model. 
When building the stacking model, for each cross-validation, we split our data into 3 sets: 
A training set consisting of 64% of the data, a validation set consisting of 16% of the data 
(obtained by splitting our original training set into two sets of 80% and 20% portions), and 
a testing set consisting of 20% of the data. We trained the 4 models on the training set and 
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made predictions on the validation set. We then ran a linear regression, where we regressed 
the functional status at transplantation in the validation set, on the predictions from each of 
the 4 models on the validation set. The coefficients resulting from the linear regression for 
each prediction gave weights to the predictions from each model. Using these weights, we 
then made predictions on the testing data and combined them into one final predicted value. 
To speed up the computations of running all the cross-validations for each model, 
we trained some of the models on smaller random samples of the training data. We tuned 
(performed cross-validation on the training data to select hyper-parameters) the gradient 
boosting with softmax, support vector machines, and neural network models on 50,000, 
100,000 and 100,000 observations, respectively; we trained these models on 100,000, 
100,000 and 150,000 observations without interactions and 100,000, observations when 
using interactions. In addition, we trained the generalized additive model with 100,000 
observations when using interactions. 
For each cross-validation sample, we used the following metrics to assess 
predictive accuracy: (i) RMSE: root mean squared error, (ii) MSE: mean squared error, 
(iii) σ MSE: the standard deviation of MSE for the ten cross-validation samples. (iv) A10: 
if the true value is X, the percent of predictions that are within (X-10 to X+10 inclusive) 
and (v) A20: if the true value is X, the percent of predictions that are within (X-20 to X+20 
inclusive), Note that RMSE penalizes inaccurate predictions more severely compared to 
A10 or A20; for example, if the true value of an observation is 70, A10 penalizes a 
prediction of 50 the same as a prediction of 10. Nevertheless, A10 or A20 may be of interest 
to physicians or patients in practice.  
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As a benchmark, we considered a model that predicts the functional status to remain 
the same between registration and transplantation (recall that 66% of the observations in 
the data have the same functional status at registration and transplantation, and hence, this 
simple benchmark model has a reasonable predictive power). 
After comparing the performance of the predictive models, we took the best 
performing model by RMSE, and removed the variable “ON_DIALYSIS” for our final 
predictive model. In the data,  “ON_DIALYSIS” may have been recorded after the waitlist 
registration and at another time period on the waitlist instead (and hence it would not be 
consistent with our goal of using information only known at waitlist registration to predict 
transplant functional status). 
All together, we compared the performance of 46 different model and variable 
selection combinations in addition to the benchmark model. 
5.3 Results 
 Table 5-2 shows the variables selected by each method including interaction 
effects. The following variables were selected by all five variable selection methods: 




Table 5-2: Variables selected by each of the variable selection methods. In the table, X:Y 
indicates an interaction between the variables X and Y. 
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 Figure 5-4 shows the top 10 ranked variables by PIRF and their respective 
permutation importance measures. Functional status at registration had the highest 
permutation importance and was ranked as the most-important predictive variable by PIRF. 
This result is consistent with the fact that 66% of the observations had the same functional 
status at transplantation as the functional status at registration. The next three most-
important variables by permutation importance were the year placed on the waitlist, the 





Figure 5-4: Top ten variables ranked by permutation importance using random forests. 
 
 
 Table 5-3 shows the RMSE, MSE, standard deviation of MSE, and accuracy of 




Table 5-3: Performance of predictive models from cross-validation. 
Table 5-3 continued 
Model/variable Set 












13.03 169.78 1.33 81.39% 92.61% 
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Table 5-3 continued 
Model/variable Set 

















13.05 170.18 1.08 81.33% 92.62% 
Permutation 
importance top 10: 
generalized additive 
model 
13.12 172.01 1.4 81.83% 92.05% 
Lasso: generalized 
additive model 13.16 173.19 1.56 81.84% 91.99% 
Permutation 
importance top 10: 
random forests 
13.21 174.49 1.64 81.98% 92.16% 
Permutation 
importance top 10: 
stacking using linear 
regression 
13.21 174.55 1.55 82.18% 92.06% 
Permutation 
importance top 10: 
neural networks 
13.22 174.7 1.6 81.94% 91.77% 
Permutation 
importance top 10: 
gradient boosting  
13.22 174.73 1.6 82.19% 92.05% 
MARS: generalized 
additive model 13.23 175.09 1.49 81.87% 91.75% 
Permutation 
importance top 10: 
support vector 
machines 









13.37 178.66 2.12 81.5% 91.72% 
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Table 5-3 continued 
Model/variable Set 


















13.5 182.29 1.4 82.39% 91% 
Permutation 
importance top 10: 
Box-Cox linear 
regression 
13.53 183.18 1.65 80.85% 92.15% 
Lasso: support vector 





13.55 183.63 4.73 80.98% 91.48% 
Lasso: Box-Cox linear 









13.57 184.25 5.2 80.47% 91.68% 
Permutation 
importance top 10: 
linear regression 
13.58 184.42 1.41 82.85% 90.78% 
MARS: Box-Cox 
linear regression 13.58 184.44 1.6 80.89% 92% 
Lasso: linear 




using linear regression 
13.61 185.25 5.1 80.89% 91.39% 
MARS interactions: 
linear regression 13.62 185.46 1.59 82.33% 91.1% 
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Table 5-3 continued 
Model/variable Set 










regression 13.63 185.78 1.46 82.91% 90.61% 
Lasso: neural networks 13.71 187.86 4.41 80.17% 91.32% 
MARS interactions: 
neural networks 13.89 192.96 9.24 79.73% 90.99% 
MARS: neural 
networks 13.9 193.18 6.16 79.72% 91.06% 
MARS: support vector 
machines 14.47 209.43 10.16 79.42% 90.17% 
Lasso: gradient 
boosting 14.51 210.73 11.36 79.07% 89.75% 
Permutation 
importance top 10: 
gradient boosting 
(classification) 
14.66 214.95 2.07 81.75% 88.82% 
Functional status same 
as registration 14.68 215.57 2.01 80.55% 88.69% 
Lasso: stacking using 
linear regression 14.7 216.17 13.98 78.85% 89.5% 






15.44 238.56 9.04 80.12% 87.37% 
MARS interactions: 





15.89 252.49 2.52 76.5% 87.54% 
MARS interactions: 
stacking using linear 
regression 
15.96 254.95 14.6 73.61% 87.59% 
MARS: random forests 16.03 257.03 15.35 72.75% 86.76% 
MARS interactions: 




16.22 263.23 2.08 77.62% 86.23% 
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Table 5-3 continued 
Model/variable Set 









MARS: stacking using 
linear regression 16.24 264.97 38.62 72.42% 87.17% 
MARS: gradient 












17.64 311.65 25.44 74.94% 82.93% 
 
 
Our final predictive model, a generalized additive model with the variables PIRF 
interactions without using ‘ON_DIALYSIS’ (GA-PIRF), resulted in an average RMSE of 
13.05 based on 20 cross-validation samples. GA-PIRF performed significantly better than 
the benchmark model with an RMSE of 14.68 (a two sided paired t-test with equal 
variances comparing the RMSE for each cross validation sample yielded a p-value less 
than 2.2*10-16).  GA-PIRF obtained an accuracy of classification within one increment of 
81.33% and accuracy within two increments of 92.62% (compared to 80.55% and 88.69%, 
respectively, for the benchmark model). Table D-4 shows that GA-PIRF performs better 
than the benchmark model for every cross-validation sample. Additional performance 
metrics including the average RMSEs for the patients whose functional status changed vs. 
stayed the same in the out-of-sample data are shown in Table 5-4. We provide example 
code to build and make predictions with GA-PIRF in Text D-1. Further, including the 
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variable, ‘ON_DIALYSIS’, did not make a statistically significant difference in model 
performance based on RMSE (a two sided paired t-test with equal variances comparing the 
RMSE for each cross validation sample between GA-PIRF and including 
‘ON_DIALYSIS’ in GA-PIRF, yielded a p-value of 0.2993). 
 
Table 5-4:  Additional performance metrics for our final predictive model compared to 
the benchmark model. Metrics include: the average RMSEs for observations where the 
functional status increased vs. decreased in the out-of-sample data, the average RMSEs 
for observations where the functional status changed vs. stayed the same in the out-of-
sample data, and the average difference between the predictions and the actual functional 
status values. The performance is based on 20 cross-validation samples of 80% training 
and 20% out-of-sample data. 




















GA-PIRF 17.76 20.31 19.37  6.9 -0.4 
Benchmark 24.1 23.96 24.02  0 -1.79 
 
The worst-performing model based on RMSE was the gradient boosting model with 
the softmax objective implemented with the variables selected by MARS, resulting in an 
RMSE of 17.64, accuracy of classification within one increment of 74.94%, and accuracy 
within two increments of 82.93%. Table D-5 gives the performance results per model, 
averaged for all variable selection methods. Table D-6 depicts the performance results per 
variable selection method, averaged across all models. We further list, in Table D-7, the 
d 
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average optimal tuning parameters found from the hyper-parameter grid searches for each 
model. 
5.4 Discussion 
 We built models to predict the functional status of a patient at transplantation, 
given information only known at waitlist registration. The model can be used to predict 
how the functional status of a patient may change while on the waitlist, from registration 
to transplantation. The model performs significantly better, across multiple metrics, 
compared to a benchmark model which assumes that the functional status will remain the 
same between registration and transplantation.  
 Predicting changes in functional status could be helpful especially when a patient 
is offered a deceased donor organ, while assessing the tradeoffs between accepting the offer 
and having a transplant, versus remaining on the waitlist for a potentially better organ offer 
that may arrive in the future. Functional status at transplantation is an important predictor 
of kidney transplant survival (controlling for other variables) (50), and hence, the decision 
to remain on the waitlist needs to consider the possibility of a change in functional status 
while on the waitlist. Figure 5-5 visualizes how higher functional status at transplantation 
is associated with higher post-transplant survival using the Kaplan–Meier estimate (26) 
using the same data we used in our analysis. Predicting the functional status at a future 
date, e.g., the (estimated) time of transplantation, can also be informative in estimating 




Figure 5-5: Post-transplant survival for different groups of patients based on their 
functional status at transplantation using the Kaplan–Meier estimate. 
 
 Our model focuses on predicting the functional status of a patient at a future date; 
it does not predict the likelihood of a patient dying while on the waitlist, nor does it predict 
the likelihood (and timing) of a patient to receive a transplant in the future. In our dataset, 
17% of patients who were on the kidney waitlist were removed from the waitlist because 
they died or were too sick to receive a transplant. Models predicting the likelihood of 
transplantation (103) or death (46) before kidney transplantation, can be found in the 
literature, and be used in conjunction with the model proposed here, e.g., while evaluating 
decisions regarding organ offers.   
 A limitation of this analysis is that the KPS has been reported to have some 
subjectivity in its recording (104). A patient’s true health status may be slightly different 
than their reported status. On the positive side, the usefulness of KPS in predicting post-
transplant survival and the likelihood of receiving a kidney has been established in previous 
literature (6,83-87,105). Hence, even if there is some subjectivity in the recording of KPS 
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at registration, the high predictive accuracy of our model would still lead to useful 
information and insights for patients and physicians.  
 The proposed model utilizes data from UNOS. Additional data on a patient’s 
lifestyle (e.g., nutrition, physical activity) can be incorporated into a more complex model 
for future research.  
 88 
CHAPTER 6. ORGAN TRANSPLANT DECISION SUPPORT 
TOOL 
 Utilizing the transplant and waitlist survival models that we built in chapters 
3 and 4, we created an interactive tool that can be used to show the survival curves of a 
patient either receiving an IRD organ or waiting for a non-IRD organ for the kidney, heart, 
liver and lung. The tool allows the user to enter and display the survival curves for custom 
characteristics of the recipient and the donor. The tool was built using the statistical 
software R version 3.3.2 (29) and key packages shiny (106) and ggplot2 (107). By default, 
the buttons on the tool are populated with the mean value for numerical variables and the 
most-common value for categorical variables, for the data used in each model scenario. In 
addition, a web and mobile version of the interactive tool is being built with the help of 
Georgia Tech Research Institute (108). 
The following modification to the transplant and waitlist survival models for the 
kidney that we built in chapter 3 was made for the tool: we used the parameter, mincriterion 
= 0.75 instead of mincriterion = 0.25 (the value of the test statistic that must be exceeded 
in order to implement a split in the random survival forest algorithm), since it allowed us 
to grow forests that were less deep and build a model with faster loading and computation 
times with similar performance.  
We also added an additional feature to the tool that shows the survival curve if the 
recipient receives a non-IRD organ immediately. For each organ, these models were trained 
on the same data that we used to train our models that predict the survival for a patient 
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receiving a non-IRD organ after waiting on the waitlist. However, we used variables known 
at transplantation in addition to information on the waiting list (for example, information 
about the donor is not known when the recipient decides to remain on the waitlist and 
receive a non-IRD organ in the future, but the donor information is known if the recipient 
is currently offered an non-IRD organ). For each organ, we built these transplant survival 
models using the same variables we used for the IRD transplant survival models. For the 
kidney, the transplant survival model was built using random survival forests with 
conditional inference trees as base learners (23,24), and the same hyper parameters we used 
for the transplant survival models in chapter 3 (25) except that we used the parameter 
mincriterion = 0.75 instead of the parameter mincriterion = 0.25. For the liver, heart and 
lung, the transplant survival models were built using the Cox proportional hazards model. 
Table 3-1 and Table 4-1 show the data used for building the models. Table 6-1 shows the 
performance of the predictive models used in the interactive tool based on ten cross-
validation samples of 80% training data and 20% out-of-sample data.  
 
Table 6-1: Performance of the predictive models used in the interactive tool based on ten 
cross-validation samples of 80% training data and 20% out-of-sample data. 
Table 6-1 continued 








IRD 0.687 0.063 0.014 
Non-IRD (after waiting) 0.697 0.068 0.007 
Waitlist 0.685 0.102 0.005 
Non-IRD (immediately) 0.702 0.067 0.006 
Heart 
IRD 0.641 0.118 0.030 
Non-IRD (after waiting) 0.591 0.126 0.008 
d 
 90 
Table 6-1 continued 







Waitlist 0.749 0.161 0.006 
Non-IRD (immediately) 0.610 0.124 0.012 
Liver 
IRD 0.593 0.120 0.039 
Non-IRD (after waiting) 0.622 0.117 0.007 
Waitlist 0.804 0.142 0.005 
Non-IRD (immediately) 0.632 0.116 0.010 
Lung 
IRD 0.596 0.182 0.023 
Non-IRD (after waiting) 0.568 0.182 0.009 
Waitlist 0.788 0.158 0.010 
Non-IRD (immediately) 0.580 0.181 0.005 
 
Figure 6-1, Figure 6-2, Figure 6-3, and Figure 6-4 show screenshots of the interactive tool 






Figure 6-1: Screenshot of the interactive decision support tool for the kidney, populated 





Figure 6-2: Screenshot of the interactive decision support tool for the heart, populated 





Figure 6-3: Screenshot of the interactive decision support tool for the liver, populated 





Figure 6-4: Screenshot of the interactive decision support tool for the lung, populated 
with the default variable values. 
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CHAPTER 7. CONCLUSION 
 We found that the simulations had, on average, higher 5-year survival probabilities 
receiving an IRD organ versus waiting for one day and receiving a non-IRD organ, for all 
four organs. As estimated wait times increased, the difference also increased, suggesting 
that patients who are likely to wait for longer times would benefit more from receiving an 
IRD organ (versus waiting and receiving a non-IRD organ later). In practice, given the high 
uncertainty about wait times, the majority of transplant recipients may have a higher 
survival probability receiving the IRD organ; in fact, it has been shown that among those 
patients who received an IRD offer and declined, only 31.0% received a non-IRD kidney 
within 5 years (43). Differences in the survival probabilities for receiving an IRD organ or 
waiting for a non-IRD organ for a particular set of donor and recipient characteristics can 
be calculated using our benefit equations or our interactive decision support tool. 
 Our transplant and waitlist survival models used training data prior to 2014. Hence, 
due to advancements in medical care in recent years, our survival estimates may be 
conservative. Figure 7-1 shows that transplant survival for kidney transplant recipients has 
improved over time (without controlling for other factors). For further research, it would 
be beneficial to see the benefit for IRD organs when we can obtain 5-year survival data 
that takes into account the latest treatments for infectious diseases. Another area for future 
research would be to explore the affects of seasonality on transplant and waitlist survival. 
Figure 7-2 shows how transplant survival was lower for patients receiving transplants on 
the weekend than during the week. It would be interesting to explore why this occurs and 
if the affect still holds when controlling for other factors.  
 Throughout this thesis, we built many predictive models. For example, when we 
predicted how the functional status of a kidney transplant patient changes from registration 
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to transplantation, we cross-validated many different predictive models and chose to use 
the model with the greatest performance. When building models to predict medical 
outcomes, it may also be important to make sure the models are explainable and 
interpretable. For further research it would be helpful to develop a framework for the 




Figure 7-1: Transplant survival (using the Kaplan–Meier estimator) for kidney transplant 
recipients based on the year they received the transplant.  The survival is based on all 
kidney transplant observations in our dataset with a recorded follow-up/death time and 
censored status (a total of 357,030 transplant observations from October 1 1987 to March 




Figure 7-2: Transplant survival (using the Kaplan–Meier estimator) for kidney transplant 
recipients over the last 10 years in our data set, based on the day of the week that they 
received a transplant.  The survival is based on all kidney transplant observations in our 
dataset with a recorded follow-up/death time and censored status between January 1 2004 
and March 31 2014 inclusive (a total of 170,381 transplant observations).  
 
 One of the take-aways from this thesis is that there is potential to improve the 
survival prospects for patients on the organ transplant waitlist. Organs with the IRD label 
remain underutilized (44). For example, IRD kidneys were found to be one-third less likely 
to be used for transplantation than non-IRD kidneys with similar characteristics (38). 
Hence, helping patients decide whether to accept an IRD organ offer can increase 
utilization of organs, help them make the best choice that maximizes their survival and 
saves lives. 
 Further, our transplant survival model with increased performance over the current 
model in the kidney allocation system, may be utilized to improve the efficiency of the 
matching process and also increase the utilization rate for standard organs.  In 2009 for 
example, 19.2% of deceased donor kidneys recovered for transplant were discarded, up 
from 5.1% in 1988 (40). Our model for how the functional status of a patient changes from 
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waitlist registration to transplantation, can also help in the allocation process by providing 
an estimate of the patient’s health when they would receive a transplant. Using similar 
methods, predicting how the MELD score changes from waitlist registration to liver 
transplantation is also a great area for further research.   
 As the majority of the kidney discard rate rise can be explained by the broadening 
donor pool (40), the methods used to compare the survival of a patient accepting an IRD 
organ offer or waiting for a non-IRD organ can be extended to other types of non-standard 
donors, such as expanded criteria donors (ECD). The use of machine learning and statistical 
methods applied in the field of healthcare is promising and can save many lives. 
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APPENDIX A. APPENDIX FOR CHAPTER 2 
Table A-1: Log-rank test for differences in cohort survival. χ2 statistic value = 259.3, p-




Text A-1: Grouping values for the variable kidney diagnosis. 
To group and reduce the number of possible values for the variable kidney diagnosis:  
1. Use domain knowledge to initially assign related values into the same group.  
2. Create binary variables (dummy variables) corresponding to each of the 
remaining values for the categorical variable.  
3. Build a Cox proportional hazards model to predict recipient post-transplant 
survival using the binary variables from step 2, in addition to other relevant 
variables to control for, such as recipient age.  
4. Sort the coefficients for the binary variables corresponding to the categorical 
variable from the Cox model into a prespecified number of quantiles, representing 
the new categorical variable values. 
 
Table A-2: Original kidney diagnosis values and their new groupings. We used the 
coefficients of a Cox model to group values with similar predicted transplant survival, 
controlling for other variables. We controlled for: recipient age, recipient diabetes, 
recipient cold ischemia time, recipient initial waitlist status, recipient ethnicity, donor age, 
Cohort Observed Expected 
1987–2001 47915 45945 
2002–2014 25860 27830 
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donor cause of death, and donor living status. We considered putting the first three values 
of kidney diagnosis in its own group. However, they had fewer than 90 observations 
combined, which may cause overfitting issues. 
Table A-2 continued 
Factor Level Coefficient New group 
THIN BASEMENT MEMBRANE DISEASE -12.018 1 
HIV NEPHROPATHY -11.659 1 
DYSPLASIA -10.185 1 
GOUT -1.655 1 
MEDULLARY CYSTIC DISEASE -1.042 1 
GOODPASTURE'S SYNDROME -0.771 1 
LYMPHOMA -0.732 1 
ALPORT'S SYNDROME -0.689 1 
IGA NEPHROPATHY -0.629 1 
ANTI-GBM -0.585 2 
FAMILIAL NEPHROPATHY -0.572 2 
POLYCYSTIC KIDNEYS -0.551 2 
RHEUMATOID ARTHRITIS -0.518 2 
HENOCH-SCHOENLEIN PURPURA -0.416 2 
FOCAL GLOMERULAR SCLEROSIS (FOCAL 
SEGMENTAL - FSG) -0.287 2 
CHRONIC PYELONEPHRITIS/REFLUX 
NEPHROPATH -0.217 2 
UROLITHIASIS -0.210 2 
IDIO/POST-INF CRESCENTIC 
GLOMERULONEPHRI -0.209 3 
CONGENITAL OBSTRUCTIVE UROPATHY -0.205 3 
NEPHROLITHIASIS -0.201 3 
CHRONIC GLOMERULONEPHRITIS 
UNSPECIFIED -0.196 3 
MEMBRANOUS GLOMERULONEPHRITIS -0.160 3 
RAPID PROGRESSIVE 
GLOMERULONEPHRITIS (RPGN) -0.094 3 
WEGENERS GRANULOMATOSIS -0.092 3 
MALIGNANT HYPERTENSION -0.077 3 
MEMBRANOUS NEPHROPATHY -0.060 3 
CHRONIC NEPHROSCLEROSIS-
UNSPECIFIED -0.054 4 
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Table A-2 continued 
Factor Level Coefficient New group 
DRUG RELATED INTERSTITIAL NEPHRITIS -0.022 4 
CHRONIC GLOMERULOSCLEROSIS 
UNSPECIFIED -0.019 4 
NEPHRITIS -0.009 4 
ACQUIRED OBSTRUCTIVE NEPHROPATHY 0.000 4 
OXALATE NEPHROPATHY (INCLUDES 
HEREDITARY OXALOSIS) 0.025 4 
HYPERTENSIVE NEPHROSCLEROSIS 0.038 4 
SYSTEMIC LUPUS ERYTHEMATOSUS 0.041 4 
RENAL CELL CARCINOMA 0.062 5 
NEPHROPHTHISIS 0.064 5 
MESANGIO-CAPILLARY 1 
GLOMERULONEPHRITIS 0.121 5 
CHOLESTEROL EMBOLIZATION 0.125 5 
POLYARTERITIS 0.137 5 
OTHER SPECIFY 0.141 5 
RENAL ARTERY THROMBOSIS 0.142 5 
ANTIBIOTIC-INDUCED NEPHRITIS 0.152 5 
SARCOIDOSIS 0.153 6 
HYPOPLASIA/DYSPLASIA/DYSGENSIS/AGE
NESIS 0.166 6 
HEROIN NEPHROTOXICITY 0.181 6 
DIABETES 0.182 6 
ANALGESIC NEPHROPATHY 0.194 6 
INCIDENTAL CARCINOMA 0.203 6 
HEMOLYTIC UREMIC SYNDROME 0.211 6 
RETRANSPLANT/GRAFT FAILURE 0.218 6 
PROGRESSIVE SYSTEMIC SCLEROSIS 0.252 6 
PRUNE BELLY SYNDROME 0.314 7 
ACUTE TUBULAR NECROSIS 0.373 7 
FABRY'S DISEASE 0.384 7 
CANCER CHEMOTHERAPY INDUCED 
NEPHRITIS 0.424 7 
MYELOMA 0.446 7 
WILMS' TUMOR 0.479 7 
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Table A-2 continued 
Factor Level Coefficient New group 
CORTICAL NECROSIS 0.486 7 
MESANGIO-CAPILLARY 2 
GLOMERULONEPHRITIS 0.491 7 
LITHIUM TOXICITY 0.506 8 
AMYLOIDOSIS 0.595 8 
SCLERODERMA 0.611 8 
CALCINEURIN INHIBITOR 
NEPHROTOXICITY 0.617 8 
CYSTINOSIS 0.685 8 
RADIATION NEPHRITIS 0.740 8 
PRE-BMTRANSPLANTATION TOTAL BODY 
IRRADIATION 0.748 8 
HEPATORENAL SYNDROME 0.765 8 
SICKLE CELL ANEMIA 1.034 8 
 
 





Table A-3: Descriptions of variables used in the proposed model. *See Table A-2 for 
variable values in this group. 
Table A-3 continued 
Variable name Description Categories 
AGE Recipient age (yrs) NA 
AGE_DON Donor age (yrs) NA 
ANY_DIAL 
Recipient on dialysis any 
time between registration 
and transplant 
NO, NOT_KNOWN, YES 
COD_CAD_DON Deceased donor-cause of death 
ANOXIA, 
CEREBROVASCULAR/STROK
E, CNS TUMOR, HEAD 
TRAUMA, NOT_KNOWN, 
OTHER SPECIFY 
COLD_ISCH_KI Kidney cold ischemic time (hours) NA 




mechanism of death 
ASPHYXIATION, BLUNT 
INJURY, CARDIOVASCULAR, 
DEATH FROM NATURAL 





NONE OF THE ABOVE, 
NOT_KNOWN, SEIZURE, 
SIDS, STAB OR GUNSHOT 
WOUND 
DIAB Recipient diabetes at registration NO, NOT_KNOWN, YES 






DRUGTRT_COPD Recipient drug treated COPD at registration NO, NOT_KNOWN, YES 
ETHCAT Recipient ethnicity category 
AMER IND/ALASKA NATIVE, 
ASIAN, BLACK, HISPANIC, 
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Table A-3 continued 





FUNC_STAT_TRR Recipient functional status at transplant 
10-20 PERCENT VERY SICK 
HOSPITALIZATION 
NECESSARY, 30-50 PERCENT 
REQUIRES CONSIDERABLE 
ASSISTANCE BUT DEATH 
NOT IMMINENT, 60-70 
PERCENT PERFORMS 
ACTIVITIES OF DAILY 
LIVING WITH SOME 
ASSISTANCE, 80-100 
PERCENT PERFORMS 
ACTIVITIES OF DAILY 
LIVING WITH NO 
ASSISTANCE, NOT 
APPLICABLE (PATIENT < 1 
YEAR OLD), NOT_KNOWN, 
PERFORMS ACTIVITIES OF 
DAILY LIVING WITH TOTAL 
ASSISTANCE. 
HCV_SEROSTATUS Recipient HCV status NEGATIVE, NOT DONE, NOT_KNOWN, POSITIVE 
HIST_DIABETES_D
ON 
Deceased donor-history of 
diabetes, including 
duration of disease 
NO, NOT_KNOWN, YES 
HIST_HYPERTENS_
DON 
Deceased donor-history of 
hypertension  NO, NOT_KNOWN, YES 
MED_COND_TRR 
Recipient medical 
condition pre-transplant at 
transplant 
HOSPITALIZED NOT IN ICU, 











DEPARTMENT OF VA, SELF, 
SOME PRIVATE BY 
PRIMARY OR SECONDARY 
REGION UNOS region where transplanted 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 
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Table A-4: Summary of variables used in the predictive models. The mean value of the 
data is given for numeric variables and the percentage of observations for each category 
is given for categorical variables. *See Table A-2 for variable values in this group. 
Table A-4 continued  
Variable Variable Summary 
AGE 48.5 
AGE_DON 38.7 
ANY_DIAL: N 6% 
ANY_DIAL: NOT KNOWN 11.3% 
ANY_DIAL: Y 82.6% 
COD_CAD_DON: ANOXIA 12.9% 
COD_CAD_DON: CEREBROVASCULAR/STROKE 24.8% 
COD_CAD_DON: CNS TUMOR 0.4% 
COD_CAD_DON: HEAD TRAUMA 28.1% 
COD_CAD_DON: NOT KNOWN 32.3% 
COD_CAD_DON: OTHER SPECIFY 1.6% 
COLD_ISCH_KI 12.8 
CREAT_TRR 7.8 
DEATH_MECH_DON: ASPHYXIATION 2.1% 
DEATH_MECH_DON: BLUNT INJURY 19.1% 
DEATH_MECH_DON: CARDIOVASCULAR 6.5% 
DEATH_MECH_DON: DEATH FROM NATURAL 
CAUSES 1.1% 
DEATH_MECH_DON: DROWNING 0.6% 
DEATH_MECH_DON: DRUG INTOXICATION 2.4% 
DEATH_MECH_DON: ELECTRICAL <0.1% 
DEATH_MECH_DON: INTRACRANIAL 
HEMORRHAGE/STROKE 25.9% 
DEATH_MECH_DON: NONE OF THE ABOVE 2% 
DEATH_MECH_DON: NOT KNOWN 32.3% 
DEATH_MECH_DON: SEIZURE 0.6% 
DEATH_MECH_DON: SIDS <0.1% 
DEATH_MECH_DON: STAB OR GUNSHOT 
WOUND 7.3% 
DIAB: NO 68.5% 
DIAB: NOT KNOWN 1.5% 
DIAB: YES 30% 
d 
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Table A-4 continued  
Variable Variable Summary 
DIAG_KI: GROUP_1* 5.6% 
DIAG_KI: GROUP_2* 16.9% 
DIAG_KI: GROUP_3* 10.5% 
DIAG_KI: GROUP_4* 25.3% 
DIAG_KI: GROUP_5* 7.3% 
DIAG_KI: GROUP_6* 31.6% 
DIAG_KI: GROUP_7* 0.7% 
DIAG_KI: GROUP_8* 1.5% 
DIAG_KI: NOT KNOWN 0.7% 
DRUGTRT_COPD: N 94.7% 
DRUGTRT_COPD: NOT KNOWN 4.3% 
DRUGTRT_COPD: Y 1% 
ETHCAT: AMER IND/ALASKA NATIVE 0.9% 
ETHCAT: ASIAN 5% 
ETHCAT: BLACK 25.6% 
ETHCAT: HISPANIC 14% 
ETHCAT: MULTIRACIAL 0.6% 
ETHCAT: NATIVE HAWAIIAN/OTHER PACIFIC 
ISLANDER 0.4% 
ETHCAT: NOT KNOWN <0.1% 
ETHCAT: WHITE 53.5% 
FUNC_STAT_TRR: 10-20 PERCENT VERY SICK 
HOSPITALIZATION NECESSARY 0.5% 
FUNC_STAT_TRR: 30-50 PERCENT REQUIRES 
CONSIDERABLE ASSISTANCE BUT DEATH NOT 
IMMINENT 
2.7% 
FUNC_STAT_TRR: 60-70 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH SOME 
ASSISTANCE 
17.7% 
FUNC_STAT_TRR: 80-100 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH NO 
ASSISTANCE 
73.3% 
FUNC_STAT_TRR: NOT APPLICABLE (PATIENT < 
1 YEAR OLD) 0.5% 
FUNC_STAT_TRR: NOT KNOWN 5.2% 
FUNC_STAT_TRR: PERFORMS ACTIVITIES OF 
DAILY LIVING WITH TOTAL ASSISTANCE. 0.1% 
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Table A-4 continued  
Variable Variable Summary 
HCV_SEROSTATUS: NEGATIVE 87.6% 
HCV_SEROSTATUS: NOT DONE 4.2% 
HCV_SEROSTATUS: NOT KNOWN 3.2% 
HCV_SEROSTATUS: POSITIVE 5.1% 
HIST_DIABETES_DON: NO 63.2% 
HIST_DIABETES_DON: NOT KNOWN 32.6% 
HIST_DIABETES_DON: YES 4.2% 
HIST_HYPERTENS_DON: N 75.4% 
HIST_HYPERTENS_DON: NOT KNOWN 7% 
HIST_HYPERTENS_DON: Y 17.7% 
MED_COND_TRR: HOSPITALIZED NOT IN ICU 1.7% 
MED_COND_TRR: IN INTENSIVE CARE UNIT 0.6% 
MED_COND_TRR: NOT HOSPITALIZED 97.8% 
PAYMENTSOURCE_AT_TRANSPLANT: CHIP 0.2% 
PAYMENTSOURCE_AT_TRANSPLANT: 







PAYMENTSOURCE_AT_TRANSPLANT: OTHER 0.1% 
PAYMENTSOURCE_AT_TRANSPLANT: OTHER 
GOVERNMENT OR DEPARTMENT OF VA 1.4% 
PAYMENTSOURCE_AT_TRANSPLANT: SELF 0.2% 
PAYMENTSOURCE_AT_TRANSPLANT: SOME 
PRIVATE BY PRIMARY OR SECONDARY 48.2% 
REGION: 1 3.1% 
REGION: 10 9.3% 
REGION: 11 9.6% 
REGION: 2 14.1% 
REGION: 3 12.6% 
REGION: 4 8.2% 
REGION: 5 15.8% 
 108 
Table A-4 continued  
Variable Variable Summary 
REGION: 6 3.8% 
REGION: 7 9.7% 
REGION: 8 6.9% 
REGION: 9 7% 
 
Table A-5: Cox proportional hazards model coefficients for the proposed model. Trained 
on a random sample of 100,000 observations. 
Table A-5 continued 
Variable Name Coefficient p-Value 
AGE 0.05 0 
AGE_DON 0.01 0 
ANY_DIAL:  Base Level - NO   
ANY_DIAL: NOT_KNOWN -0.05 0.37 
ANY_DIAL: YES 0.45 0 
COD_CAD_DON:  Base Level - ANOXIA   
COD_CAD_DON: CEREBROVASCULAR 
STROKE -0.08 0.21 
COD_CAD_DON: CNS TUMOR -0.21 0.15 
COD_CAD_DON: HEAD TRAUMA -0.01 0.85 
COD_CAD_DON: NOT_KNOWN -0.35 0 
COD_CAD_DON: OTHER SPECIFY -0.13 0.12 
COLD_ISCH_KI 0 0 
CREAT_TRR -0.03 0 
DEATH_MECH_DON:  Base Level - 
ASPHYXIATION   
DEATH_MECH_DON: BLUNT INJURY 0 0.98 
DEATH_MECH_DON: CARDIOVASCULAR 0.07 0.38 
DEATH_MECH_DON: DEATH FROM 
NATURAL CAUSES 0.3 0.01 
DEATH_MECH_DON: DROWNING 0.09 0.55 
DEATH_MECH_DON: DRUG 
INTOXICATION -0.02 0.8 
DEATH_MECH_DON: ELECTRICAL -0.98 0.17 
d 
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Table A-5 continued 
Variable Name Coefficient p-Value 
DEATH_MECH_DON: INTRACRANIAL 
HEMORRHAGE STROKE 0.16 0.11 
DEATH_MECH_DON: NONE OF THE ABOVE 0.16 0.12 
DEATH_MECH_DON: SEIZURE 0.22 0.12 
DEATH_MECH_DON: SIDS -0.64 0.52 
DEATH_MECH_DON: STAB OR GUNSHOT 
WOUND -0.01 0.9 
DIAB:  Base Level - NO   
DIAB: NOT_KNOWN -0.01 0.88 
DIAB: YES 0.28 0 
DIAG_KI:  Base Level - GROUP_1   
DIAG_KI: GROUP_2 0.28 0 
DIAG_KI: GROUP_3 0.5 0 
DIAG_KI: GROUP_4 0.7 0 
DIAG_KI: GROUP_5 0.69 0 
DIAG_KI: GROUP_6 0.79 0 
DIAG_KI: GROUP_7 0.79 0 
DIAG_KI: GROUP_8 1.05 0 
DIAG_KI: NOT_KNOWN 0.61 0 
DRUGTRT_COPD:  Base Level - NO   
DRUGTRT_COPD: NOT_KNOWN 0.04 0.42 
DRUGTRT_COPD: YES 0.33 0 
ETHCAT:  Base Level - AMER IND/ALASKA 
NATIVE   
ETHCAT: ASIAN -0.29 0 
ETHCAT: BLACK -0.01 0.93 
ETHCAT: HISPANIC -0.18 0.06 
ETHCAT: MULTIRACIAL 0.17 0.28 
ETHCAT: NATIVE HAWAIIAN OTHER 
PACIFIC ISLANDER -0.02 0.92 
ETHCAT: NOT_KNOWN 3.58 0 
ETHCAT: WHITE 0.14 0.12 
FUNC_STAT_TRR:  Base Level - 10-20 




Table A-5 continued 
Variable Name Coefficient p-Value 
FUNC_STAT_TRR: 30 50 PERCENT 
REQUIRES CONSIDERABLE ASSISTANCE 
BUT DEATH NOT IMMINENT 
-0.6 0 
FUNC_STAT_TRR: 60 70 PERCENT 
PERFORMS ACTIVITIES OF DAILY LIVING 
WITH SOME ASSISTANCE 
-0.81 0 
FUNC_STAT_TRR: 80 100 PERCENT 
PERFORMS ACTIVITIES OF DAILY LIVING 
WITH NO ASSISTANCE 
-1.03 0 
FUNC_STAT_TRR: NOT APPLICABLE  
PATIENT   1 YEAR OLD -0.56 0 
FUNC_STAT_TRR: NOT_KNOWN -0.94 0 
FUNC_STAT_TRR: PERFORMS ACTIVITIES 
OF DAILY LIVING WITH TOTAL 
ASSISTANCE 
-0.63 0.06 
HCV_SEROSTATUS:  Base Level - NEGATIVE   
HCV_SEROSTATUS: NOT DONE 0.03 0.47 
HCV_SEROSTATUS: NOT_KNOWN 0.07 0.13 
HCV_SEROSTATUS: POSITIVE 0.52 0 
HIST_HYPERTENS_DON:  Base Level - NO   
HIST_HYPERTENS_DON: NOT_KNOWN 0.22 0 




Figure A-2: Proposed model’s 5-year survival predictions for different variable values. In 
each plot, variable values not shown are held constant and listed in Table A-6. The model 




Table A-6: Variables held constant in Figure A-2. *See Table A-2 for variable values in 
this group.  
Table A-6 continued 













80-100 PERCENT PERFORMS 
ACTIVITIES OF DAILY 





MED_COND_TRR NOT HOSPITALIZED 
PAYMENTSOURCE_AT_TRANSPLANT SOME PRIVATE BY PRIMARY OR SECONDARY 
REGION 5 
 
Table A-7: Factor level legend for Figure A-2. 
Table A-7 continued 
Factor level name Description 
DIAG_KI G1 GROUP_1* 
DIAG_KI G2 GROUP_2* 
DIAG_KI G3 GROUP_3* 




Table A-7 continued 
Factor level name Description 
DIAG_KI G5 GROUP_5* 
DIAG_KI G6 GROUP_6* 
DIAG_KI G7 GROUP_7* 
DIAG_KI G8 GROUP_8* 
DIAG_KI G9 NOT_KNOWN 
FUNC_STAT_TRR G1 10-20 PERCENT VERY SICK HOSPITALIZATION NECESSARY 
FUNC_STAT_TRR G2 30-50 PERCENT REQUIRES CONSIDERABLE ASSISTANCE BUT DEATH NOT IMMINENT 
FUNC_STAT_TRR G3 60-70 PERCENT PERFORMS ACTIVITIES OF DAILY LIVING WITH SOME ASSISTANCE 
FUNC_STAT_TRR G4 80-100 PERCENT PERFORMS ACTIVITIES OF DAILY LIVING WITH NO ASSISTANCE 
FUNC_STAT_TRR G5 NOT APPLICABLE (PATIENT < 1 YEAR OLD) 
FUNC_STAT_TRR G6 NOT_KNOWN 
FUNC_STAT_TRR G7 PERFORMS ACTIVITIES OF DAILY LIVING WITH TOTAL ASSISTANCE. 
MED_COND_TRR G1 HOSPITALIZED NOT IN ICU 
MED_COND_TRR G2 IN INTENSIVE CARE UNIT 
MED_COND_TRR G3 NOT HOSPITALIZED 
 
Table A-8: Concordance index at different days after transplant for the proposed model. 
The performance is calculated from 10 random samples of 80,000 training observations 
and 20,000 out-of-sample observations. 
Table A-8 continued 












Table A-9: Proposed model performance by category. Performance from a random sample 
of 100,000 training observations and 25,000 out-of-sample observations. 
Table A-9 continued 
Group 5-Year integrated Brier score C-index 
AGE_DON: 0 - 24 0.051 0.730 
AGE_DON: 24 - 35 0.044 0.742 
AGE_DON: 35 - 44 0.057 0.717 
AGE_DON: 44 - 53 0.064 0.710 
AGE_DON: 53 - 84 0.090 0.688 
AGE: 0 - 36 0.023 0.670 
AGE: 36 - 47 0.038 0.702 
AGE: 47 - 55 0.061 0.652 
AGE: 55 - 62 0.079 0.640 
AGE: 62 - 90 0.109 0.637 
COLD_ISCH_KI: 0.01 - 1.4 0.037 0.732 
COLD_ISCH_KI: 1.4 - 8.4 0.053 0.731 
COLD_ISCH_KI: 8.4 - 15  0.070 0.707 
COLD_ISCH_KI: 15 - 22 0.073 0.703 
COLD_ISCH_KI: 22 - 99 0.077 0.703 
DIAB: NO 0.046 0.727 
DIAB: YES 0.095 0.650 
FUNC_STAT_TRR: 30-50 PERCENT 
REQUIRES CONSIDERABLE 
ASSISTANCE BUT DEATH NOT 
IMMINENT 
0.103 0.704 
FUNC_STAT_TRR: 60-70 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH SOME ASSISTANCE  
0.078 0.686 
FUNC_STAT_TRR: 80-100 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH NO ASSISTANCE 
0.055 0.730 
FUNC_STAT_TRR: NOT_KNOWN 0.064 0.714 
HIST_DIABETES_DON: NO 0.070 0.706 
HIST_DIABETES_DON: NOT_KNOWN 0.039 0.732 
d 
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Table A-9 continued 
Group 5-Year integrated Brier score C-index 
HIST_DIABETES_DON: YES 0.108 0.682 
HIST_HYPERTENS_DON: NO 0.055 0.728 
HIST_HYPERTENS_DON: 
NOT_KNOWN 0.052 0.736 
HIST_HYPERTENS_DON: YES 0.091 0.674 
PAYMENTSOURCE_AT_TRANSPLAN
T: MEDICAID 0.051 0.727 
PAYMENTSOURCE_AT_TRANSPLAN
T: MEDICARE 0.072 0.699 
PAYMENTSOURCE_AT_TRANSPLAN




Table A-10: Additional model testing. 10 random samples of 80,000 training 
observations and 20,000 out-of-sample observations. **Donor variables that were 
removed: AGE_DON, COD_CAD_DON, COLD_ISCH_KI, DEATH_MECH_DON, 
HIST_DIABETES_DON, and HIST_HYPERTENS_DON. 
Table A-10 continued 




EPTS for Adult Recipients and Deceased 
Donors Using the Same Cross-
Validation Data as the Proposed Model 
0.665 Not Calculated 
Proposed Model Using PMM Imputation 
for Adult Recipients and Deceased 




Table A-11: Proposed model and EPTS model cross-validation results in Table 2-3. C-
index based on 10 random samples of 80,000 training observations and 20,000 out-of-
sample observations. Using a paired two sample Student's t-test, we reject the null 
hypothesis that the difference in model performance means is equal to 0 (p-value = 2.4x10-
d 
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11). We also used a Shapiro-Wilk normality test and an F test for equality of variances to 
verify the assumptions of the t-test (Shapiro-Wilk p-value of 0.654 and 0.298 for the 
proposed model data and EPTS model data respectively; hence we don’t reject the null 
hypothesis of normally distributed model performance results. F test p-value of 0.605; 
hence we don’t reject the null hypothesis of equality of model performance variance). 
Table A-11 continued 
Test Proposed model 
EPTS 
model 
1 0.721 0.698 
2 0.727 0.701 
3 0.724 0.694 
4 0.724 0.695 
5 0.721 0.692 
6 0.715 0.685 
7 0.727 0.700 
8 0.720 0.695 
9 0.729 0.702 











APPENDIX B. APPENDIX FOR CHAPTER 3 
Table B-1: Summary of all the variables considered in the analysis after the initial data 
preparation. The mean value in the data is shown for numeric variables, and the 
percentage of observations for each category is shown for categorical variables. †See 
Table B-2 for categories in this group. 
Table B-1 continued 












ABO: A 33.8% 35% 32.3%  35.4% 
ABO: A1 1.1% 1.3% 0.9%  1.2% 
ABO: A1B 0.1% 0.1% 0.1%  0.1% 
ABO: A2 0.2% 0.2% 0.1%  0.2% 
ABO: A2B 0% <0.1% <0.1%  <0.1% 
ABO: AB 5.1% 5.2% 3.8%  4.7% 
ABO: B 12.2% 13% 14.4%  13% 
ABO: O 47.4% 45.2% 48.3%  45.3% 
ABO_DON: A 12.8%    19.7% 
ABO_DON: A1 20.6%    12% 
ABO_DON: A1B 1.5%    0.8% 
ABO_DON: A2 2.1%    1.6% 
ABO_DON: A2B 0.4%    0.2% 
ABO_DON: AB 1.6%    1.6% 
ABO_DON: B 11.5%    10.6% 
ABO_DON: O 49.4%    53.6% 
ABO_MAT: 
COMPATIBLE 3.6%    10.4% 
ABO_MAT: 
IDENTICAL 96.3%    89% 
d 
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Table B-1 continued 













INCOMPATIBLE 0.1%    0.5% 
AGE 50.6    48.6 
AGE_DON 33.4   33.5 38.7 
AMIS: 0 14.4%    19.3% 
AMIS: 1 37.1%    41.6% 
AMIS: 2 48.5%    39.2% 
ANTICONV_DON: 
N 94.3%    93.7% 
ANTICONV_DON: 
Y 5.7%    6.3% 
ANTIHYPE_DON: N 77.8%    81.2% 
ANTIHYPE_DON: Y 22.2%    18.8% 
ANY_DIAL: N 1.5%    5.8% 
ANY_DIAL: Y 98.5%    94.2% 
ARGININE_DON: N 45%    44.5% 
ARGININE_DON: Y 55%    55.5% 
BLOOD_INF_DON: 
0 90.9%    92.3% 
BLOOD_INF_DON: 
1 9.1%    7.7% 
BMI_CALC 28.1    27.3 
BMI_DON_CALC 26.3    26.8 
BMIS: 0 10.8%    14.8% 
BMIS: 1 24.6%    33.1% 
BMIS: 2 64.7%    52.1% 
BUN_DON 16.6    15.3 
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Table B-1 continued 













N: NO 96%    89.9% 
CANCER_SITE_DO
N: YES 4%    10.1% 
CARDARREST_NE
URO: N 89.1%    93.4% 
CARDARREST_NE
URO: Y 10.9%    6.6% 
CLIN_INFECT_DO
N: N 45.6%    56.4% 
CLIN_INFECT_DO
N: Y 54.4%    43.6% 
CMV_DON: 
NEGATIVE 35.2%    37.3% 
CMV_DON: 
POSITIVE 64.8%    62.7% 
CMV_IGG: 
NEGATIVE 32.6%    34.9% 
CMV_IGG: NOT 
DONE 0.7%    0.8% 
CMV_IGG: 
POSITIVE 66.7%    64.2% 
CMV_IGM: 
NEGATIVE 56.2%    58% 
CMV_IGM: NOT 
DONE 38.8%    36% 
CMV_IGM: 
POSITIVE 5%    6% 
COD_CAD_DON: 




18.9%    36.2% 
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Table B-1 continued 













CNS TUMOR 0.2%    0.6% 
COD_CAD_DON: 
HEAD TRAUMA 43.3%    41% 
COD_CAD_DON: 
OTHER SPECIFY 2.6%    2.4% 
COLD_ISCH_KI 18.1    13.7 
CREAT_DON 1.3    1.1 
CREAT_TRR 8.2   8.2 8 
DAYSWAIT_CHRO
N 903.7 869.3  895.4 671.9 
DDAVP_DON: N 80%    73.6% 









18.6%    30.9% 
DEATH_CIRCUM_
DON: HOMICIDE 10.6%    6.3% 
DEATH_CIRCUM_
DON: MVA 19.8%    21.9% 
DEATH_CIRCUM_
DON: NON-MVA 11.2%    9.6% 
DEATH_CIRCUM_
DON: NONE OF 
THE ABOVE 
22.6%    21.6% 
DEATH_CIRCUM_
DON: SUICIDE 16.8%    8.9% 
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Table B-1 continued 













N: ASPHYXIATION 6.4%    3.3% 
DEATH_MECH_DO





9.4%    9.9% 
DEATH_MECH_DO
N: DEATH FROM 
NATURAL CAUSES 









20.1%    37.9% 
DEATH_MECH_DO
N: NONE OF THE 
ABOVE 
3.1%    4.8% 
DEATH_MECH_DO
N: STAB OR 
GUNSHOT WOUND 
15.2%    10.6% 
DIAB: NO 66% 66.6% 59% 66% 69.1% 
DIAB: NOT 
KNOWN 1.2% 1% 1.1% 1.3% 1.3% 
DIAB: YES 32.8% 32.4% 39.9% 32.7% 29.7% 
DIABETES_DON: N 95.4%    95.4% 
DIABETES_DON: Y 4.6%    4.6% 
DIAG_KI: 
GROUP_1* 21%   20.7% 22% 
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Table B-1 continued 













GROUP_2* 8.4%   8.3% 10.8% 
DIAG_KI: 
GROUP_3* 54.2%   54.4% 43.9% 
DIAG_KI: 
GROUP_4* 8.4%   8.2% 8.8% 
DIAG_KI: 
GROUP_5* 7.4%   7.8% 13.9% 
DIAG_KI: NOT 
KNOWN 0.5%   0.6% 0.7% 
DIAL_TRR: N 10%    16.6% 
DIAL_TRR: Y 90%    83.4% 
DISTANCE 225.5    167.5 
DON_RETYP: N 54.5%    62% 
DON_RETYP: Y 45.5%    38% 
DRMIS: 0 19.3%    21.3% 
DRMIS: 1 44.8%    46.1% 
DRMIS: 2 35.9%    32.6% 
DRUGTRT_COPD: 
N 99.1% 98.8% 98.7%  99% 
DRUGTRT_COPD: 
Y 0.9% 1.2% 1.3%  1% 
EBV_SEROSTATUS
: NEGATIVE 11.2%    11% 
EBV_SEROSTATUS
: NOT DONE 16.2%    25% 
EBV_SEROSTATUS
: POSITIVE 72.6%    64% 
ECD_DONOR: 0 93.9%   93.8% 83.8% 
ECD_DONOR: 1 6.1%   6.2% 16.2% 
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Table B-1 continued 






















0.1%    0.2% 
END_STAT_KI: KI: 













0.9% 1.1% 0.9%  0.9% 
ETHCAT: ASIAN 6% 6.1% 5.9%  5.2% 
ETHCAT: BLACK 31.4% 30.5% 28%  26% 
ETHCAT: 
HISPANIC 15.8% 15.6% 15.6%  14.5% 
ETHCAT: 





0.4% 0.4% 0.5%  0.4% 
ETHCAT: WHITE 45% 45.7% 48.6%  52.4% 
ETHCAT_DON: 
AMER 0.4%    0.5% 
 124 
Table B-1 continued 















ASIAN 1.1%    2.7% 
ETHCAT_DON: 
BLACK 14.4%    13.1% 
ETHCAT_DON: 
HISPANIC 12.4%    13.9% 
ETHCAT_DON: 






0.1%    0.2% 
ETHCAT_DON: 




















 15.7% 17.3% 16.6% 12.7% 
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Table B-1 continued 





















 76.2% 72.4% 75.4% 78.6% 
FUNC_STAT_TCR: 
NOT APPLICABLE 
(PATIENT < 1 
YEAR OLD) 
 0.2% 0.4% 0.2% 0.3% 
FUNC_STAT_TCR: 






















23.2%    17% 
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70.4%    74.7% 
FUNC_STAT_TRR: 
NOT APPLICABLE 
(PATIENT < 1 
YEAR OLD) 
<0.1
%    0.5% 
FUNC_STAT_TRR: 
NOT KNOWN 3.3%    5.5% 
GENDER: F 37.1% 40.8% 39.9%  39.6% 
GENDER: M 62.9% 59.2% 60.1%  60.4% 
GENDER_DON: F 29.8%    46.6% 
GENDER_DON: M 70.2%    53.4% 
HBV_CORE: 
NEGATIVE 82.1%    79.6% 
HBV_CORE: NOT 
DONE 10%    12.6% 
HBV_CORE: 
POSITIVE 7.9%    7.8% 
HBV_CORE_DON: 
NEGATIVE 93.9%    91.9% 
HBV_CORE_DON: 
NOT DONE 0.1%    4.3% 
HBV_CORE_DON: 
POSITIVE 6%    3.8% 
HBV_SUR_ANTIGE
N: NEGATIVE 96.5%    96.2% 
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N: NOT DONE 1%    1.8% 
HBV_SUR_ANTIGE




0%    <0.1% 
HEP_C_ANTI_DON: 
INDETERMINATE 0%    <0.1% 
HEP_C_ANTI_DON: 
NEGATIVE 99.9%    97.5% 
HEP_C_ANTI_DON: 
NOT DONE 0.1%    0.1% 
HEP_C_ANTI_DON: 
PENDING 0%    <0.1% 
HEP_C_ANTI_DON: 
POSITIVE 0%    2.4% 
HEPARIN_DON: N 6.2%    8.6% 
HEPARIN_DON: Y 93.8%    91.4% 
HGT_CM_CALC 169.7    169 
HGT_CM_DON_CA
LC 172.4    168.9 
HIST_CANCER_DO
N: N 98.3%    97.8% 
HIST_CANCER_DO
N: Y 1.7%    2.2% 
HIST_CIG_DON: N 71.4%    72.5% 
HIST_CIG_DON: Y 28.6%    27.5% 
HIST_DIABETES_D
ON: NO 92.9%    63% 
HIST_DIABETES_D
ON: NOT KNOWN 2.6%    32.8% 
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ON: YES 4.5%    4.2% 
HIST_HYPERTENS
_DON: N 81.1%   81% 81% 
HIST_HYPERTENS
_DON: Y 18.9%   19% 19% 
HIST_OTH_DRUG_
DON: N 35.3%    70.3% 
HIST_OTH_DRUG_
DON: Y 64.7%    29.7% 
HLAMIS: 0 8.1%    9.8% 
HLAMIS: 1 1.4%    3.3% 
HLAMIS: 2 4.4%    8.4% 
HLAMIS: 3 11.9%    17.6% 
HLAMIS: 4 27.7%    22% 
HLAMIS: 5 30.8%    25.7% 
HLAMIS: 6 15.6%    13.2% 
INIT_AGE  48 49.3 48.2 46.8 
INIT_STAT: 
ACTIVE 82.5% 84.1% 80%  86.2% 
INIT_STAT: 





0% 0.1% <0.1%  <0.1% 
INOTROP_AGENTS
: N 96.6%    96.7% 
INOTROP_AGENTS
: Y 3.4%    3.3% 
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T_DON: N 51.8%    43.5% 
INOTROP_SUPPOR
T_DON: Y 48.2%    56.5% 
INSULIN_DON: N 41.2%    39.9% 
INSULIN_DON: Y 58.8%    60.1% 
LT_KI_BIOPSY: N 65.2%    62.1% 
LT_KI_BIOPSY: Y 34.8%    37.9% 
MALIG: N 94.4%    94.9% 
MALIG: Y 5.6%    5.1% 
MALIG_TCR_KI: N 95% 95.2% 94.7%  95.4% 
MALIG_TCR_KI: Y 5% 4.8% 5.3%  4.6% 
MALIG_TRR: N 99.4%    99.4% 
MALIG_TRR: Y 0.6%    0.6% 
MED_COND_TRR: 
HOSPITALIZED 
NOT IN ICU 








99.1%    98.7% 
NON_HRT_DON: N 87.4%    89.8% 
NON_HRT_DON: Y 12.6%    10.2% 
NUM_PREV_TX 0.1 0.1 0.2  0.1 
ON_DIALYSIS: N 21.5% 21.1% 25.6%  27.4% 
ON_DIALYSIS: Y 78.5% 78.9% 74.4%  72.6% 
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GISTRATION: N  14.3% 10.2% 14.9% 18% 
ON_DIALYSIS_RE
GISTRATION: Y  85.7% 89.8% 85.1% 82% 
ON_EXPAND_DON
OR: 0 52.9% 50.8%   54.3% 
ON_EXPAND_DON
OR: 1 47.1% 49.2%   45.7% 
ON_IEXPAND_DO
NOR: 0 58.7% 58.5%   60.4% 
ON_IEXPAND_DO
NOR: 1 41.3% 41.5%   39.6% 
ORG_REC_ON: ICE 77.5%    84.8% 
ORG_REC_ON: 












1.5%    1.8% 
PAYMENTSOURCE
_AT_TRANSPLANT
: SOME PRIVATE 
BY PRIMARY OR 
SECONDARY 
31.3%    47.6% 
PERIP_VASC: N 96% 95.9% 95%  96.4% 
PERIP_VASC: Y 4% 4.1% 5%  3.6% 
PREV_KI_TX: N 88%    88.2% 
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SOME PRIVATE BY 
PRIMARY OR 
SECONDARY 
 49.5% 51.5%  57.4% 
PROTEIN_URINE: 
N 54.8%    63.5% 
PROTEIN_URINE: 
Y 45.2%    36.5% 
PT_DIURETICS_DO
N: N 42.9%    45.7% 
PT_DIURETICS_DO
N: Y 57.1%    54.3% 
PT_STEROIDS_DO
N: N 30.8%    28.7% 
PT_STEROIDS_DO
N: Y 69.2%    71.3% 
PT_T3_DON: N 99%    98.5% 
PT_T3_DON: Y 1%    1.5% 
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PT_T4_DON: N 43.3%    48.3% 
PT_T4_DON: Y 56.7%    51.7% 
PULM_INF_DON: 0 56.4%    67.2% 
PULM_INF_DON: 1 43.6%    32.8% 
PUMP_KI: N 60.1%    71.6% 
PUMP_KI: Y 39.9%    28.4% 
REGION: 1 4.2% 3.7% 3.7%  4.1% 
REGION: 2 13.4% 11.9% 14.3%  14.3% 
REGION: 3 10.1% 15.2% 12.9%  12.8% 
REGION: 4 8% 9% 9.8%  8.6% 
REGION: 5 14.9% 15.8% 18.5%  16.2% 
REGION: 6 3.5% 3.7% 2.7%  3.4% 
REGION: 7 9.9% 7.4% 9.3%  9.7% 
REGION: 8 7.3% 6.9% 5%  6.1% 
REGION: 9 8.5% 6.9% 7.4%  7% 
REGION: 10 9.8% 8.2% 7.7%  8.5% 
REGION: 11 10.4% 11.1% 8.8%  9.4% 
RT_KI_BIOPSY: N 64.6%    61.6% 
RT_KI_BIOPSY: Y 35.4%    38.4% 
SGOT_DON 159.8    118 
SGPT_DON 153.4    100.2 
SHARE_TY: 3 73.2%    82% 
SHARE_TY: 4 10.5%    5.5% 
SHARE_TY: 5 16.3%    12.5% 
SHARE_TY: 6 0%    <0.1% 
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TATTOOS: N 50.3%    75.3% 
TATTOOS: Y 49.7%    24.7% 
TBILI_DON 1    1 
TOT_SERUM_ALB
UM 3.9 3.9 3.8  3.9 
TX_PROCEDUR_T













0.4%    0.8% 
TXKID: E 1.3%    2% 
TXKID: L 45.4%    59.2% 
TXKID: R 53.3%    38.8% 
URINE_INF_DON: 0 90.7%    90.8% 
URINE_INF_DON: 1 9.3%    9.2% 
VASODIL_DON: N 87.1%    87.5% 




0%    <0.1% 
VDRL_DON: 
NEGATIVE 96.7%    98.7% 
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DONE 2.1%    0.7% 
VDRL_DON: 
POSITIVE 1.2%    0.5% 
WAITLIST_YEAR 2006.8 2006.3 2007.2  2005.2 
YEAR 2009.3    2007 
  
Table B-2: Coefficients of original categories for kidney diagnosis and their new 
grouping. Controlled for: recipient age, diabetes, functional status, and donor age. We 
used the following method to group the variable values: (1) Create binary variables 
(dummy variables) corresponding to each of the values for the categorical variable. (2) 
Build a Cox proportional hazards model to predict recipient post-transplant survival using 
the binary variables from step 2, in addition to other relevant variables to control for, 
such as recipient age. (3) Sort the coefficients for the binary variables corresponding to 
the categorical variable from the Cox model into a prespecified number of quantiles, 
representing the new categorical variable values. Note that the Cox model used to group 
the variable values was trained on the entire dataset, and we did not exclude HCV 
positive recipients, nor donors with HCV antibody, HCV RNA, and HCV RIBA status. 
Table B-2 continued 
Factor Level Coefficient New Group 
THIN BASEMENT MEMBRANE DISEASE -1.893 Group 1 
IGA NEPHROPATHY -0.644 Group 1 
LYMPHOMA -0.581 Group 1 
GOODPASTURE'S SYNDROME -0.552 Group 1 
ALPORT'S SYNDROME -0.526 Group 1 
d 
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Table B-2 continued 
Factor Level Coefficient New Group 
FAMILIAL NEPHROPATHY -0.495 Group 1 
DYSPLASIA -0.457 Group 1 
POLYCYSTIC KIDNEYS -0.453 Group 1 
GOUT -0.452 Group 1 
HIV NEPHROPATHY -0.337 Group 1 
MEDULLARY CYSTIC DISEASE -0.330 Group 1 
RAPID PROGRESSIVE 
GLOMERULONEPHRITIS (RPGN) -0.329 Group 1 
FOCAL GLOMERULAR SCLEROSIS (FOCAL 
SEGMENTAL - FSG) -0.179 Group 1 
LITHIUM TOXICITY -0.176 Group 1 
ANTI-GBM -0.174 Group 1 
MEMBRANOUS GLOMERULONEPHRITIS -0.142 Group 2 
CHRONIC PYELONEPHRITIS/REFLUX 
NEPHROPATH -0.130 Group 2 
SARCOIDOSIS -0.112 Group 2 
IDIO/POST-INF CRESCENTIC 
GLOMERULONEPHRI -0.103 Group 2 
CONGENITAL OBSTRUCTIVE UROPATHY -0.082 Group 2 
NEPHROLITHIASIS -0.079 Group 2 
CHRONIC GLOMERULONEPHRITIS 
UNSPECIFIED -0.074 Group 2 
POLYARTERITIS -0.069 Group 2 
WEGENERS GRANULOMATOSIS -0.060 Group 2 
HENOCH-SCHOENLEIN PURPURA -0.041 Group 2 
NEPHROPHTHISIS -0.034 Group 2 
NEPHRITIS -0.007 Group 2 
RHEUMATOID ARTHRITIS -0.006 Group 2 
MESANGIO-CAPILLARY 1 
GLOMERULONEPHRITIS -0.004 Group 2 
ACQUIRED OBSTRUCTIVE NEPHROPATHY 0.000 Group 2 
MESANGIO-CAPILLARY 2 
GLOMERULONEPHRITIS 0.008 Group 3 
PROGRESSIVE SYSTEMIC SCLEROSIS 0.011 Group 3 
DIABETES MELLITUS - TYPE OTHER / 
UNKNOWN 0.018 Group 3 
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Factor Level Coefficient New Group 
MEMBRANOUS NEPHROPATHY 0.039 Group 3 
CHRONIC NEPHROSCLEROSIS-UNSPECIFIED 0.073 Group 3 
MALIGNANT HYPERTENSION 0.080 Group 3 
DRUG RELATED INTERSTITIAL NEPHRITIS 0.084 Group 3 
UROLITHIASIS 0.089 Group 3 
DIABETES MELLITUS - TYPE II 0.090 Group 3 
CHRONIC GLOMERULOSCLEROSIS 
UNSPECIFIED 0.093 Group 3 
HEROIN NEPHROTOXICITY 0.107 Group 3 
ACUTE TUBULAR NECROSIS 0.116 Group 3 
OTHER SPECIFY 0.120 Group 3 
HYPERTENSIVE NEPHROSCLEROSIS 0.123 Group 3 
SYSTEMIC LUPUS ERYTHEMATOSUS 0.124 Group 4 
ANTIBIOTIC-INDUCED NEPHRITIS 0.126 Group 4 
ANALGESIC NEPHROPATHY 0.129 Group 4 
DIABETES MELLITUS - TYPE I 0.175 Group 4 
CORTICAL NECROSIS 0.196 Group 4 
RENAL CELL CARCINOMA 0.197 Group 4 
OXALATE NEPHROPATHY (INCLUDES 
HEREDITARY OXALOSIS) 0.215 Group 4 
HYPOPLASIA/DYSPLASIA/DYSGENSIS/AGEN
ESIS 0.273 Group 4 
HEMOLYTIC UREMIC SYNDROME 0.282 Group 4 
WILMS' TUMOR 0.296 Group 4 
PRUNE BELLY SYNDROME 0.299 Group 4 
PRE-BMTRANSPLANTATION TOTAL BODY 
IRRADIATION 0.327 Group 4 
CHOLESTEROL EMBOLIZATION 0.333 Group 4 
INCIDENTAL CARCINOMA 0.359 Group 4 
MYELOMA 0.362 Group 4 
RETRANSPLANT/GRAFT FAILURE 0.363 Group 5 
RENAL ARTERY THROMBOSIS 0.402 Group 5 
HEPATORENAL SYNDROME 0.412 Group 5 
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Factor Level Coefficient New Group 
DIABETES - TYPE II NON-INSULIN 
DEP/ADULT 0.414 Group 5 
DIABETES - TYPE I NON-INSULIN DEP/JUV 
ON 0.455 Group 5 
DIABETES - TYPE II INSULIN DEP/ADULT 
ONS 0.461 Group 5 
CANCER CHEMOTHERAPY INDUCED 
NEPHRITIS 0.485 Group 5 
DIABETES - TYPE I INSULIN DEP/JUV ONSET 0.490 Group 5 
CYSTINOSIS 0.531 Group 5 
FABRY'S DISEASE 0.541 Group 5 
CALCINEURIN INHIBITOR NEPHROTOXICITY 0.692 Group 5 
AMYLOIDOSIS 0.727 Group 5 
SCLERODERMA 0.748 Group 5 
RADIATION NEPHRITIS 0.837 Group 5 
SICKLE CELL ANEMIA 1.161 Group 5 
  
 
Table B-3: Description of variables used in predictive models. †See Table B-2 for 
categories in this group. 
Table B-3 continued 
Variable Name Description Categories 
AGE Recipient age (yrs) NA 
AGE_DON Donor age (yrs) NA 
CREAT_TRR Recipient serum creatinine at time of transplant NA 
DAYSWAIT_CHRON Total days on waiting list including inactive time NA 











Table B-3 continued 
Variable Name Description Categories 
GROUP_5†, 
NOT_KNOWN 
DIAL_TRR Recipient pretransplant dialysis (y,n) at transplant NO, YES 
ECD_DONOR ECD donor 0, 1 









































Table B-3 continued 
Variable Name Description Categories 

























(PATIENT < 1 
YEAR OLD), 
NOT_KNOWN 
HIST_HYPERTENS_DON Deceased donor-history of hypertension (y,n) NO, YES 
INIT_AGE Candidate age in years at time of listing NA 
ON_DIALYSIS Candidate on dialysis? (waitlist most recent) NO, YES 
ON_DIALYSIS_REGISTRAT
ION 
Recipient was on dialysis 
prior to waitlist registration. 
This was calculated by taking 
the difference between the 
date placed on the waitlist 
(INIT_DATE from the 
UNOS data) and the date first 
placed on dialysis (we used 
the minimum of 
DIALYSIS_DATE and 
DIAL_DATE as the date first 
NO, YES 
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Table B-3 continued 
Variable Name Description Categories 
placed on dialysis). If we had 
both (1) missing data from 
the dates, and (2) both 
DIAL_TCR and DIAL_TRR 
were set to 'No', we set the 
value of 
ON_DIALYSIS_REGISTRA
TION to be zero. Negative 
values were also set to zero. 
ON_EXPAND_DONOR Accept local expanded donor kidney? 0, 1 
ON_IEXPAND_DONOR Accept imported expanded donor kidney? 0, 1 
PERIP_VASC Recipient peripheral vascular disease at registration NO, YES 
PROJECTED_PAYMENTSO
URCE_AT_REGISTRATION 
Recipient primary payment 







REGION UNOS region where transplanted 
1, 2, 3, 4, 5, 6, 7, 8, 
9, 10, 11 
TOT_SERUM_ALBUM Recipient total serum albumin at registration NA 
WAITLIST_YEAR Date placed on waiting list NA 
 
Table B-4: Variables with the top 10 permutation importance. Variables also selected by 
Lasso are marked with an †. 
Table B-4 continued 
IRD Waitlist Non-IRD 
AGE_DON† DIAB† DAYSWAIT_CHRON† 
AGE† ETHCAT† DIAB† 
CREAT_TRR† FUNC_STAT_TCR† ETHCAT† 
DIAB† INIT_AGE† INIT_AGE† 
DIAG_KI† ON_DIALYSIS† ON_DIALYSIS† 
ECD_DONOR† PERIP_VASC† ON_EXPAND_DONOR† 
d 
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Table B-5: Performance of predictive models. Performance based on 10 random samples 
of 80% training data and 20% out-of-sample validation data. When preforming 
imputation in the out-of-sample data when cross-validating our predictive models, we did 
not use the response variable (patient survival time and censored status) in the 
imputation. For the waitlist kidney model, we used a random sample of 80,000 training 
observations and 20,000 out-of-sample validation observations, instead of using 80% and 
20% of all waitlist records. 
Table B-5 continued 











IRD Organ 0.690 0.064 0.023 0.006 
Non-IRD 
Organ 0.698 0.068 0.007 0.001 
Waitlist 0.688 0.101 0.005 0.001 
 
Table B-6: Example of using the benefit equation. 
Table B-6 continued 
Variable 
values: 
DIAL_TRR:Y=1, PERIP_VASC:Y=0, DIAB:YES=0, 
ON_EXPAND_DONOR:1=0, ETHCAT:WHITE=1, DIAB:NOT 
KNOWN=0, ON_IEXPAND_DONOR:1=0, 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATION:MEDI
CARE=0, CREAT_TRR=7.991, AGE=48.607, 
WAITLISTDAYS=671.879, AGE_DON=38.697, REGION:5=1, 
REGION:3=0, FUNC_STAT_TRR:80-100 PERCENT PERFORMS 




Table B-6 continued 
WAITLIST_YEAR=2005.174, ETHCAT:HISPANIC=0, 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATION:SOME 










4.12 (A potential recipient with these variable values is predicted to 
have a 4.12% higher survival probability receiving an IRD kidney 





APPENDIX C. APPENDIX FOR CHAPTER 4 
Table C-1: Coefficients of original categories for patient diagnosis and their new 
grouping. Controlled for: recipient age, diabetes, functional status, and donor age. We 
used the following method to group the variable values: (1) Create binary variables 
(dummy variables) corresponding to each of the values for the categorical variable. (2) 
Build a Cox proportional hazards model to predict recipient post-transplant survival using 
the binary variables from step 2, in addition to other relevant variables to control for, 
such as recipient age. (3) Sort the coefficients for the binary variables corresponding to 
the categorical variable from the Cox model into a prespecified number of quantiles, 
representing the new categorical variable values. Note that the Cox model used to group 
the variable values was trained on the entire dataset, and we did not exclude HCV 
positive recipients, nor donors with HCV antibody, HCV RNA, and HCV RIBA status. 
Table C-1 continued 
Organ Factor level Coefficient New group 
Heart 
RESTRICTIVE MYOPATHY: 
ENDOCARDIAL FIBROS -0.870 Group 1 
RESTRICTIVE MYOPATHY: 
SARCOIDOSIS -0.734 Group 1 
RESTRICTIVE MYOPATHY: 
OTHER SPECIFY -0.456 Group 1 
HYPERTROPHIC 
CARDIOMYOPATHY -0.393 Group 1 
DILATED MYOPATHY: VIRAL -0.359 Group 1 
DILATED MYOPATHY: FAMILIAL -0.353 Group 1 
CONGENITAL HEART DEFECT - 
WITHOUT SURGERY -0.252 Group 1 
DILATED MYOPATHY: 
MYOCARDITIS -0.241 Group 2 
DILATED MYOPATHY: OTHER 
SPECIFY -0.229 Group 2 
DILATED MYOPATHY: 
IDIOPATHIC -0.148 Group 2 
VALVULAR HEART DISEASE -0.137 Group 2 
OTHER - SPECIFY -0.080 Group 2 
RESTRICTIVE MYOPATHY: 
IDIOPATHIC -0.072 Group 2 
DILATED MYOPATHY: 
ADRIAMYCIN -0.015 Group 3 
CORONARY ARTERY DISEASE -0.009 Group 3 
CANCER 0.000 Group 3 
DILATED MYOPATHY: ISCHEMIC 0.028 Group 3 
d 
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Table C-1 continued 
CONGENITAL HEART DEFECT - 
PRIOR SURGERY UNKNOWN 0.182 Group 3 
HEART RE-TX/GF: NON-SPECIFIC 0.188 Group 3 
DILATED MYOPATHY: 
ALCOHOLIC 0.230 Group 4 
HEART RE-TX/GF: CORONARY 
ARTERY DISEASE 0.236 Group 4 
HEART RE-TX/GF: CHRONIC 
REJECTION 0.254 Group 4 
HEART RE-TX/GF: ACUTE 
REJECTION 0.349 Group 4 
CONGENITAL HEART DEFECT - 
WITH SURGERY 0.368 Group 4 
CONGENITAL HEART DEFECT - 
HYPOPLASTIC LEFT HEART 
SYNDROME - UNOPERATED 
0.377 Group 4 
DILATED MYOPATHY: POST 
PARTUM 0.405 Group 5 
RESTRICTIVE MYOPATHY: 
AMYLOIDOSIS 0.493 Group 5 
HEART RE-TX/GF: 
RESTRICTIVE/CONSTRICTIVE 0.609 Group 5 
HEART RE-TX/GF: OTHER 
SPECIFY 0.743 Group 5 
RESTRICTIVE MYOPATHY: SEC 
TO RADIAT/CHEM 0.753 Group 5 
HEART RE-TX/GF: PRIMARY 
FAILURE 0.857 Group 5 
HEART RE-TX/GF: HYPERACUTE 
REJECTION 1.438 Group 5 
Liver 
BENIGN TUMOR: HEPATIC 
ADENOMA -11.543 Group 1 
METDIS: MAPLE SYRUP URINE 
DISEASE -2.096 Group 1 
BILIARY HYPOPLASIA: 
NONSYNDROMIC PAUCITY OF 
INTRAHEPATIC BILE DUCT 
-0.909 Group 1 
METDIS: WILSON'S DISEASE, 
OTHER COPPER METABOLISM 
DISORDER 
-0.709 Group 1 
AHN: TYPE A -0.709 Group 1 
METDIS: TYROSINEMIA -0.591 Group 1 
PSC: ULCERATIVE COLITIS -0.493 Group 1 
BILIARY ATRESIA: 
EXTRAHEPATIC -0.437 Group 1 
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PSC: NO BOWEL DISEASE -0.433 Group 1 
CONGENITAL HEPATIC FIBROSIS -0.431 Group 1 
METDIS: ALPHA-1-ANTITRYPSIN 
DEFIC A-1-A -0.379 Group 1 
CIRRHOSIS: TYPE B- HBSAG+ -0.372 Group 1 
AHN: TYPE B- HBSAG+ -0.332 Group 1 
PRIMARY BILIARY CIRRHOSIS 
(PBC) -0.274 Group 1 
CIRRHOSIS: DRUG/INDUST 
EXPOSURE OTHER SPECIFY -0.263 Group 1 
PSC: CROHN'S DISEASE -0.249 Group 2 
BENIGN TUMOR: POLYCYSTIC 
LIVER DISEASE -0.249 Group 2 
BILIARY HYPOPLASIA: 
ALAGILLE SYNDROME (PAUCITY 
OF INTRAHEPATIC BILE DUCT) 
-0.245 Group 2 
CIRRHOSIS: FATTY LIVER 
(NASH) -0.210 Group 2 
CIRRHOSIS: CRYPTOGENIC 
(IDIOPATHIC) -0.186 Group 2 
FAMILIAL CHOLESTASIS: OTHER 
SPECIFY -0.173 Group 2 
METDIS: GLYC STOR DIS TYPE I 
(GSD-I) -0.167 Group 2 
CIRRHOSIS: CHRONIC ACTIVE 
HEPATITIS: ETIOLOGY 
UNKNOWN 
-0.167 Group 2 
AHN: TYPE B AND D -0.115 Group 2 
FAMILIAL CHOLESTASIS: 
BYLER'S DISEASE -0.109 Group 2 
CIRRHOSIS: TYPE A -0.071 Group 2 
METDIS: GLYC STOR DIS TYPE IV 
(GSD-IV) -0.069 Group 2 
BUDD-CHIARI SYNDROME -0.065 Group 2 
BILIARY ATRESIA OR 
HYPOPLASIA: OTHER, SPECIFY -0.062 Group 2 
ALCOHOLIC CIRRHOSIS -0.060 Group 3 
CIRRHOSIS: AUTOIMMUNE -0.049 Group 3 
AHN: DRUG OTHER SPECIFY -0.044 Group 3 
SEC BILIARY CIRRHOSIS: 
CAROLI'S DISEASE -0.044 Group 3 
AHN: OTHER, SPECIFY (E.G., 
ACUTE VIRAL INFECTION, -0.018 Group 3 
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AUTOIMMUNE HEPATITIS - 
FULMINANT) 
CIRRHOSIS: TYPE B AND D -0.007 Group 3 
ACUTE ALCOHOLIC HEPATITIS 0.000 Group 3 
AHN: ETIOLOGY UNKNOWN 0.023 Group 3 
PSC: OTHER SPECIFY 0.036 Group 3 
CHOLES LIVER DISEASE: OTHER 
SPECIFY 0.097 Group 3 
BENIGN TUMOR: OTHER 
SPECIFY 0.111 Group 3 
METDIS: HEMOCHROMATOSIS - 
HEMOSIDEROSIS 0.151 Group 3 
AHN: TYPE D 0.164 Group 3 




0.168 Group 3 
METDIS: OTHER SPECIFY 0.194 Group 4 
CIRRHOSIS: TYPE B AND C 0.200 Group 4 
ALCOHOLIC CIRRHOSIS WITH 
HEPATITIS C 0.209 Group 4 
PLM: HEPATOMA (HCC) AND 





0.226 Group 4 
PLM: HEPATOMA - 
HEPATOCELLULAR CARCINOMA 0.228 Group 4 
TPN/HYPERALIMENTATION IND 
LIVER DISEASE 0.242 Group 4 
SECONDARY HEPATIC 
MALIGNANCY OTHER SPECIFY 0.243 Group 4 
CIRRHOSIS: TYPE C 0.257 Group 4 
OTHER SPECIFY 0.312 Group 4 
SEC BILIARY CIRRHOSIS: 
CHOLEDOCHOL CYST 0.338 Group 4 
NEONATAL CHOLESTATIC LIVER 
DISEASE 0.353 Group 4 
AHN: TYPE B AND C 0.367 Group 4 
NEONATAL HEPATITIS OTHER 
SPECIFY 0.373 Group 4 
AHN: TYPE C 0.398 Group 5 
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Table C-1 continued 
CIRRHOSIS: CRYPTOGENIC- 




0.495 Group 5 
SEC BILIARY CIRRHOSIS: OTHER 
SPECIFY 0.535 Group 5 
CYSTIC FIBROSIS 0.612 Group 5 
CIRRHOSIS: TYPE D 0.667 Group 5 
GRAFT FAILURE 0.706 Group 5 
PLM: OTHER SPECIFY (I.E., 
KLATZKIN TUMOR, 
LEIOMYSARCOMA) 




0.730 Group 5 
TRAUMA OTHER SPECIFY 0.735 Group 5 
PLM: HEPATOBLASTOMA (HBL) 0.781 Group 5 
PLM: CHOLANGIOCARCINOMA 
(CH-CA) 0.804 Group 5 
GRAFT VS. HOST DIS SEC TO 
NON-LI TX 0.849 Group 5 
PLM: FIBROLAMELLAR (FL-HC) 0.851 Group 5 
BILE DUCT CANCER: 
(CHOLANGIOMA, BILIARY 
TRACT CARCINOMA) 
1.107 Group 5 
Lung 
CARCINOID TUMORLETS -13.775 Group 1 
HERMANSKY PUDLAK 
SYNDROME -13.696 Group 1 
FIBROCAVITARY LUNG DISEASE -13.690 Group 1 
KARTAGENER'S SYNDROME -13.633 Group 1 
EISENMENGER'S SYN: PDA -13.537 Group 1 
FIBROSING MEDIASTINITIS -13.482 Group 1 
SCHWACKMAN-DIAMOND 
SYNDROME -13.461 Group 1 
PORTOPULMONARY 
HYPERTENSION -13.379 Group 1 
CONGENITAL MALFORMATION -13.298 Group 1 
LYMPHANGIOLEIOMYOMATOSIS -0.772 Group 1 
SILICOSIS -0.661 Group 1 
CREST - PULMONARY 
HYPERTENSION -0.627 Group 1 
EISENMENGER'S SYN: ATRIAL 
SEPTAL DEFEC -0.583 Group 1 
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Table C-1 continued 
IDIOPATHIC PULMONARY 
HEMOSIDEROSIS -0.569 Group 1 
HYPOGAMMAGLOBULINEMIA -0.548 Group 1 
BRONCHOPULMONARY 
DYSPLASIA -0.527 Group 1 
SCLERODERMA -0.502 Group 2 
GRANULOMATOUS LUNG 
DISEASE -0.376 Group 2 
HYPERSENSITIVITY 
PNEUMONITIS -0.322 Group 2 
ALPHA - 1 - ANTITRYPSIN 
DEFICIENCY -0.320 Group 2 
WEGENER'S GRANULOMA - 
BRONCHIECTASIS -0.296 Group 2 
ALVEOLAR PROTEINOSIS -0.291 Group 2 
SARCOIDOSIS -0.260 Group 2 
PULMONARY VASCULAR 
DISEASE -0.242 Group 2 
OTHER - SPECIFY -0.230 Group 2 
BRONCHIECTASIS -0.212 Group 2 
COPD/EMPHYSEMA -0.190 Group 2 
CYSTIC FIBROSIS -0.189 Group 2 
SJOGREN'S SYNDROME -0.182 Group 2 
RHEUMATOID DISEASE -0.152 Group 2 
OBSTRUCTIVE LUNG DISEASE -0.152 Group 2 
IDIOPATHIC PULMONARY 
FIBROSIS / USUAL INTERSTITIAL 
PNEUMONITIS 
-0.146 Group 2 
OBLITERATIVE BRONCHIOLITIS 
(NON-RETRANSP -0.142 Group 3 
SURFACTANT PROTEIN B 
DEFICIENCY -0.106 Group 3 
EOSINOPHILIC GRANULOMA -0.100 Group 3 
BOOP -0.076 Group 3 
PULMONARY FIBROSIS OTHER 
SPECIFY CAUSE -0.067 Group 3 
SCLERODERMA - PULMONARY 
HYPERTENSION -0.064 Group 3 
PRIMARY PULMONARY 
HYPERTENSION -0.054 Group 3 
OCCUPATIONAL LUNG DISEASE 
OTHER SPECIFY -0.016 Group 3 
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0.000 Group 3 
CHRONIC PNEUMONITIS OF 
INFANCY 0.003 Group 3 
SCLERODERMA - RESTRICTIVE 0.055 Group 3 
SECONDARY PULMONARY 
HYPERTENSION 0.063 Group 3 
ARDS/PNEUMONIA 0.099 Group 3 
LYMPHOCYTIC INTERSTITIAL 
PNEUMONITIS 0.105 Group 3 
PULMONARY VENO-OCCLUSIVE 
DISEASE 0.163 Group 3 
MIXED CONNECTIVE TISSUE 
DISEASE 0.171 Group 4 
LUNG RE-TX/GF: OBLITERATIVE 
BRONCHIOLITIS-OBSTRUCTIVE 0.192 Group 4 
CONSTRICTIVE BRONCHIOLITIS 0.218 Group 4 
LUNG RE-TX/GF: NON-SPECIFIC 0.228 Group 4 
POLYMYOSITIS 0.266 Group 4 
LUNG RE-TX/GF: OBLITERATIVE 
BRONCHIOLITIS-RESTRICTIVE 0.274 Group 4 
LUNG RE-TX/GF: OBLITERATIVE 
BRONCHIOLITI 0.287 Group 4 
PULMONARY 
THROMBOEMBOLIC DISEASE 0.325 Group 4 
LUPUS 0.331 Group 4 
LUNG RE-TX/GF: OBSTRUCTIVE 0.356 Group 4 
GRAFT-VS-HOST DISEASE 
(GVHD) 0.379 Group 4 
LUNG RE-TX/GF: PRIMARY 
GRAFT FAILURE 0.570 Group 4 
PULMONARY TELENGECTASIA - 
RESTRICTIVE 0.665 Group 4 
INHALATION BURNS/TRAUMA 0.690 Group 4 
BRONCHOALVEOLAR 
CARCINOMA (BAC) 0.729 Group 4 
LUNG RE-TX/GF: OTHER SPECIFY 0.732 Group 4 
PULMONARY HYALINIZING 
GRANULOMA 0.780 Group 5 
WEGENER'S GRANULOMA - 
RESTRICTIVE 0.800 Group 5 
LUNG RE-TX/GF: ACUTE 
REJECTION 0.801 Group 5 
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Table C-1 continued 
EHLERS-DANLOS SYNDROME 0.810 Group 5 
PRIMARY CILIARY DYSKINESIA 0.910 Group 5 
COMMON VARIABLE IMMUNE 
DEFICIENCY 1.015 Group 5 
PULMONARY TELENGECTASIA - 
PULMONARY HYPERTENSION 1.024 Group 5 
EISENMENGER'S SYN: OTHER 
SPECIFY 1.336 Group 5 
LUNG RE-TX/GF: RESTRICTIVE 1.568 Group 5 
TUBEROUS SCLEROSIS 1.570 Group 5 
SWYER JAMES SYNDROME 1.697 Group 5 
CREST - RESTRICTIVE 1.789 Group 5 
EISENMENGER'S SYN: MULTI 
CONGENITAL ANOM 1.948 Group 5 
EISENMENGER'S SYN: VSD 2.128 Group 5 
PULMONIC STENOSIS 2.389 Group 5 
THROMBOEMBOLIC 
PULMONARY HYPERTENSION 2.586 Group 5 
 
Table C-2: Description of variables used in predictive models. *See Table C-1 for 
categories in this group. 
Table C-2 continued 
Variable Name Description Categories 
AGE Recipient age (yrs) NA 
AGE_DON Donor age (yrs) NA 




BMI_CALC Calculated recipient bmi NA 
CIG_USE History of cigarette use NO, YES 
CREAT_TRR Recipient serum creatinine at time of transplant NA 
DAYSWAIT_CHRON Total days on waiting list NA 
DEATH_MECH_DO
N 










Table C-2 continued 































ECMO_TCR Patient on life support - ecmo at registration 0, 1 














Type of exception relative to 





Table C-2 continued 
Variable Name Description Categories 
FINAL_DIALYSIS_P
RIOR_WEEK 
Most recent waiting list 
dialysis twice in prior week or 
at removal if removed 
A, NO, YES 




























(PATIENT < 1 
YEAR OLD), 
NOT_KNOWN 













Table C-2 continued 





















Lu/hl diagnosis grouping on 
wl(on 
thoracic_dgn/tcr_tgn/trr_dgn) 
A, B, C, D 
HGT_CM_DON_CAL
C Calculated donor height (cm) NA 
HGT_CM_TCR Recipient height at registration NA 
HIST_CIG_DON 
Deceased donor-history of 
cigarettes in past at >20pack 
yrs 
NO, YES 
INIT_AGE Age in years at time of listing NA 
INIT_ALBUMIN Initial waiting list albumin NA 
INIT_BILIRUBIN Initial waiting list bilirubin NA 
INIT_BLU_FLG Lung preference at listing - both (1=y) 0, 1 
INIT_INR Initial waiting list inr NA 
INIT_MELD_OR_PE
LD 
Initial waiting list use meld or 
peld MELD, PELD 
INIT_O2 O2 requirement at rest at tcr/listing NA 
INIT_RLU_FLG Lung preference at listing - right (1=y) 0, 1 
INIT_SERUM_CREA
T 
Initial waiting list serum 
creatinine NA 
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Table C-2 continued 
Variable Name Description Categories 





INOTROPES_TCR IB inotropes at registration 0, 1 
INSULIN_DON 
Deceased donor-was donor 




Recipient life support 
calculated on tcr_life_sup and 
vad_device_ty 
NO, YES 
LIFE_SUP_TCR Recipient life support at registration NO, YES 
LIFE_SUP_TRR Recipient life support pre-transplant   at transplant NO, YES 
MED_COND_TRR Recipient medical condition pre-transplant   at transplant 
HOSPITALIZE








Recipient most recent absolute 
creatinine at registration NA 
NUM_PREV_TX The number of previous transplants NA 
ON_VENT_TRR Recipient on ventilator at transplant 0, 1 
PAYMENTSOURCE_
AT_TRANSPLANT 
Recipient primary payment 









Recipient previous upper 





Tcr prior cardiac surgery at 




Recipient primary payment 






Table C-2 continued 
Variable Name Description Categories 
PRIMARY OR 
SECONDARY 
REGION Wl unos/optn region where listed/transplanted 
1, 2, 3, 4, 5, 6, 7, 
8, 9, 10, 11 
SGPT_DON Deceased donor-terminal sgpt/alt NA 









Recipient total serum albumin  
at registration NA 
TRANSFUSIONS 
Events occurring between 





Candidate type of vad device at 
listing  
VENTILATOR_TCR Patient on life support - ventilator at registration 0, 1 
WAITLIST_YEAR Date placed on waiting list NA 
 
Table C-3: Variables with the top 10 permutation importance. Variables also selected by 
Lasso are marked with an *. 
Table C-3 continued 
Organ IRD Non-IRD Waitlist 
Heart 
AGE_DON* CIG_USE* ECMO_TCR* 
AGE* DAYSWAIT_CHRON* FUNC_STAT_TCR* 
CREAT_TRR* ETHCAT* HGT_CM_TCR* 
DEATH_MECH_DO
N* INIT_AGE* INIT_STAT* 
DIAG* MOST_RCNT_CREAT* INOTROPES_TCR* 
FUNC_STAT_TRR* PRIOR_CARD_SURG_TCR* LIFE_SUP* 
INSULIN_DON* PROJECTED_PAYMENTSOURC MOST_RCNT_CREAT* 
d 
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Table C-3 continued 













TRANSFUSIONS* WAITLIST_YEAR* WAITLIST_YEAR* 
Liver 
AGE* DGN_TCR* EXC_HCC* 
ASCITES_TX* DIAB* FUNC_STAT_TCR* 
BMI_CALC* FUNC_STAT_TCR* INIT_ALBUMIN* 
FINAL_DIALYSIS_P
RIOR_WEEK* INIT_AGE* INIT_BILIRUBIN* 







LIFE_SUP_TRR* INIT_SERUM_CREAT* INIT_STAT* 
MED_COND_TRR* NUM_PREV_TX* LIFE_SUP_TCR* 








AGE* FUNC_STAT_TCR* CIG_USE* 
BMI_CALC GROUPING* FUNC_STAT_TCR* 
DIAG* INIT_AGE* GROUPING* 
GROUPING* INIT_BLU_FLG* INIT_O2* 
HGT_CM_DON_CAL
C* INIT_CREAT INIT_RLU_FLG* 
HIST_CIG_DON* INIT_O2* LIFE_SUP 
ISCHTIME NUM_PREV_TX REGION* 
MED_COND_TRR PROJECTED_PAYMENTSOURC THORACIC_DGN* 
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Table C-3 continued 
Organ IRD Non-IRD Waitlist 
E_AT_REGISTR
ATION 
REGION REGION* VENTILATOR_TCR 
STEROID THORACIC_DGN* WAITLIST_YEAR* 
 
Table C-4: Summary of all the variables used in the predictive models for the heart and 
their distribution in the general heart transplant population in the data. The mean value in 
the data is shown for numeric variables, and the percentage of observations for each 
category is shown for categorical variables. *See Table C-1 for categories in this group. 
Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 
HCV positive donors 
or recipients) 
AGE 49.4    45.1 
AGE_DON 27.9   27.9 28.1 
CIG_USE: N 56.1% 59.9%   59.7% 
CIG_USE: Y 43.9% 40.1%   40.3% 
CREAT_TR
R 1.2   1.2 1.2 
DAYSWAIT















4.8%   4.7% 5.4% 
d 
 158 
Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 


































23.3%   23.3% 18.1% 
DIAG: 
GROUP_1* 7.2%    7.3% 
DIAG: 
GROUP_2* 42.5%    42.7% 
DIAG: 
GROUP_3* 39.8%    38.6% 
DIAG: 
GROUP_4* 7.1%    8.7% 
DIAG: 
GROUP_5* 3.4%    2.7% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 
HCV positive donors 
or recipients) 
ECMO_TCR
: 0 98.7% 98.6% 97.5%  98.6% 
ECMO_TCR





0.1% 0.3% 0.3%  0.3% 
ETHCAT: 
ASIAN 3.1% 3.2% 2.6%  2.9% 
ETHCAT: 
BLACK 18.4% 19.4% 19.2%  18.2% 
ETHCAT: 











0.3% 0.3% 0.3%  0.3% 
ETHCAT: 















 24.9% 19.4% 26.7% 19.5% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 








































< 1 YEAR 
OLD) 
 9% 18.1% 4.9% 18.2% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 










































25%    23.8% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 



















< 1 YEAR 
OLD) 





2.2%    3% 
HGT_CM_T
CR  162.9 162.8  163.7 
















34.9% 34.1% 38.1%  37.6% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 







1.8% 2.2% 2.6%  1.9% 
INOTROPES
_TCR: 0 66.1% 63.2% 63.7%  62.1% 
INOTROPES
_TCR: 1 33.9% 36.8% 36.3%  37.9% 
INSULIN_D
ON: N 39.5%   39.8% 36.7% 
INSULIN_D
ON: Y 60.5%   60.2% 63.3% 
LIFE_SUP: 
N 45.8% 45.7% 47.2%  46.7% 
LIFE_SUP: 
Y 54.2% 54.3% 52.8%  53.3% 
MOST_RCN























54.8%    57.9% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 













































 57% 58.1% 58.6% 59.9% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 

























 2.8% 3.2% 3% 2.6% 
TOT_SERU
M_ALBUM 3.7 3.7   3.6 
TRANSFUSI
ONS: N 78%   77.5% 74.3% 
TRANSFUSI
















 2.4% 2.1%  2% 
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Table C-4 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population 
(including both IRD 
and non-IRD donors, 
without removing 















 0.4% 0.3%  0.3% 
VENTILAT
OR_TCR: 0 96.6% 95.1% 92.8%  94.7% 
VENTILAT
OR_TCR: 1 3.4% 4.9% 7.2%  5.3% 
WAITLIST_
YEAR 2008.8 2008.3 2007.3  2006.7 
 
 
Table C-5: Summary of all the variables used in the predictive models for the liver and 
their distribution in the general liver transplant population in the data. The mean value in 
the data is shown for numeric variables, and the percentage of observations for each 
category is shown for categorical variables. *See Table C-1 for categories in this group. 
Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 
positive donors or 
recipients) 
AGE 49.4    49 
d 
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Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 
positive donors or 
recipients) 
ASCITES_TX: 
ABSENT 22.3%   23.3% 24.2% 
ASCITES_TX: 
MODERATE 28.9%   28.5% 26.8% 
ASCITES_TX: 
SLIGHT 48.8%   48.2% 49% 
BMI_CALC 27.7   27.9 27.3 
DAYSWAIT_C
HRON 240.2 217.1  251.1 248.7 
DGN_TCR: 
GROUP_1*  22.2% 12.5%  14.6% 
DGN_TCR: 
GROUP_2*  21.7% 12%  10.6% 
DGN_TCR: 
GROUP_3*  33.1% 21.7%  20.3% 
DGN_TCR: 
GROUP_4*  19.2% 49.1%  49.3% 
DGN_TCR: 
GROUP_5*  3.8% 4.7%  5.1% 
DGN_TCR: 
NOT KNOWN  <0.1% <0.1%  0.1% 
DIAB: NO 73.8% 76.5% 75.6%  77.5% 
DIAB: NOT 
KNOWN 1.4% 1.3% 2%  2.1% 
DIAB: YES 24.8% 22.2% 22.4%  20.4% 
EXC_HCC: 
HCC 14.7% 12.7% 12.6%  19.3% 
EXC_HCC: 








89.9%   91.1% 89.6% 
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Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 












































 36.2% 41.7% 37.6% 42.2% 
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Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 





(PATIENT < 1 
YEAR OLD) 






































23.8%    31.3% 
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Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 










(PATIENT < 1 
YEAR OLD) 




2.6%    4.2% 
INIT_AGE  46 49.4 50.9 48.3 
INIT_ALBUMI
N 3 3 3  3 
INIT_BILIRUBI
N 8.4 8.3 6.1  6.8 




94.2% 88.8% 93.5%  92.3% 
INIT_MELD_O
R_PELD: PELD 5.8% 11.2% 6.5%  7.7% 
INIT_SERUM_
CREAT 1.3 1.2 1.3 1.3 1.2 
INIT_STAT: <= 
10  20.9% 25.2%  27.8% 
INIT_STAT: >= 
25  20.3% 15%  15.2% 
INIT_STAT: 11-
18  33.9% 38.7%  35% 
INIT_STAT: 1A  6.6% 3.2%  3.4% 
INIT_STAT: 1B  0.3% 0.1%  0.1% 
INIT_STAT: 24-
19  16.9% 14.5%  14.1% 
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Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 
positive donors or 
recipients) 
INIT_STAT: 2A  <0.1% 0.3%  0.3% 
INIT_STAT: 2B  0.2% 1.6%  2.9% 
INIT_STAT: 




 1% 1.4%  1.2% 
LIFE_SUP_TC
R: N 94.2% 94.3% 95% 95.7% 95.6% 
LIFE_SUP_TC
R: Y 5.8% 5.7% 5% 4.3% 4.4% 
LIFE_SUP_TR
R: N 90%    92.3% 
LIFE_SUP_TR




D NOT IN ICU 














D NOT IN ICU 





17.6%    14.1% 
MED_COND_T
RR: NOT 62.2%    69.1% 
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Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 





X 0.1 0.1 0.1  0.1 
ON_VENT_TR
R: 0 91.5%   93.6% 93.5% 
ON_VENT_TR
R: 1 8.5%   6.4% 6.5% 
PREV_AB_SU
RG_TCR: N 59.7% 59.2% 60%  60.5% 
PREV_AB_SU



























 63.1% 61.9%  64.3% 
SGPT_DON 100.9   108.3 68.7 
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Table C-5 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including 
both IRD and non-
IRD donors, without 
removing HCV 
positive donors or 
recipients) 
VENTILATOR_
TCR: 0 94.5% 94.7% 95.5%  96% 
VENTILATOR_
TCR: 1 5.5% 5.3% 4.5%  4% 
WAITLIST_YE
AR 2008.6 2008.1 2007.3  2006.5 
 
 
Table C-6: Summary of all the variables used in the predictive models for the lung and 
their distribution in the general lung transplant population in the data. The mean value in 
the data is shown for numeric variables, and the percentage of observations for each 
category is shown for categorical variables. *See Table C-1 for categories in this group. 
Table C-6 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including both 
IRD and non-IRD donors, 
without removing HCV 
positive donors or 
recipients) 
AGE 53.8    52.8 
CIG_USE: N   42.5%  40.4% 
CIG_USE: Y   57.5%  59.6% 
DAYSWAIT
_CHRON 219.7 222.1  219.7 227.3 
DIAG: 
GROUP_1* 1%    1.3% 
DIAG: 
GROUP_2* 84%    82.8% 
DIAG: 
GROUP_3* 9.5%    10.9% 
d 
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Table C-6 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including both 
IRD and non-IRD donors, 
without removing HCV 
positive donors or 
recipients) 
DIAG: 
GROUP_4* 5.3%    4.7% 
DIAG: 







































 16% 14.6% 14.6% 16.7% 
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Table C-6 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including both 
IRD and non-IRD donors, 
without removing HCV 










< 1 YEAR 
OLD) 

































37.9%    40.5% 
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Table C-6 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including both 
IRD and non-IRD donors, 
without removing HCV 




















< 1 YEAR 
OLD) 




1.4%    1.9% 
GROUPING: 
A 35.7% 32% 31.2% 37.5% 33.3% 
GROUPING: 
B 2.2% 3.6% 4.9% 2.2% 3.5% 
GROUPING: 
C 13.3% 13.3% 13.1% 12.7% 13.3% 
GROUPING: 
D 48.8% 51.1% 50.8% 47.6% 49.8% 
HGT_CM_D
ON_CALC 173.9   173.8 170.7 
HIST_CIG_D
ON: N 83.8%   83% 88.1% 
HIST_CIG_D
ON: Y 16.2%   17% 11.9% 
INIT_AGE  52.1 51.6 53.3 52.2 
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Table C-6 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including both 
IRD and non-IRD donors, 
without removing HCV 
positive donors or 
recipients) 
INIT_BLU_F
LG: 0 25.2% 25.3% 22.1%  25.5% 
INIT_BLU_F
LG: 1 74.8% 74.7% 77.9%  74.5% 
INIT_O2 3.9 3.8 4  3.7 
INIT_RLU_F
LG: 0 61.8% 60.8% 64.2%  61.2% 
INIT_RLU_F
































 60.8% 60.2%  61.5% 
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Table C-6 continued 
Variable MIRD MNon-IRD MWait M'IRD 
General 
population (including both 
IRD and non-IRD donors, 
without removing HCV 




REGION: 1 2% 2.8% 3%  2.6% 
REGION: 2 12.9% 11.6% 15.5%  15.8% 
REGION: 3 10.3% 12.4% 12.2%  11.4% 
REGION: 4 13.8% 12.2% 11.6%  11.6% 
REGION: 5 13.8% 15.7% 14.5%  14.5% 
REGION: 6 3% 3.2% 3%  3% 
REGION: 7 9.7% 8% 7.9%  8.2% 
REGION: 8 8.2% 7.6% 7%  7% 
REGION: 9 1.9% 4% 3.8%  3.6% 
REGION: 10 11.3% 11.6% 11.6%  11.1% 
























 <0.1% <0.1% 0% <0.1% 
WAITLIST_
YEAR 2008.8 2008.3 2008.8  2008.2 
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Table C-7: Performance of predictive models. Performance based on 10 random samples 
of 80% training data and 20% out-of-sample validation data. For the waitlist liver model, 
we used a random sample of 80,000 training observations and 20,000 out-of-sample 
validation observations, instead of using 80% and 20% of all waitlist records. 
Table C-7 continued 
Model Random survival forests Cox proportional hazards model 


















































0.620 0.117 0.008 0.002 0.622 0.117 0.007 0.002 
Waitlist 
liver 0.777 0.144 0.007 0.002 0.804 0.142 0.005 0.002 
IRD lung 0.589 0.181 0.020 0.014 0.596 0.182 0.023 0.012 
Non-
IRD lung 0.568 0.182 0.009 0.002 0.568 0.182 0.009 0.002 
Waitlist 
lung 0.775 0.158 0.011 0.005 0.788 0.158 0.010 0.006 
 
Table C-8: Example of using the benefit equations. 
Table C-8 continued 







PRIVATE BY PRIMARY OR SECONDARY=1, 





Table C-8 continued 








LIFE_SUP:Y=1, INOTROPES_TCR:1=0, AGE=45.083, 
WAITLISTDAYS=190.687, HGT_CM_TCR=163.746, 
AGE_DON=28.073, WAITLIST_YEAR=2006.682, 
DEATH_MECH_DON:STAB OR GUNSHOT 
WOUND=0, FUNC_STAT_TRR:60-70 PERCENT 
PERFORMS ACTIVITIES OF DAILY LIVING WITH 
SOME ASSISTANCE=1, TOT_SERUM_ALBUM=3.647, 
DIAG:GROUP_3=0, 
DEATH_MECH_DON:INTRACRANIAL 
HEMORRHAGE/STROKE=0, INIT_STAT:HR: STATUS 
1B=0, TRANSFUSIONS:Y=0, CREAT_TRR=1.201, 
















WAITLIST_YEAR=2006.485, DIAB:NOT KNOWN=0, 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATIO
N:MEDICARE=0, FUNC_STAT_TRR:60-70 PERCENT 
PERFORMS ACTIVITIES OF DAILY LIVING WITH 
SOME ASSISTANCE=0, ASCITES_TX:SLIGHT=1, 
MED_COND_TRR:NOT HOSPITALIZED=1, 
MED_COND_TRR:IN INTENSIVE CARE UNIT=0, 
ON_VENT_TRR:1=0, 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATIO




Table C-8 continued 
FUNC_STAT_TRR:80-100 PERCENT PERFORMS 








PERCENT PERFORMS ACTIVITIES OF DAILY 
LIVING WITH SOME ASSISTANCE=1, 
FUNC_STAT_TRR:80-100 PERCENT PERFORMS 
ACTIVITIES OF DAILY LIVING WITH NO 
ASSISTANCE=0, CIG_USE:Y=1, 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATIO
N:MEDICARE=0, INIT_RLU_FLG:1=0, REGION:5=0, 
INIT_BLU_FLG:1=1, 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATIO





Table C-9: Benefit equation for the 5-year survival probability of receiving an IRD organ 
minus the 5-year survival probability of waiting for a non-IRD organ. The benefit 
equation predicts the increase (positive value) or decrease (negative value) in probability 
(multiplied by 100) of surviving to 5 years with an IRD organ vs. waiting for a non-IRD 
organ. Reference levels for heart categorical Factors: CIG_USE:  No. 
DEATH_MECH_DON:  Blunt injury. DIAG:  Group_2. ECMO_TCR:  0. ETHCAT:  
Black. FUNC_STAT_TRR:  30-50 percent requires considerable assistance but death not 
imminent. INIT_STAT:  Hr: status 1a. INOTROPES_TCR:  0. INSULIN_DON:  No. 
LIFE_SUP:  No. PAYMENTSOURCE_AT_TRANSPLANT:  Medicaid. 
PRIOR_CARD_SURG_TCR:  No. TRANSFUSIONS:  No. VAD_DEVICE_TY_TCR:  
Lvad. VENTILATOR_TCR:  0. Reference levels for liver categorical Factors: 
ASCITES_TX:  Absent. DGN_TCR:  Group_1. DIAB:  No. EXC_HCC:  Hcc. 
FINAL_DIALYSIS_PRIOR_WEEK:  A. FUNC_STAT_TRR:  30-50 percent requires 
considerable assistance but death not imminent. INIT_MELD_OR_PELD:  Meld. 
INIT_STAT:  <= 10. LIFE_SUP_TRR:  No. MED_COND_TRR:  Hospitalized not in 
icu. ON_VENT_TRR:  0. PREV_AB_SURG_TCR:  No. 
PROJECTED_PAYMENTSOURCE_AT_REGISTRATION:  Medicaid. 
VENTILATOR_TCR:  0. Reference levels for lung categorical Factors: CIG_USE:  No. 
DIAG:  Group_2. FUNC_STAT_TRR:  30-50 percent requires considerable assistance 
but death not imminent. GROUPING:  A. HIST_CIG_DON:  No. INIT_BLU_FLG:  0. 
d 
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INIT_RLU_FLG:  0. PROJECTED_PAYMENTSOURCE_AT_REGISTRATION:  
Medicaid. REGION:  2. *See Table C-1 for categories in this group.  
Table C-9 continued 
Organ Variable Coefficients P-Values 
Heart 
(INTERCEPT) 2275.823 <0.01 
ECMO_TCR: 1 10.850 <0.01 
PAYMENTSOURCE_AT_TRANSPLANT
: SOME PRIVATE BY PRIMARY OR 
SECONDARY 
8.949 <0.01 
FUNC_STAT_TRR: NOT APPLICABLE 
(PATIENT < 1 YEAR OLD) 8.203 <0.01 
DIAG: GROUP_4* 7.824 <0.01 
INSULIN_DON: Y 7.492 <0.01 
PAYMENTSOURCE_AT_TRANSPLANT
: MEDICARE 5.125 <0.01 
VAD_DEVICE_TY_TCR: 
LVAD/RVAD/TAH UNSPECIFIED 4.623 <0.01 
MOST_RCNT_CREAT 4.501 <0.01 
PRIOR_CARD_SURG_TCR: Y 4.469 <0.01 
VENTILATOR_TCR: 1 4.100 <0.01 
VAD_DEVICE_TY_TCR: NONE 2.422 <0.01 
CIG_USE: Y 1.992 <0.01 
LIFE_SUP: Y 0.772 <0.01 
INOTROPES_TCR: 1 0.461 <0.01 
AGE 0.108 <0.01 
WAITLISTDAYS 0.029 <0.01 
HGT_CM_TCR -0.063 <0.01 
AGE_DON -0.214 <0.01 
WAITLIST_YEAR -1.125 <0.01 
DEATH_MECH_DON: STAB OR 
GUNSHOT WOUND -1.299 <0.01 
FUNC_STAT_TRR: 60-70 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH SOME ASSISTANCE 
-1.964 <0.01 
TOT_SERUM_ALBUM -2.334 <0.01 
DIAG: GROUP_3* -2.862 <0.01 
DEATH_MECH_DON: INTRACRANIAL 
HEMORRHAGE/STROKE -2.914 <0.01 
d 
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Table C-9 continued 
INIT_STAT: HR: STATUS 1B -3.424 <0.01 
TRANSFUSIONS: Y -5.324 <0.01 
CREAT_TRR -5.508 <0.01 
INIT_STAT: HR: STATUS 2 -5.688 <0.01 
ETHCAT: HISPANIC -6.450 <0.01 
ETHCAT: WHITE -6.629 <0.01 
Liver 
(INTERCEPT) 1024.296 <0.01 
INIT_STAT: >= 25 14.262 <0.01 
EXC_HCC: NON-HCC 10.852 <0.01 
FINAL_DIALYSIS_PRIOR_WEEK: N 9.019 <0.01 
DGN_TCR: GROUP_4* 7.795 <0.01 
FINAL_DIALYSIS_PRIOR_WEEK: Y 6.131 <0.01 
NUM_PREV_TX 5.147 <0.01 
VENTILATOR_TCR: 1 4.976 <0.01 
DGN_TCR: GROUP_3* 4.442 <0.01 
DIAB: YES 3.207 <0.01 
PREV_AB_SURG_TCR: Y 2.877 <0.01 
INIT_MELD_OR_PELD: PELD 1.724 <0.01 
INIT_STAT: 18-11 1.691 <0.01 
INIT_SERUM_CREAT 1.521 <0.01 
LIFE_SUP_TRR: Y 0.619 0.01 
INIT_INR 0.412 <0.01 
INIT_BILIRUBIN 0.392 <0.01 
AGE 0.207 <0.01 
WAITLISTDAYS 0.025 <0.01 
SGPT_DON 0.016 <0.01 
BMI_CALC -0.380 <0.01 
WAITLIST_YEAR -0.513 <0.01 
DIAB: NOT KNOWN -1.525 <0.01 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: MEDICARE -1.677 <0.01 
FUNC_STAT_TRR: 60-70 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH SOME ASSISTANCE 
-2.198 <0.01 
ASCITES_TX: SLIGHT -2.324 <0.01 
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Table C-9 continued 
MED_COND_TRR: NOT 
HOSPITALIZED -2.616 <0.01 
MED_COND_TRR: IN INTENSIVE 
CARE UNIT -3.864 <0.01 
ON_VENT_TRR: 1 -3.964 <0.01 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: SOME PRIVATE BY 
PRIMARY OR SECONDARY 
-4.201 <0.01 
INIT_ALBUMIN -4.612 <0.01 
FUNC_STAT_TRR: 80-100 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH NO ASSISTANCE 
-5.079 <0.01 
ASCITES_TX: MODERATE -8.173 <0.01 
Lung 
(INTERCEPT) 1601.523 <0.01 
GROUPING: C 17.000 <0.01 
GROUPING: D 5.642 <0.01 
DIAG: GROUP_4* 3.707 <0.01 
INIT_O2 1.708 <0.01 
REGION: 4 1.674 <0.01 
HGT_CM_DON_CALC 0.443 <0.01 
WAITLISTDAYS 0.020 <0.01 
AGE -0.111 <0.01 
WAITLIST_YEAR -0.828 <0.01 
FUNC_STAT_TRR: 60-70 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH SOME ASSISTANCE 
-1.590 <0.01 
FUNC_STAT_TRR: 80-100 PERCENT 
PERFORMS ACTIVITIES OF DAILY 
LIVING WITH NO ASSISTANCE 
-1.687 <0.01 
CIG_USE: Y -1.995 <0.01 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: MEDICARE -2.099 <0.01 
INIT_RLU_FLG: 1 -2.436 <0.01 
REGION: 5 -4.904 <0.01 
INIT_BLU_FLG: 1 -6.337 <0.01 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: SOME PRIVATE BY 
PRIMARY OR SECONDARY 
-7.477 <0.01 
DIAG: GROUP_3* -15.121 <0.01 
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Table C-9 continued 




APPENDIX D. APPENDIX FOR CHAPTER 5 
Table D-1: Description of the variables considered for the predictive models, and the 
percent of missing data per variable. 
Table D-1 continued 
Variable 
name Description Categories 
Missing 
percent 
ABO Recipient blood group at registration 
A, A1, A1B, A2, A2B, 
AB, B, O, 
NOT_KNOWN 
0% 
BMI_TCR BMI at listing NA 5.8% 






Days on dialysis prior to 
registration. 
DIALYSIS_DAYS_TO_W
AITLIST was calculated by 
taking the difference 
between the date placed on 
the kidney waitlist 
(INIT_DATE_KI from the 
UNOS data) and the date 
first placed on dialysis (we 
used the minimum of 
DIALYSIS_DATE and 
DIAL_DATE as the date 
first placed on dialysis). If 
we had both (1) missing 
data from the dates, and (2) 
both DIAL_TCR and 
DIAL_TRR were set to 
'No', we set the value of 
DIALYSIS_DAYS_TO_W
AITLIST to be zero. 
Negative values of 
DIALYSIS_DAYS_TO_W
AITLIST were also set to 
zero. 
NA 10.3% 









Table D-1 continued 
Variable 








Functional status at 
registration NA 7.3% 
FUNC_STA
T_TRR_TEN 
Functional status at 
transplant NA 0% 
GENDER Recipient gender F, M 0% 
HCV_SERO
STATUS Recipient HCV status 
NEGATIVE, NOT 
DONE, POSITIVE 18% 
HGT_CM_T
CR 
Recipient height at 
registration NA 5.5% 
INIT_AGE Candidate age in years at time of listing NA 0% 










Day of month at 
registration 
1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12 0% 
INIT_STAT Initial waiting list status code 
ACTIVE, INACTIVE, 






Recipient previous malig. 
at registration (kidney) NO, YES 18.6% 
NUM_PREV
_TX 
The number of previous 
transplants NA 0% 
ON_DIALY
SIS 
Candidate on dialysis? 




vascular disease  at 
registration 






Recipient primary payment 
source at registration 
MEDICAID, 
MEDICARE, OTHER, 




REGION UNOS region where transplanted 
1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11 0% 
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Table D-1 continued 
Variable 





Recipient total serum 
albumin at registration NA 46.4% 
WAITLIST_
YEAR Date placed on waiting list NA 0% 
 
Table D-2: Summary statistics of the variables used in the analysis. The mean is shown 
for numerical variables and the percent of each category is shown for categorical 
variables. 
Table D-2 continued 
Variable Mean/Distribution 
ABO: A 36.2% 
ABO: A1 0.9% 
ABO: A1B 0.1% 
ABO: A2 0.2% 
ABO: A2B <0.1% 
ABO: AB 4.7% 
ABO: B 12.8% 
ABO: O 45.1% 
ABO: UNK <0.1% 
BMI_TCR 29.5 
DIAB: NO 69.8% 
DIAB: NOT KNOWN 1.1% 
DIAB: YES 29.1% 
DIALYSIS_DAYS_TO_WAITLIST 598.2 
ETHCAT: AMER IND/ALASKA 
NATIVE 0.9% 
ETHCAT: ASIAN 4.7% 
ETHCAT: BLACK 24.9% 
ETHCAT: HISPANIC 13.3% 
ETHCAT: MULTIRACIAL 0.6% 
ETHCAT: NATIVE HAWAIIAN/OTHER 
PACIFIC ISLANDER 0.4% 
ETHCAT: WHITE 55.2% 
d 
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GENDER: F 39.4% 
GENDER: M 60.6% 
HCV_SEROSTATUS: NEGATIVE 91% 
HCV_SEROSTATUS: NOT DONE 3.4% 
HCV_SEROSTATUS: POSITIVE 5.6% 
HGT_CM_TCR 169 
INIT_AGE 45.5 
INIT_DAY: FRIDAY 24% 
INIT_DAY: MONDAY 16.3% 
INIT_DAY: SATURDAY 0.8% 
INIT_DAY: SUNDAY 0.5% 
INIT_DAY: THURSDAY 20.5% 
INIT_DAY: TUESDAY 18.6% 
INIT_DAY: WEDNESDAY 19.3% 
INIT_MONTH: 01 7.9% 
INIT_MONTH: 02 8% 
INIT_MONTH: 03 8.9% 
INIT_MONTH: 04 8.4% 
INIT_MONTH: 05 8.5% 
INIT_MONTH: 06 8.4% 
INIT_MONTH: 07 8.3% 
INIT_MONTH: 08 8.7% 
INIT_MONTH: 09 8.2% 
INIT_MONTH: 10 9% 
INIT_MONTH: 11 8% 
INIT_MONTH: 12 7.9% 
INIT_STAT: ACTIVE 88.6% 
INIT_STAT: INACTIVE 11.3% 
INIT_STAT: KI: ACTIVE - CRITICAL 
STATUS (6) 0.1% 
MALIG_TCR_KI: N 95.7% 
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Table D-2 continued 
Variable Mean/Distribution 
MALIG_TCR_KI: Y 4.3% 
NUM_PREV_TX 0.1 
ON_DIALYSIS: N 40.7% 
ON_DIALYSIS: Y 59.3% 
PERIP_VASC: N 96.3% 
PERIP_VASC: Y 3.7% 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: MEDICAID 7.2% 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: MEDICARE 33% 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: OTHER 2.7% 
PROJECTED_PAYMENTSOURCE_AT_
REGISTRATION: SOME PRIVATE BY 
PRIMARY OR SECONDARY 
57.2% 
REGION: 1 4.4% 
REGION: 2 14.1% 
REGION: 3 12% 
REGION: 4 8.7% 
REGION: 5 16.2% 
REGION: 6 3.2% 
REGION: 7 10.2% 
REGION: 8 6.1% 
REGION: 9 7% 
REGION: 10 9% 




Table D-3: The original values of functional status that come with the data and the values 
we grouped them into, for this analysis. 
Table D-3 continued 
Grouped Values Original Values 
10 10% - Moribund, fatal processes progressing rapidly 
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Table D-3 continued 
Grouped Values Original Values 
10 10% - No play; does not get out of bed 
20 20% - Very sick, hospitalization necessary: active treatment necessary 
20 20% - Often sleeping; play entirely limited to very passive activities 
30 30% - Severely disabled: hospitalization is indicated, death not imminent 
30 30% - In bed; needs assistance even for quiet play 
40 40% - Disabled: requires special care and assistance 
40 40% - Mostly in bed; participates in quiet activities 
50 Performs activities of daily living with TOTAL assistance. 
50 50% - Requires considerable assistance and frequent medical care 
50 50% - Can dress but lies around much of day; no active play; can take part in quiet play/activities 
60 Performs activities of daily living with SOME assistance. 
60 60% - Requires occasional assistance but is able to care for needs 
60 60% - Up and around, but minimal active play; keeps busy with quieter activities 
70 70% - Cares for self: unable to carry on normal activity or active work 
70 70% - Both greater restriction of and less time spent in play activity 
80 80% - Normal activity with effort: some symptoms of disease 
80 80% - Active, but tires more quickly 
90 90% - Able to carry on normal activity: minor symptoms of disease 
90 90% - Minor restrictions in physically strenuous activity 
100 Performs activities of daily living with NO assistance. 
100 100% - Normal, no complaints, no evidence of disease 




Table D-4: Cross-Validation RMSE results for the model with the lowest RMSE 
compared to the benchmark model for each cross-validation sample. 









1 13.06 14.68 
2 13.09 14.69 
3 13.02 14.74 
4 12.99 14.63 
5 13.03 14.73 
6 13.01 14.69 
7 13.02 14.72 
8 13.07 14.64 
9 12.99 14.66 
10 13.04 14.66 
11 13.03 14.73 
12 13.06 14.77 
13 13.1 14.55 
14 13.06 14.57 
15 13.03 14.61 
16 13.01 14.67 
17 13.11 14.65 
18 13.06 14.85 
19 13.14 14.71 




Table D-5: Performance results from cross-validations per model, averaged for all 
variable selection methods. The results of the final model, GA-PIRF, were excluded from 
this table. 
Table D-5 continued 










model 13.17 173.58 81.42% 92.21% 
Box-Cox linear 
regression 13.54 183.3 81.08% 91.99% 
linear regression 13.59 184.58 82.7% 90.83% 
neural networks 13.62 185.47 80.61% 91.37% 
random forests 14.68 216.9 77.24% 89.45% 
support vector 
machines 14.68 216.99 79.25% 89.48% 
gradient boosting 14.74 218.99 77.51% 89.49% 
stacking using linear 
regression 14.74 219.18 77.59% 89.54% 
gradient boosting 
(classification) 16.31 267.62 78.13% 85.61% 
 
Table D-6: Performance results from cross-validations per variable selection method, 
averages across all models. The results of the final model, GA-PIRF, were excluded from 
this table. 
Table D-6 continued 











Permutation importance top 10 13.45 181.05 81.93% 91.5% 
Permutation importance 
interactions 13.93 195.1 80.59% 90.76% 
Lasso 14.25 204.11 80.01% 90.12% 




Table D-6 continued 











MARS interactions 15.06 229.06 77.58% 88.77% 
 
Table D-7:  Optimal tuning parameters for each model, averaged over all cross-validation 
samples. Note that for random forests, a ‘splitrule’ value of 2 is ‘variance’ and a 
‘splitrule’ value of 1 is ‘maxstat’. 
Table D-7 continued 






size: 52.75 mtry: 8.14 nrounds: 156 nrounds: 800 gamma: 3.4 
decay: 18.53 splitrule: 1.63 max_depth: 16.4 max_depth: 8.4 lambda: 8.20e-05 
 min.node.size: 28.9 eta: 0.09 eta: 0.13  
  gamma: 0 gamma: 0  
  colsample_bytree: 1 
colsample_bytre
e: 1  
  min_child_weight: 9.1 
min_child_weig
ht: 4.6  
  subsample: 1 subsample: 1  
 
 
Text D-1: Code for R to build the predictive model with the lowest RMSE and make 






model_formula = as.formula(FUNC_STAT_TRR_ten ~ FUNC_STAT_TCR_ten +  
s(WAITLIST_YEAR, k = -1, bs = "cs") +  
s(INIT_AGE, k = -1, bs = "cs") +  
 s(dialysis_days_to_waitlist, k = -1, bs = "cs") +  
REGION +  
 s(HGT_CM_TCR, k = -1, bs = "cs") +  
projected_paymentsource_at_registration +  
     DIAB +  
s(BMI_TCR, k = -1, bs = "cs") +  
s(WAITLIST_YEAR, by = REGION, k = -1, bs = "cs")  +  
FUNC_STAT_TCR_ten:WAITLIST_YEAR + 
FUNC_STAT_TCR_ten:TOT_SERUM_ALBUM) 
model <- gam(model_formula, data = Data, family=gaussian()) 
#use model to predict new data (in this example, we take a random observation and change 
#a few variables) 
prediction_data = Data[1,] 
prediction_data$INIT_AGE=40  
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prediction_data$DIAB = 'No' 
prediction_data$REGION = '3' 
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